<SEC-DOCUMENT>0001047469-20-001933.txt : 20200331
<SEC-HEADER>0001047469-20-001933.hdr.sgml : 20200331
<ACCEPTANCE-DATETIME>20200331090127
ACCESSION NUMBER:		0001047469-20-001933
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20200512
FILED AS OF DATE:		20200331
DATE AS OF CHANGE:		20200331
EFFECTIVENESS DATE:		20200331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		20759834

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2241179zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg13801_table_of_contents">  Table of Contents</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy Statement Pursuant to Section&nbsp;14(a) of<BR>
the Securities Exchange Act of 1934 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>(Amendment
No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> INSMED INCORPORATED</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1) and 0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule&nbsp;0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=349729,FOLIO='blank',FILE='DISK108:[20ZAD1.20ZAD13801]BA13801A.;3',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>NOTICE  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>and  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>for  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>ANNUAL MEETING OF SHAREHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>MAY 12, 2020  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g962448.jpg" ALT="LOGO" WIDTH="388" HEIGHT="132">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> 700 US Highway 202/206<BR>
Bridgewater, New Jersey 08807  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=797720,FOLIO='blank',FILE='DISK108:[20ZAD1.20ZAD13801]BC13801A.;3',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>Insmed Incorporated<BR>  </B></FONT><FONT SIZE=2><B>700 US Highway 202/206<BR>
Bridgewater, New Jersey 08807<BR>
(908)&nbsp;977-9900  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>March&nbsp;31, 2020 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To
Our Shareholders: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cordially invite you to attend the 2020 Annual Meeting of Shareholders of Insmed Incorporated (Insmed), which, in light of the COVID-19 pandemic and related public health concerns,
will be held virtually via the Internet at www.virtualshareholdermeeting.com/INSM2020 on May&nbsp;12, 2020, at 9:00&nbsp;a.m. Eastern time (the Annual Meeting). A formal notice of the Annual
Meeting accompanies this letter. At the Annual Meeting, the following items will be submitted to a shareholder vote: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>election
of three Class&nbsp;II directors, Clarissa Desjardins, Ph.D., David W.J. McGirr, and Elizabeth McKee Anderson, to serve until the 2023 Annual Meeting of
Shareholders;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>an
advisory vote on the 2019 compensation of our named executive officers;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2020;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>approval
of an amendment to the Insmed Incorporated 2019 Incentive Plan; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>transaction
of such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important, and the company encourages you to vote. Please read the notice and proxy materials carefully, and vote promptly in advance of the meeting by telephone,
electronically through the Internet, or by returning a completed proxy card by mail. You may also attend the Annual Meeting and vote and submit questions during the Annual Meeting via the Internet at
www.virtualshareholdermeeting.com/INSM2020. Whether or not you plan to attend the Annual Meeting and regardless of the number of shares of Insmed common stock you own, please vote by proxy prior to
the Annual Meeting. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sincerely yours,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;WILLIAM H. LEWIS<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>WILLIAM H. LEWIS<BR></FONT> <FONT SIZE=2><I>Chairman of the Board</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>This
Proxy Statement is first being mailed to shareholders on or about March&nbsp;31, 2020. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=974180,FOLIO='blank',FILE='DISK108:[20ZAD1.20ZAD13801]BE13801A.;8',USER='CHE108048',CD='28-MAR-2020;19:06' -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>INSMED INCORPORATED<BR>  </B></FONT><FONT SIZE=2><B>700 US Highway 202/206<BR>
Bridgewater, New Jersey 08807<BR>
(908)&nbsp;977-9900  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF ANNUAL MEETING OF SHAREHOLDERS<BR>
TO BE HELD ON MAY 12, 2020  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTICE IS HEREBY GIVEN that the 2020 Annual Meeting of Shareholders of Insmed Incorporated (Insmed) will be held virtually via the Internet at
www.virtualshareholdermeeting.com/INSM2020, on May&nbsp;12, 2020, at 9:00&nbsp;a.m. Eastern time (the Annual Meeting), and at any adjournment or postponement thereof, for the following
purposes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
elect three Class&nbsp;II directors, Clarissa Desjardins, Ph.D., David W.J. McGirr, and Elizabeth McKee Anderson, to serve until the 2023 Annual Meeting of
Shareholders;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
conduct an advisory vote on the 2019 compensation of our named executive officers;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2020;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
approve an amendment to the Insmed Incorporated 2019 Incentive Plan; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
to the COVID-19 pandemic and public health concerns, the Annual Meeting will be a completely virtual meeting of shareholders. Holders of record of shares of Insmed common stock at
the close of business on March&nbsp;18, 2020 will be entitled to vote at the Annual Meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are requested to vote promptly in advance of the Annual Meeting by telephone, electronically through the Internet, or by returning a completed proxy card by mail regardless of
whether you expect to attend the Annual Meeting. If you attend the Annual Meeting, you may vote even if you already have sent in your proxy. If you are a beneficial owner, you may not vote your shares
at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/ CHRISTINE PELLIZZARI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT>
 </TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Christine Pellizzari<BR></FONT> <FONT SIZE=2><I>Corporate Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>March&nbsp;31,
2020 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE INSMED INCORPORATED ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 12, 2020: The Proxy Statement and
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019 are available at <U>www.proxyvote.com</U>.  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=415290,FOLIO='blank',FILE='DISK108:[20ZAD1.20ZAD13801]BE13801A.;8',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="BG13801A_main_toc"></A> </FONT> <FONT SIZE=2><B>PROXY STATEMENT<BR>
for<BR>
ANNUAL MEETING OF SHAREHOLDERS<BR>
of<BR>
INSMED INCORPORATED<BR>
To be held May&nbsp;12, 2020  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="bg13801_table_of_contents"> </A>
<BR>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG13801_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da13801_general_information_ab__da102253"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da13801_general_information_ab__da102253"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc13801_proposal_no._1_election_of_class_ii_directors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 1 ELECTION OF CLASS II DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc13801_proposal_no._1_election_of_class_ii_directors"><FONT SIZE=2>6</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de13801_corporate_governance"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CORPORATE GOVERNANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de13801_corporate_governance"><FONT SIZE=2>17</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg13801_audit_committee_report_and_independent_auditor_fees"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>AUDIT COMMITTEE REPORT AND INDEPENDENT AUDITOR FEES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg13801_audit_committee_report_and_independent_auditor_fees"><FONT SIZE=2>24</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg13801_certain_relationships_and_related_party_transactions"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg13801_certain_relationships_and_related_party_transactions"><FONT SIZE=2>25</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg13801_delinquent_section_16(a)_reports"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DELINQUENT SECTION&nbsp;16(a) REPORTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg13801_delinquent_section_16(a)_reports"><FONT SIZE=2>26</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg13801_security_ownership_of_certain___sec02924"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND
MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg13801_security_ownership_of_certain___sec02924"><FONT SIZE=2>26</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di13801_proposal_no._2_advisory_vote_o__pro03175"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 2 ADVISORY VOTE ON THE 2019 COMPENSATION OF OUR NAMED EXECUTIVE
OFFICERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di13801_proposal_no._2_advisory_vote_o__pro03175"><FONT SIZE=2>31</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di13801_compensation_discussion_and_analysis"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>COMPENSATION DISCUSSION AND ANALYSIS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di13801_compensation_discussion_and_analysis"><FONT SIZE=2>32</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm13801_compensation_committee_report"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>COMPENSATION COMMITTEE REPORT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm13801_compensation_committee_report"><FONT SIZE=2>46</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#do13801_compensation_committee__do102484"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do13801_compensation_committee__do102484"><FONT SIZE=2>56</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#do13801_dodd-frank_mandated_ceo_pay_ratio"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DODD-FRANK MANDATED PAY RATIO DISCLOSURE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do13801_dodd-frank_mandated_ceo_pay_ratio"><FONT SIZE=2>56</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#do13801_director_compensation"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIRECTOR COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do13801_director_compensation"><FONT SIZE=2>57</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#do13801_proposal_no._3_ratification_of__pro03758"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 3 RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do13801_proposal_no._3_ratification_of__pro03758"><FONT SIZE=2>59</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#PROPOSAL_NO4"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 4 AMENDMENT NO. 1 TO THE INSMED INCORPORATED 2019 INCENTIVE PLAN</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#PROPOSAL_NO4"><FONT SIZE=2>60</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq13801_proposals_for_2021_annual_meeting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSALS FOR 2021 ANNUAL MEETING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq13801_proposals_for_2021_annual_meeting"><FONT SIZE=2>71</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq13801_annual_report_on_form_10-k"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ANNUAL REPORT ON FORM 10-K</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq13801_annual_report_on_form_10-k"><FONT SIZE=2>71</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq13801_separate_copies_for_beneficial_holders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEPARATE COPIES FOR BENEFICIAL HOLDERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq13801_separate_copies_for_beneficial_holders"><FONT SIZE=2>71</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#la13801_appendix_a"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>APPENDIX A: AMENDMENT NO. 1 TO INSMED INCORPORATED 2019 INCENTIVE PLAN</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#la13801_appendix_a"><FONT SIZE=2>A-1</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>In
this Proxy Statement, we use the words "Insmed Incorporated" to refer to Insmed Incorporated, a Virginia corporation, and we use the words "Company," "Insmed," "we," "us" and "our" to refer to
Insmed Incorporated and its consolidated subsidiaries. Insmed, CONVERT and ARIKAYCE are trademarks of Insmed Incorporated. This Proxy Statement also contains trademarks of third parties. Each
trademark of another company appearing in this Proxy Statement is the property of its owner. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=522797,FOLIO='blank',FILE='DISK108:[20ZAD1.20ZAD13801]BG13801A.;6',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da13801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>PROXY STATEMENT<BR>
for<BR>
ANNUAL MEETING OF SHAREHOLDERS<BR>
of<BR>
INSMED INCORPORATED<BR>
To be held May&nbsp;12, 2020  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="da13801_general_information_ab__da102253"> </A>
<A NAME="toc_da13801_1"> </A>
<BR>  GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="da13801_distribution_of_proxy_solicita__dis03250"> </A>
<A NAME="toc_da13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Distribution of Proxy Solicitation and Other Required Annual Meeting Materials    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors (the Board) of Insmed Incorporated is soliciting your proxy for the Annual Meeting of Shareholders on May&nbsp;12,
2020, at 9:00&nbsp;a.m. Eastern time (the Annual Meeting), and any adjournment or postponement thereof. Due to the COVID-19 pandemic and related public health concerns, the Annual Meeting will be
held virtually via the Internet at www.virtualshareholdermeeting.com/INSM2020. We intend to make the Proxy Statement and related proxy materials available to our shareholders on or about
March&nbsp;31, 2020. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="da13801_information_about_the_annual_m__inf03300"> </A>
<A NAME="toc_da13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Information about the Annual Meeting and Voting at or Prior to the Annual Meeting    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I>Why Did I Receive a One-page Notice in the Mail Regarding the Internet Availability of Proxy Materials this Year
Instead of a Full Set of Proxy Materials?</I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to rules adopted by the SEC, we have elected to mail to many of our shareholders a Notice of Internet Availability of the Proxy Materials (the Notice) instead of a paper copy
of the proxy materials. All shareholders receiving the Notice will have the ability to access the proxy materials over the Internet and receive a paper copy of the proxy materials by mail on request.
Instructions on how to access the proxy materials over the Internet or to request a paper copy may be found in the Notice. In addition, the Notice contains instructions on how you may request proxy
materials in printed form by mail or electronically on an ongoing basis. This process has allowed us to expedite our shareholders' receipt of proxy materials, lower the costs of distribution and
reduce the environmental impact of our Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Who May Vote Shares in Connection with the Annual Meeting?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholders
of record at the close of business on March&nbsp;18, 2020 (the Record Date), will be entitled to notice of and to vote at the Annual Meeting. As of the Record Date, we
had 89,859,549 outstanding shares of our common stock, $0.01 par value per share (the Common Stock). Each share of our Common Stock entitles the holder to one vote with respect to all matters
submitted to shareholders at the Annual Meeting. Beneficial owners of shares of our Common Stock may direct the record holder of the shares on how to vote the shares held on their behalf. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Who may participate in the Annual Meeting?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
year's Annual Meeting will take place virtually through the Internet, in light of the COVID-19 pandemic and related public health concerns. We have designed the format of this
year's Annual Meeting to ensure that our shareholders who attend the Annual Meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting. You are
entitled to attend and participate in the Annual Meeting only if you were a shareholder of record as of the close of business on the Record Date, or if you hold a valid proxy for the meeting, as
described below. To be admitted to the Annual Meeting at www.virtualshareholdermeeting.com/INSM2020, you must enter the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=312670,FOLIO='1',FILE='DISK108:[20ZAD1.20ZAD13801]DA13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_da13801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>16-digit
control number found on your proxy card or other proxy materials. If you do not have a control number, please contact the brokerage firm, bank, dealer, or other similar organization that
holds your account as soon as possible so that you can be provided with a control number. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What is a Shareholder of Record and How Can I Vote if I am a Shareholder of Record?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
as of the close of business on the Record Date, shares of our Common Stock were registered directly in your name with our transfer agent, then you are a shareholder of record. As a
shareholder of record, you may vote by proxy in advance or at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a shareholder of record, you may vote or submit a proxy as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>By Internet</I></FONT><FONT SIZE=2>&#151; </FONT>
<BR>

<P style="font-family:times;"><FONT SIZE=2><I>Before the Annual Meeting</I></FONT><FONT SIZE=2>&#151;You may authorize the voting of your shares by following the "Vote by Internet" instructions set forth on the
Notice or proxy card through 11:59&nbsp;p.m. Eastern Time on Monday, May&nbsp;11, 2020. You must specify how you want your shares voted or your vote will not be completed and you will receive an
error message.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>During the Annual Meeting</I></FONT><FONT SIZE=2>&#151;You may vote online during the Annual Meeting. You may cast your vote electronically during the Annual Meeting
using the 16-digit control number found on your proxy card or other proxy materials and following the instructions at www.virtualshareholdermeeting.com/INSM2020.  </FONT></P>

</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>By Telephone</I></FONT><FONT SIZE=2>&#151;Dial 1-800-690-6903 using any touch-tone phone to transmit your voting instructions through
11:59&nbsp;p.m. Eastern Time on Monday, May&nbsp;11, 2020. Have your proxy card in hand when you call and follow the voting instructions given to you over the phone.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>By Mail</I></FONT><FONT SIZE=2>&#151;Complete and sign the proxy card and mail it in accordance with the instructions on the proxy
card. Completed proxy cards must be received by 11:59&nbsp;p.m. Eastern Time on Monday, May&nbsp;11, 2020. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
all cases, your shares will be voted according to your instructions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What is a Beneficial Owner of Shares and How Can I Vote if I am a Beneficial Owner?</I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
on the Record Date, your shares of our Common Stock were not held in your name with our transfer agent, but instead were held in an account at a brokerage firm, bank, dealer, or
other similar organization, then you are the beneficial owner of shares held in "street name," and these proxy materials have been forwarded to you by that organization. The organization holding your
account is considered to be the shareholder of record of shares of our Common Stock for purposes of voting at the Annual Meeting and is required to vote those shares in accordance with your
instructions. If you do not give instructions to the organization holding your account, then the organization will have discretion to vote the shares with respect to "routine" matters but will not be
permitted to vote the shares with respect to "non-routine" matters. See "What Matters at the Annual Meeting are 'Routine' and 'Non-Routine'?" below. As a beneficial owner, you are invited to attend
the Annual Meeting via the Internet at www.virtualshareholdermeeting.com/INSM2020. If you are a beneficial owner and not the shareholder of record, you may not vote your shares at the Annual Meeting
unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=7,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=670763,FOLIO='2',FILE='DISK108:[20ZAD1.20ZAD13801]DA13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_da13801_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What if I Need Technical Assistance During the Annual Meeting?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
encourage you to access the Annual Meeting before it begins. Online check-in will start shortly before the meeting on May&nbsp;12, 2020. If you encounter any difficulties accessing
the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual Annual Meeting log-in page. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What is the Quorum Requirement?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
quorum of shareholders is necessary to hold the Annual Meeting. Shares of our Common Stock representing a majority of the votes entitled to be cast on a matter at the Annual Meeting
(or 44,929,775 shares as of the Record Date) will constitute a quorum for the transaction of business with respect to such matter, unless otherwise provided by law or in our Articles of Incorporation,
as amended (Articles of Incorporation). Votes withheld, abstentions and broker non-votes count as present for establishing a quorum. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What Matters at the Annual Meeting are "Routine" and "Non-Routine"?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal
1, the election of Class&nbsp;II directors, Proposal 2, the advisory vote on the 2019 compensation of our named executive officers, and Proposal 4, the approval of an
amendment to the Insmed Incorporated 2019 Incentive Plan (the 2019 Incentive Plan), are non-routine matters. Proposal 3, the ratification of the appointment of our independent registered public
accounting firm, is a routine matter. If you are a beneficial owner of shares of our Common Stock and do not instruct your broker or other agent how to vote, your shares will not be voted on
"non-routine" matters and your shares will be "broker non-votes" with respect to those proposals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What are the Voting Requirements to Approve Each Proposal to be Submitted to Shareholders?</I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
vote required to elect directors and approve each of the matters scheduled for a vote at the Annual Meeting is set forth below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="149pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="126pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Proposal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vote Required </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board Recommendation </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1.&nbsp;&nbsp;&nbsp;&nbsp;Election of three Class&nbsp;II directors</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Plurality of votes cast</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2.&nbsp;&nbsp;&nbsp;&nbsp;Advisory vote to approve the 2019 compensation of our named executive officers</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Majority of votes cast</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>3.&nbsp;&nbsp;&nbsp;&nbsp;Ratification of appointment of Ernst&nbsp;&amp; Young&nbsp;LLP (Ernst&nbsp;&amp; Young) as our independent registered public accounting firm for the year ending December&nbsp;31,
2020</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Majority of votes cast</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>4.&nbsp;&nbsp;&nbsp;&nbsp;Approval of an amendment to the 2019 Incentive Plan</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Majority of votes cast</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal
1, the election of Class&nbsp;II directors, requires a plurality of the votes cast. This means that the three nominees who receive the highest number of affirmative votes
cast will be elected irrespective of how small the number of affirmative votes is in comparison to the total number of shares voted. Our Board, however, has adopted a director resignation policy,
under which a director nominee in an uncontested election must submit his or her resignation for consideration by our Nominations and Governance Committee and our Board if the number of votes withheld
with respect to such director's election exceeds the number of votes "for" such director's election. See "Corporate Governance&#151;Corporate Governance Matters&#151;Director Resignation
Policy" for additional information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=8,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=186966,FOLIO='3',FILE='DISK108:[20ZAD1.20ZAD13801]DA13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_da13801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal
2, the advisory vote on the 2019 compensation of our named executive officers, is not binding on, nor does it overrule, any decisions of the Company, the Board or the
Compensation Committee. We value the input of our shareholders, and in the event that Proposal 2 is not approved by a majority of votes cast, the Board and the Compensation Committee will consider our
shareholders' concerns and evaluate what actions, if any, may be appropriate to address those concerns. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal
3, the ratification of the appointment of Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the year ending December&nbsp;31, 2020, does not
require shareholder ratification under Virginia law, our Articles of Incorporation, or our Amended and Restated Bylaws (Bylaws). However, the Board is submitting the appointment of Ernst&nbsp;&amp;
Young to the shareholders for ratification as a matter of good corporate governance. In the event that Proposal 3 is not approved by a majority of
votes cast, the Audit Committee will consider the vote in future independent auditor selection decisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal
4, the approval of an amendment to the 2019 Incentive Plan, requires the affirmative vote of a majority of the votes cast at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What Is the Effect of Votes Withheld, Abstentions and Broker Non-Votes On Each of the Proposals?</I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes
that are withheld or any abstentions from voting will not be counted in determining the number of votes cast with respect to any of the proposals. As explained above, because
Proposals 1, 2 and 4 are considered "non-routine," if a beneficial owner does not instruct the broker or other agent how to vote the shares, broker non-votes will result. Broker non-votes will not be
counted in determining the number of votes cast with respect to these proposals. Because Proposal 3 is considered "routine," the broker or other agent will have discretion to vote any shares with
respect to which a beneficial owner does not provide instructions, and no broker non-votes will occur with respect to this proposal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What if I Submit a Proxy But Do Not Specify How I Would Like to Vote?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we receive a signed and dated proxy card or receive your instructions by Internet or by telephone and your instructions do not specify how your shares are to be voted, your shares
will be voted as follows:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FOR the election of each of the three Class&nbsp;II nominees for director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FOR the approval of the 2019 compensation of our named executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FOR the ratification of the appointment of Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the year ending
December&nbsp;31, 2020; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FOR the approval of an amendment to the 2019 Incentive Plan. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unsigned
proxy cards will not be voted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What If Other Matters Not on the Proxy Card Are Brought Before the Annual Meeting for Action by the Shareholders?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this Proxy Statement, the Board does not intend to present any matters other than those described herein at the Annual Meeting and is not aware of any matters to be
presented by other parties. If other matters are properly brought before the Annual Meeting, or any adjournment or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=9,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=470344,FOLIO='4',FILE='DISK108:[20ZAD1.20ZAD13801]DA13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_da13801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>postponement
thereof, for action by the shareholders, proxies will be voted in accordance with the recommendation of the Board or, in the absence of such a recommendation, in accordance with the
judgment of the proxy holders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>How Can I Revoke a Proxy Once I Have Voted?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anyone
giving a proxy may revoke it at any time before it is exercised by voting at the Annual Meeting or by delivering, including by phone or Internet, a later dated proxy or written
notice of revocation to our Corporate Secretary. Attendance at the Annual Meeting will not itself revoke a proxy. A proxy, if executed, properly delivered and not revoked, will be voted at the Annual
Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>What is the Expected Cost of Soliciting Proxies and Who Will Pay for this Cost?</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay the cost of soliciting proxies. In addition to the use of mail and e-mail, proxies may be solicited in person or by telephone by our employees, with no additional
remuneration. We have engaged The Proxy Advisory Group,&nbsp;LLC to assist in the solicitation of proxies and provide related
advice and informational support, for a service fee, plus customary disbursements, which are not expected to exceed $15,000 in total. </FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="da13801_principal_executive_offices_of_insmed"> </A>
<A NAME="toc_da13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Principal Executive Offices of Insmed    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The address of our principal executive offices is 700&nbsp;US Highway 202/206, Bridgewater, New Jersey&nbsp;08807. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=10,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=748867,FOLIO='5',FILE='DISK108:[20ZAD1.20ZAD13801]DA13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc13801_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc13801_proposal_no._1_election_of_class_ii_directors"> </A>
<A NAME="toc_dc13801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1<BR>    <BR>    <BR>    ELECTION OF CLASS II DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Bylaws currently provide that our Board will consist of not less than six or more than 10 directors. Our Board has adopted resolutions
providing for up to nine directors. The directors are divided into three classes&#151;Class&nbsp;I, Class&nbsp;II, and Class&nbsp;III. Each class of directors serves for three years on a
staggered term basis, and the term of our Class&nbsp;II directors will expire at the Annual Meeting. Accordingly, the Board has nominated Clarissa Desjardins, Ph.D., David W.J. McGirr and Elizabeth
McKee Anderson for election as Class&nbsp;II directors. Each of the nominees was recommended for election by the Nominations and Governance Committee, and such recommendation was approved by the
Board. If elected, the term of office for these nominees will expire at our 2023 Annual Meeting of Shareholders. If one of these bona fide nominees set forth in this Proxy Statement is unable to serve
or for good cause will not serve, proxy holders may vote for another nominee proposed by the Board or, as an alternative, the Board may reduce the number of
directors to be elected at the Annual Meeting. The information below describes the primary experience, qualifications and skills of Dr.&nbsp;Desjardins, Mr.&nbsp;McGirr and Ms.&nbsp;Anderson. </FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Clarissa Desjardins, Ph.D.</B></FONT><FONT SIZE=2>, age 53 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director since November 2019 </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Clementia Pharmaceuticals&nbsp;Inc. (2011&nbsp;-&nbsp;2019),
 acquired by Ipsen&nbsp;S.A. in 2019 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Founder </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President and Chief Executive Officer </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Centre of Excellence in Personalized Medicine (CEPMED)
 (2009&nbsp;-&nbsp;2011) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President and Chief Executive Officer </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Caprion Pharmaceuticals&nbsp;Inc. (1998&nbsp;-&nbsp;2007)
 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Co-Founder </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Senior Vice President, Corporate Development </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Director </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Advanced
 Bioconcept&nbsp;Inc. (1992&nbsp;-&nbsp;1998) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p>
 <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Co-Founder </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Vice President, Business Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Current Public Board Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director, BELLUS Health&nbsp;Inc. (Nasdaq: BLU; TSX: BLU) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director, Xenon Pharmaceuticals&nbsp;Inc. (Nasdaq: XENE) </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Education:</U></FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>McGill University&nbsp;-&nbsp;B.Sc.,
 anatomical sciences and history and philosophy of science </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>McGill University&nbsp;-&nbsp;Ph.D., neurology and neurosurgery </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font
 size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>McGill University&nbsp;-&nbsp;Medical Research Council postdoctoral fellow, Douglas Hospital Research Centre</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Dr.&nbsp;Desjardins has more than 20&nbsp;years of leadership experience in biotechnology, pharmaceuticals and research. The Board believes that Dr.&nbsp;Desjardins' skills, including her unique
experience in the founding of several pharmaceutical and biotechnology companies, leadership roles, corporate development expertise, public company experience and medical education, make her a valuable asset to the Board.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=25371,FOLIO='6',FILE='DISK108:[20ZAD1.20ZAD13801]DC13801A.;12',USER='CHE109878',CD='28-MAR-2020;18:43' -->
<A NAME="page_dc13801_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 David W.J. McGirr</B></FONT><FONT SIZE=2>, age 65 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director since October 2013 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Chair of the Audit Committee </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Menlo Therapeutics Inc. (2017&nbsp;-&nbsp;2020) </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>Director until merger with Foamix Pharmaceuticals Ltd. </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Roka Bioscience,&nbsp;Inc. (2013&nbsp;-&nbsp;2018) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2>
 </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director until sale of assets to the Institute for Environmental Health,
 &nbsp;Inc. </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Relypsa,
 &nbsp;Inc. (2013&nbsp;-&nbsp;2016) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director until acquisition by Galencia AG </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2>
 &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Cubist Pharmaceuticals,&nbsp;Inc. (2002&nbsp;-&nbsp;2014), acquired by Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. (NYSE: MRK) in 2015 </FONT><FONT
 SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Senior Advisor to the CEO </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Senior Vice President </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Chief Financial Officer </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Treasurer </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>hippo&nbsp;inc. (1999&nbsp;-&nbsp;2002) </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Chief Operating Officer </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>GAB Robins North America,&nbsp;Inc. (1996&nbsp;-&nbsp;1999) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font
 size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>CEO </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Private
 Equity Investor (1995&nbsp;-&nbsp;1996) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>S.G. Warburg Group (1978&nbsp;-&nbsp;1995) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT
 FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Chief Financial Officer (U.S.) </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Chief Administrative Officer </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Managing Director of S.G. Warburg&nbsp;&amp;&nbsp;Co.,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Current Public Board Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director, Rhythm Pharmaceuticals,&nbsp;Inc. (Nasdaq: RYTM) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director, X4 Pharmaceuticals,&nbsp;Inc. (Nasdaq: XFOR), formerly known as Arsanis,&nbsp;Inc. </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2>
 <U>Education:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT
 SIZE=2>University of Glasgow&nbsp;-&nbsp;B.S., civil engineering </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>University of Pennsylvania&nbsp;-&nbsp;M.B.A.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Mr.&nbsp;McGirr has more than 30&nbsp;years of experience as a senior financial executive, including nearly 12&nbsp;years at Cubist, during which the company secured a number of product approvals and
launched these products across multiple markets. The Board believes that Mr.&nbsp;McGirr brings a unique combination of skills to the Board, including public company executive and board experience, capital markets insight, operational and corporate
development experience, and significant expertise in the healthcare sector, specifically with infectious diseases. Mr.&nbsp;McGirr's background as a senior financial executive provides significant value to the Board in the areas of accounting,
financing and business development.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=593176,FOLIO='7',FILE='DISK108:[20ZAD1.20ZAD13801]DC13801A.;12',USER='CHE109878',CD='28-MAR-2020;18:43' -->
<A NAME="page_dc13801_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Elizabeth McKee Anderson</B></FONT><FONT SIZE=2>, age 62 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director since November 2018 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Chair of the Nominations and Governance Committee </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT
 SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Janssen Pharmaceuticals,&nbsp;Inc., a
 Johnson&nbsp;&amp; Johnson company (2003&nbsp;-&nbsp;2014) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times"
 SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Worldwide Vice President, Global Strategic Marketing and Market Access, Infectious Diseases and Vaccines </FONT><FONT SIZE=2> </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>Worldwide Vice President, Global Strategic Marketing and Market Access, Vaccines </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Worldwide Vice President, Immunology, Global Strategic Marketing </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>Worldwide Vice President, BIO Strategic Marketing </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT
 FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Vice President, Global Biologics Strategic Marketing, Centocor </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Vice President, Strategic Planning&nbsp;&amp; Market Research, Centocor </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Wyeth (1997&nbsp;-&nbsp;2002) </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Vice President&nbsp;&amp; General Manager, Wyeth Lederle Vaccines </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Rhone-Poulenc Rorer Pharmaceuticals&nbsp;Inc.
 (1993&nbsp;-&nbsp;1997) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Senior Vice President and General Manager, North America, Centeon&nbsp;LLC </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Vice President and General Manager, North America, Armour Pharmaceutical Company </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Vice President, Worldwide Business Operations, Armour Pharmaceutical </FONT><FONT SIZE=2> </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>American National Red Cross (1983&nbsp;-&nbsp;1993)
 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Mobay Chemical Company
 (1979&nbsp;-&nbsp;1983)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Current Public Board Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director, Bavarian Nordic A/S (CHP: BAVA) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director, BioMarin Pharmaceutical&nbsp;Inc. (Nasdaq: BMRN) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font
 size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director, Revolution Medicines,&nbsp;Inc. (Nasdaq: RVMD) </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2>
 <U>Current Private Board and Other Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director, Aro Biotherapeutics&nbsp;Inc. </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director, Context Therapeutics,&nbsp;Inc. </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Education:</U></FONT><FONT SIZE=2> </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Loyola University Maryland&nbsp;-&nbsp;M.B.A., finance
 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Rutgers
 University&nbsp;-&nbsp;B.S., engineering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Ms.&nbsp;Anderson has over 30&nbsp;years of leadership in biotechnology, pharmaceuticals and vaccines. The Board believes that Ms.&nbsp;Anderson's experience, including extensive global marketing and
infectious disease experience, makes her well-suited to guide the Board in commercial and market access matters.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dc13801_vote_required_for_election_of_director_nominees"> </A>
<A NAME="toc_dc13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Vote Required for Election of Director Nominees    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Class&nbsp;II directors will be elected by a plurality of the votes properly cast at the Annual Meeting. Votes withheld and broker
non-votes will not have any effect on the outcome of this vote. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dc13801_recommendation"> </A>
<A NAME="toc_dc13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Recommendation    <BR>    </B></FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


THE BOARD RECOMMENDS THAT YOU VOTE "FOR" EACH OF THE CLASS II DIRECTOR NOMINEES.  </B></FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=149208,FOLIO='8',FILE='DISK108:[20ZAD1.20ZAD13801]DC13801A.;12',USER='CHE109878',CD='28-MAR-2020;18:43' -->
<A NAME="page_dc13801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dc13801_our_remaining_board_members"> </A>
<A NAME="toc_dc13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Our Remaining Board Members    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information below describes the primary experience, qualifications and skills of each of our Class&nbsp;III directors, David R. Brennan,
Melvin Sharoky, M.D., and Leo Lee, and Class&nbsp;I directors, Alfred F. Altomari, Steinar J. Engelsen, M.D., and William H. Lewis. The term of the Class&nbsp;III directors will expire at the 2021
Annual Meeting of Shareholders, and the term of the Class&nbsp;I directors will expire at the 2022 Annual Meeting of Shareholders. </FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Incumbent Directors Whose Term Expires at the 2021 Annual Meeting of Shareholders (Class&nbsp;III
Directors)  </I></B></FONT></P>
 <div style="margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 David R. Brennan</B></FONT><FONT SIZE=2>, age 66 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director since May 2014 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Lead Independent Director since November 2018 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Member of the Compensation Committee </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2> </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Alexion Pharmaceuticals (Nasdaq: ALXN)
 (2016&nbsp;-&nbsp;2017) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Interim CEO </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>AstraZeneca&nbsp;PLC (NYSE: AZN) (1999&nbsp;-&nbsp;2012) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2>
 </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>CEO </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Executive Vice President of North America </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times"
 SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Senior Vice President of Commercialization and Portfolio Management </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>
 Director </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Astra Merck,
 &nbsp;Inc. (1995&nbsp;-&nbsp;1999) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. (1975&nbsp;-&nbsp;1994)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Current Public Board Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Chairman, Alexion Pharmaceuticals </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Education:</U></FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Gettysburg College&nbsp;-&nbsp;B.A., business
 administration</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Mr.&nbsp;Brennan has nearly 40&nbsp;years of experience in the pharmaceutical industry. The Board believes that Mr.&nbsp;Brennan's experience at public pharmaceutical companies, including board
experience and roles in executive management, commercialization and product management, makes him a valuable asset to the Board.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=56781,FOLIO='9',FILE='DISK108:[20ZAD1.20ZAD13801]DC13801A.;12',USER='CHE109878',CD='28-MAR-2020;18:43' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dd13801_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Melvin Sharoky, M.D.</B></FONT><FONT SIZE=2>, age 69 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director since May 2001 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Chairman from June 2009&nbsp;-&nbsp;December 2010 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2>
 &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Member of the Nominations and Governance Committee </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Member of the Science and Technology Committee </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Par Pharmaceutical Companies,&nbsp;Inc. (2007&nbsp;-&nbsp;2012) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font
 size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director until acquisition by Endo International&nbsp;plc (Nasdaq:
 ENDP) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Somerset
 Pharmaceuticals,&nbsp;Inc. (1995&nbsp;-&nbsp;2001; 2002&nbsp;-&nbsp;2007) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT
 FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2>
 </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>CEO </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Consultant </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Watson
 Pharmaceuticals,&nbsp;Inc. (now Allergan&nbsp;PLC) (1995&nbsp;-&nbsp;1998) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT
 FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2>
 &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Circa Pharmaceuticals,&nbsp;Inc., a wholly-owned subsidiary of Watson Pharmaceuticals,&nbsp;Inc. (1988&nbsp;-&nbsp;1998) </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>CEO </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Pharmakinetics Laboratories,&nbsp;Inc. (1986&nbsp;-&nbsp;1988) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font
 size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Vice President </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Education:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT
 SIZE=2>University of Maryland in Baltimore County&nbsp;-&nbsp;B.A., biology </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>University of Maryland School of Medicine&nbsp;-&nbsp;M.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Dr.&nbsp;Sharoky has more than 30&nbsp;years of experience in the pharmaceutical industry. The Board believes that, in addition to his medical experience as a physician, Dr.&nbsp;Sharoky's background
as an executive of pharmaceutical companies, as well as his public company board service, brings valuable senior management, leadership, financial and strategic planning experience to our Board.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=913420,FOLIO='10',FILE='DISK108:[20ZAD1.20ZAD13801]DD13801A.;16',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<A NAME="page_dd13801_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Leo Lee</B></FONT><FONT SIZE=2>, age 50 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director since May 2018 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Member of the Compensation Committee </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Member of the Science and Technology Committee </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Regeneus&nbsp;Ltd. (ASX: RGS) (Regeneus)
 (2017&nbsp;-&nbsp;present) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Chief Executive Officer </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Executive Director </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Merck KGaA (2015&nbsp;-&nbsp;2017) </FONT><FONT SIZE=2> </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>President, Japan </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Allergan&nbsp;plc (2011&nbsp;-&nbsp;2015) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT
 FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President, Japan </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font
 size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Merck&nbsp;&amp;&nbsp;Co. (2008&nbsp;-&nbsp;2011) </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Vice President of Sales </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT
 SIZE=2>IQVIA (Cegedim Dendrite) (2003&nbsp;-&nbsp;2008) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times"
 SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>General Manager </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2>
 </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Vice President of Sales and Marketing, Asia Pacific </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>Director of Global Accounts Operation, Asia </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Accelrys,&nbsp;Inc. (1997&nbsp;-&nbsp;2003) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Senior Director of Western Regional Sales </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>President and Representative Director </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p>
 <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>General Manager of Asia Pacific </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2>
 </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Sales Manager for Asia Pacific</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Current Public Board Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Executive Director, Regeneus </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Education:</U></FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>University of California, Los Angeles&nbsp;-&nbsp;B.S., molecular
 genetics and microbiology</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Mr.&nbsp;Lee has more than 21&nbsp;years of experience in the pharmaceutical industry in Japan. The Board believes that Mr.&nbsp;Lee's experience in commercial leadership roles in Japan and the Asia
Pacific region brings value to the Board as the Company seeks to expand in this geography.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=8850,FOLIO='11',FILE='DISK108:[20ZAD1.20ZAD13801]DD13801A.;16',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<A NAME="page_dd13801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Incumbent Directors Whose Term Expires at the 2022 Annual Meeting of Shareholders (Class&nbsp;I
Directors)  </I></B></FONT></P>
 <div style="margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Alfred F. Altomari</B></FONT><FONT SIZE=2>, age 61 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Director since August 2012 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Chair of the Compensation Committee </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Member of the Audit Committee </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2> </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Agile Therapeutics,&nbsp;Inc. (Nasdaq: AGRX) (Agile)
 (2004&nbsp;-&nbsp;present) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Chairman of the Board </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>CEO </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER"
 SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Executive Chairman </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Consultant </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT
 SIZE=2>Barrier Therapeutics,&nbsp;Inc. (2003&nbsp;-&nbsp;2008) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times"
 SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>CEO </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Chief Operating Officer </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Chief Commercial Officer </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Johnson&nbsp;&amp; Johnson (NYSE: JNJ) (1982&nbsp;-&nbsp;2003) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font
 size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Numerous executive roles in general management, commercial
 operations, business development, product launch preparation, and finance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Current Public Board Service:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Executive Chairman, Agile </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Chairman, Baudax Bio (Nasdaq: BXRX) </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Education:</U></FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Drexel University&nbsp;-&nbsp;B.S., finance </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Drexel University&nbsp;-&nbsp;B.S., accounting
 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Rider
 University&nbsp;-&nbsp;M.B.A.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Mr.&nbsp;Altomari is a pharmaceutical industry veteran with more than 30&nbsp;years of experience. The Board believes that Mr.&nbsp;Altomari's executive experience in pharmaceutical companies with
commercialized products, product launches, and more than 20&nbsp;years of focus on the development and marketing of specialty pharmaceutical products, along with his public company board service, makes him uniquely suited to guide the Board in
strategic planning, as well as operational and commercial matters.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=691623,FOLIO='12',FILE='DISK108:[20ZAD1.20ZAD13801]DD13801A.;16',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<A NAME="page_dd13801_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Steinar J. Engelsen, M.D.</B></FONT><FONT SIZE=2>, age 69 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director since November 1999 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director of Insmed Pharmaceuticals&nbsp;Inc. from 1998&nbsp;-&nbsp;2000 </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Chair of the Science and Technology Committee </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Member of the Audit Committee </font> <p
 align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career Highlights:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Teknoinvest AS (1996&nbsp;-&nbsp;present) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Partner </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Soleno Therapeutics,&nbsp;Inc. (Nasdaq: SLNO) (2003&nbsp;-&nbsp;2017)
 , formerly known as Capnia,&nbsp;Inc. </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Director </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Centaur Pharmaceuticals,&nbsp;Inc. (2000) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT
 FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Acting CEO </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Hafslund Nycomed AS (1989&nbsp;-&nbsp;1996) </FONT><FONT SIZE=2>
 </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font
 size=2></FONT><FONT SIZE=2>Senior Vice President, Research and Development among other management positions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Education and Certifications:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>University of Oslo&nbsp;-&nbsp;M.S., nuclear chemistry </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>University of Oslo&nbsp;-&nbsp;M.D. </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Norwegian School of Economics&nbsp;-&nbsp;Certified European Financial Analyst</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Dr.&nbsp;Engelsen has more than 25&nbsp;years of experience in the pharmaceutical industry, including his experience as a financial analyst and as an investor in biopharmaceutical companies. The Board
believes that Dr.&nbsp;Engelsen's finance and management experience as well as his public company board experience in biopharmaceutical companies enables him to provide operating insights.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=528935,FOLIO='13',FILE='DISK108:[20ZAD1.20ZAD13801]DD13801A.;16',USER='CHE108048',CD='28-MAR-2020;19:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de13801_1_14"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>
 <div style="margin-top:12pt;margin-left:0pt;margin-right:0pt;">
<div style="box-sizing:border-box;overflow:auto;zoom:1;width:auto;padding-right:12pt;">
<div style="overflow:auto;zoom:1;border-left:solid #000000 1.0pt;border-right:solid #000000 1.0pt;padding-top:2pt;border-top:solid #000000 1.0pt;padding-bottom:2pt;border-bottom:solid #000000 1.0pt;background-color:#FFFFFF;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="8pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="8pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 William H. Lewis</B></FONT><FONT SIZE=2>, age 51 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font
 size=2></FONT><FONT SIZE=2>Chairman of the Board since November 2018 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Director since September 2012 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p
 align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>President and CEO since September 2012 </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2>
 &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Consultant to Board from June&nbsp;-&nbsp;September 2012 </font> <p align=left style="font-family:times;margin-top:11pt;margin-left:0pt;"> <font size=2> <U>Career
 Highlights:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Aegerion
 Pharmaceuticals,&nbsp;Inc. (Nasdaq: AEGR) (Aegerion) (2005&nbsp;-&nbsp;2011) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT
 FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>Co-founder </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2>
 </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT SIZE=2>President </FONT><FONT SIZE=2>  </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:36pt;"><font size=2> </FONT><FONT FACE="COURIER" SIZE=2>&#111;</FONT><FONT FACE="times" SIZE=2></font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:53pt;"><font size=2></FONT><FONT
 SIZE=2>Chief Financial Officer </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT
 SIZE=2>Wells Fargo&nbsp;&amp;&nbsp;Co. (2002&nbsp;-&nbsp;2004) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Robertson Stephens Capital (2000&nbsp;-&nbsp;2002) </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2>
 &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>JP Morgan Chase&nbsp;&amp;&nbsp;Co. (1995&nbsp;-&nbsp;2000) </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Foreign Service for the U.S. Government (1989&nbsp;-&nbsp;1992)
 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 <U>Education:</U></FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Oberlin
 College&nbsp;-&nbsp;B.A. </FONT><FONT SIZE=2>  </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT
 SIZE=2>Case Western Reserve University&nbsp;-&nbsp;M.B.A. </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:11pt;margin-bottom:-12pt;margin-left:17pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:34pt;"><font size=2></FONT><FONT SIZE=2>Case Western Reserve University&nbsp;-&nbsp;J.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><U>Qualifications</U>: Mr.&nbsp;Lewis has nearly 15&nbsp;years of executive experience in the life sciences industry and a track record of success for over 20&nbsp;years in the pharmaceutical and finance industries both in
the United States and internationally. During his tenure at Aegerion, Mr.&nbsp;Lewis played a pivotal role in re-orienting the company's strategy to focus on rare disease indications, enabling Aegerion to conduct a successful initial public offering
in 2010. The Board believes that Mr.&nbsp;Lewis brings significant qualifications to his role as Chairman due to his experience as our CEO since 2012 and his experience as an executive at Aegerion. His professional experience offers the Board
significant insights and experience with financing, orphan drug development and commercialization, and international business development.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </div>
</div>
</div>
 <P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_executive_officers"> </A>
<A NAME="toc_de13801_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


<U>Executive Officers</U>    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our current executive officers, their ages, the positions currently held by each such person as of the date of
this Proxy Statement and the period holding such positions. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="187pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Period During Which<BR>
Officer Served in Such<BR>
Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>President and CEO</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>September 2012&#151;Present</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Sara Bonstein</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 2020&#151;Present</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>September 2016&#151;Present</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Martina Flammer, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>October 2019&#151;Present</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Chief Legal Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>July 2013&#151;Present</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Chief People Strategy Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 2013&#151;Present</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>John Soriano</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Chief Compliance Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>January 2018&#151;Present</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;William H. Lewis.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Lewis's biographical information is summarized above under "Incumbent
Directors Whose Term Expires at the 2022 Annual
Meeting of Shareholders (Class&nbsp;I Directors)." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sara Bonstein.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Bonstein joined Insmed as Chief Financial Officer in January 2020.
Ms.&nbsp;Bonstein brings more than 15&nbsp;years of
operational and financial leadership in the life sciences </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=91946,FOLIO='14',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>industry.
Prior to joining the Company, Ms.&nbsp;Bonstein was Chief Financial Officer&nbsp;&amp; Chief Operating Officer of OncoSec Medical Incorporated, a position she held since May 2018. From
February 2014 to April 2018, Ms.&nbsp;Bonstein served as the Chief Financial Officer, Secretary, Treasurer and Executive Vice President at Advaxis,&nbsp;Inc. Prior to Advaxis, Ms.&nbsp;Bonstein
was a Six Sigma Champion&nbsp;&amp; Black Belt at Eli Lilly and Company (Lilly) from January 2012 to February 2014. From August 2004 to December 2011, Ms.&nbsp;Bonstein served in various finance roles
at ImClone Systems (acquired by Lilly in 2008), including Director of Development Finance. From May 2001 to August 2004, Ms.&nbsp;Bonstein was a financial analyst at Johnson&nbsp;&amp; Johnson in both
the Ortho McNeil Pharmaceuticals and Ortho Biotech divisions. Ms.&nbsp;Bonstein holds a Masters of Business Administration from Rider University and a Bachelor of Science in Finance from The College
of New Jersey. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roger Adsett.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Adsett joined Insmed as Chief Commercial Officer in September 2016 and was
promoted to Chief Operating Officer in November
2019. Mr.&nbsp;Adsett has over 20&nbsp;years of experience in the global biotechnology and pharmaceutical industry. From January 2015 to September 2016, Mr.&nbsp;Adsett was Senior Vice
President, Head of Gastrointestinal and Internal Medicine Business Unit at Shire&nbsp;Plc (Shire), a global specialty biopharmaceutical company. From August 2008 to January 2015, Mr.&nbsp;Adsett
was Senior Vice President, Gastrointestinal Business Unit Leader at Shire. From October 2005 to August 2008, Mr.&nbsp;Adsett was General Manager, Oral IBD Products of the Gastroenterology Business
Unit of Shire. From November 1994 to October 2005, Mr.&nbsp;Adsett held various marketing and commercial roles at AstraZeneca&nbsp;plc, a multinational pharmaceutical and biopharmaceutical
company. Mr.&nbsp;Adsett was a senior analyst at Accenture&nbsp;PLC, a global professional services company, from September 1991 to November 1994. Mr.&nbsp;Adsett holds a Masters of Business
Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Martina Flammer, M.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Flammer joined Insmed as Chief Medical Officer in December 2019.
Dr.&nbsp;Flammer has over 17&nbsp;years of
experience in both medical and commercial roles in the global biotechnology and pharmaceutical industry. From February 2018 to October 2019, Dr.&nbsp;Flammer was Head of Corporate Division Customer
Value, Senior Vice President at Boehringer Ingelheim International. From 2012 to 2018, Dr.&nbsp;Flammer held various positions at Boehringer Ingelheim, including Vice President, Clinical Development
and Medical Affairs (2016&nbsp;-&nbsp;2018), Vice President of Medicine, Regulatory Affairs&nbsp;&amp; Pharmacovigilance (2014&nbsp;-&nbsp;2016), and Senior Global Medical Director, Clinical
Development&nbsp;&amp; Medical Affairs Virology (2012&nbsp;-&nbsp;2014). Prior to her time at Boehringer
Ingelheim, Dr.&nbsp;Flammer served in various roles at Pfizer,&nbsp;Inc. from 2000 to 2011. Dr.&nbsp;Flammer holds an M.B.A. from New York University Stern School of Business and an M.D. from
University of Vienna Medical School. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christine Pellizzari.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Pellizzari joined Insmed as General Counsel and Corporate Secretary
in July 2013 and was promoted to Chief Legal
Officer in January 2018. Ms.&nbsp;Pellizzari has over 20&nbsp;years of experience in the global biotechnology and pharmaceutical industry, including senior-level leadership roles. From August 2007
to December 2011, Ms.&nbsp;Pellizzari served as Executive Vice President, General Counsel and Secretary for Aegerion and served as a legal consultant for Aegerion from January 2012 to June 2012.
From 1998 to 2007, Ms.&nbsp;Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International,&nbsp;Inc., a publicly traded company that provided the global
pharmaceutical industry with sales effectiveness, promotional and compliance solutions until it was acquired by Cegedim&nbsp;S.A. in 2007. Prior to her tenure at Dendrite, Ms.&nbsp;Pellizzari
practiced law at the firm of Wilentz, Goldman&nbsp;&amp; Spitzer where she specialized in health care transactions and related regulatory matters. Before joining Wilentz, Ms.&nbsp;Pellizzari served as
a law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Ms.&nbsp;Pellizzari received her Bachelor of Arts degree, cum laude, from the University of
Massachusetts, Amherst and her Juris Doctor degree from the University of Colorado, Boulder. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=668539,FOLIO='15',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;S. Nicole Schaeffer.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Schaeffer joined Insmed as Senior Vice President, Human Resources and
Corporate Services in January 2013 and was
promoted to Chief People Strategy Officer in January 2018. From October through December 2012, Ms.&nbsp;Schaeffer was a consultant to Insmed. Ms.&nbsp;Schaeffer has more than 25&nbsp;years of
experience in human resources, organizational development, corporate operations, and building life science organizations. From March 2005 to June 2012, Ms.&nbsp;Schaeffer served as Senior Vice
President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities, and information technology functions. Prior to Amicus, she served
as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures (now Flagship Pioneering), a venture capital firm, and in that capacity she managed human resources for three
life sciences companies. Ms.&nbsp;Schaeffer also held HR leadership positions with Oak Industries, from 1997 to 2000, and EMC Corporation, from 1994 to 1996. Ms.&nbsp;Schaeffer received her
Bachelor of Arts degree from the University of Rochester and her Masters of Business Administration degree from Boston University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John Soriano.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Soriano joined Insmed as Chief Compliance Officer in January 2018, bringing
over 30&nbsp;years of experience in legal and
compliance leadership roles. From August 2010 to November 2017,
Mr.&nbsp;Soriano served as Senior Vice President and Chief Compliance Officer at Celgene Corporation where he oversaw the Global Compliance Program. From November 2000 to February 2010,
Mr.&nbsp;Soriano served as Vice President-Compliance and Deputy General Counsel at Ingersoll-Rand Company. Prior to that, Mr.&nbsp;Soriano worked as a litigation attorney at Becton Dickinson
and&nbsp;Co. (December 1998&#151;November 2000), Johnson&nbsp;&amp; Johnson (February 1998&#151;December 1998), and Simpson Thacher&nbsp;&amp; Bartlett (September 1987&#151;February
1998). Mr.&nbsp;Soriano received his Bachelor of Arts degree from Princeton University's Woodrow Wilson School of Public and International Affairs and his Juris Doctor degree from Harvard Law
School. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=501568,FOLIO='16',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de13801_corporate_governance"> </A>
<A NAME="toc_de13801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_corporate_governance_matters_1"> </A>
<A NAME="toc_de13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Corporate Governance Matters    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Governance Materials and Practices.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our written corporate governance materials,
including our Bylaws, Corporate Governance Guidelines,
Code of Business Conduct and Ethics, Audit Committee Charter, Compensation Committee Charter, Nominations and Governance Committee Charter, Science and Technology Committee Charter, and Director
Resignation Policy are posted on our website at www.insmed.com under the heading "Investors&#151;Corporate Governance." None of the information in or that can be accessed through our website is
incorporated by reference in this Proxy Statement. Our corporate governance practices include the following:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Board currently has a lead independent director, which our Corporate Governance Guidelines require in the event that the positions of
Chairman and CEO are combined, and all of our non-employee directors and board committee members are independent. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Board has adopted a director resignation policy in uncontested director elections. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Board oversees succession planning for executive officers, including the CEO. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Directors have access to all levels of management and are provided with opportunities to meet with members of management on a regular basis. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Directors may retain their own independent advisors, at our expense. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Board and each committee thereof conduct self-evaluations at least once per year to assess their performance and ways in which performance
could be improved. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Board addresses the importance of incorporating new viewpoints on the Board through the director evaluation and nomination process. Our
director composition reflects a mix of tenure on the Board (ranging from less than one year to 20&nbsp;years), which we believe provides an effective balance of historical perspective and an
understanding of the evolution of the Company with fresh perspectives and insights. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Share ownership guidelines are in place for our directors and executive officers. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Code of Business Conduct and Ethics.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics
that applies to all of our directors, officers (including
our CEO, chief financial officer, controller and any person performing similar functions) and employees. Our Code of Business Conduct and Ethics contains written standards designed to communicate our
expectations of our directors, officers, and employees when making decisions and conducting themselves in corporate activities, including the ethical handling and use of confidential information;
actual or apparent conflicts of interest; compliance with applicable governmental laws, rules and regulations; protection of our assets and proprietary information; the ethical handling of payments
and gifts received in the normal course of business and of payments made to government personnel; prompt internal reporting of violations of our Code of Business Conduct and Ethics; and accountability
for adherence to our Code of Business Conduct and Ethics. We have established a means for individuals to report a violation or suspected violation of the Code of Business Conduct and Ethics
anonymously, including those violations relating to accounting, internal controls or auditing matters, and federal securities laws. We intend to satisfy the disclosure requirements regarding any
amendment to, or waiver from, a provision of the Code of Business </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=767731,FOLIO='17',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Conduct
and Ethics by making disclosures concerning such matters available on our website at www.insmed.com under the heading "Investors&#151;Corporate Governance." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Governance Guidelines.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have adopted Corporate Governance Guidelines to assist
and guide the Board in the exercise of its
responsibilities and establish a framework for our corporate governance practices. The Corporate Governance Guidelines contain written standards pertaining to director qualifications, director
responsibilities, structure of our Board, director access to management and independent advisors, director compensation, and performance evaluation of our Board and committees, among other things. The
Corporate Governance Guidelines help to ensure that the Board is independent from management, the Board adequately performs its oversight functions, and the interests of the Board and management align
with the interests of our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings of the Board.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board held 10 meetings during 2019. Each director attended at
least 75% of
the aggregate number of Board and committee meetings that occurred in 2019 during his or her tenure on the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director Resignation Policy.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any nominee for director in an uncontested election who has a
greater number of votes "withheld" from his or her
election than votes cast "for" his or her election must submit his or her resignation to the Board promptly following certification of the election results. Within 90&nbsp;days after the date of the
certification of the election results, the Nominations and Governance Committee will make a recommendation to the Board as to whether to accept or reject the submitted resignation. Within
45&nbsp;days after receiving this recommendation, the Board must accept or reject the resignation or pursue another action unless doing so would cause us to fail to comply with federal or state law
or Nasdaq listing standards. If more than a majority of the members of the Nominations and Governance Committee do not receive a greater number of votes cast "for" their election than votes
"withheld," the independent directors whose classes were not nominated for election will appoint a special committee to consider the resignations and make a recommendation to the Board. Any director
whose resignation is under consideration will not participate in any deliberation or vote regarding his or her resignation. If the Board accepts a director's resignation pursuant to this policy, the
Board may decrease the size of the Board or fill the resulting vacancy in accordance with the Virginia Stock Corporation Act and our Articles of Incorporation and Bylaws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independence of the Directors.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board makes an affirmative determination regarding the
independence of each director annually, based on the
recommendation of the Nominations and Governance Committee. The Board has determined that the following members of the Board are independent, as that term is defined under the general independence
standards of the Nasdaq listing standards: Mr.&nbsp;Altomari, Mr.&nbsp;Brennan, Dr.&nbsp;Desjardins, Dr.&nbsp;Engelsen, Mr.&nbsp;McGirr, Ms.&nbsp;Anderson, Dr.&nbsp;Sharoky and
Mr.&nbsp;Lee. Mr.&nbsp;Lewis is not considered independent because he is currently employed by the Company. The Board also determined that Mr.&nbsp;Hayden, who resigned as a director in May
2019, was an independent director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Board's Role in Strategy.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board actively participates in Company strategy decisions and
oversight throughout the year. The Board annually
reviews the company's strategic plan, including key risks and decisions facing the Company. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_director_nominating_process"> </A>
<A NAME="toc_de13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Director Nominating Process    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Nominations and Governance Committee, which is described more fully below under "Corporate Governance&#151;Committees of the
Board&#151;Nominations and Governance Committee," serves as an independent and objective party to identify, assess, recruit and recommend to the Board qualified candidates for directorship,
consistent with criteria approved by the Board, and establishes and annually </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=23,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=126846,FOLIO='18',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>reviews
such criteria based on factors it considers appropriate. The Board evaluates each nominee in the context of the Board as a whole, with the objective of recommending a group of directors that
can best oversee the business and affairs of the Company and use its diversity of experience to represent shareholder interests through the exercise of sound judgment. The Board seeks director
nominees with experience in the pharmaceutical and biotechnology industries, as well as business, management, accounting and financial experience, among other areas. Among the factors that the Board
and the Nominations and Governance Committee consider are strength of character, sound business judgment, career specialization, relevant technical skills, independence, the ability to commit
sufficient time to the Board, and the extent to which the candidate would fill a present need on the Board, along with geographic, gender, age, racial and ethnic diversity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Nominations and Governance Committee Process for Identifying and Evaluating Director Candidates.</I></FONT><FONT SIZE=2> The Nominations and Governance Committee
evaluates all director candidates in accordance with the director qualification standards described above. The Nominations and Governance Committee evaluates a candidate's qualifications to serve as a
member of the Board based on the skills and characteristics of such individual Board member, as well as the composition of the Board as a whole. In addition, the Nominations and Governance Committee
will evaluate a candidate's independence, diversity, skills and experience in the context of the Board's needs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director Candidate Recommendations and Nominations by Shareholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Nominations and Governance
Committee's charter provides that the committee
will consider director candidate recommendations by shareholders. Shareholders should submit any such recommendations for the Nominations and Governance Committee through the method described below
under "Corporate Governance&#151;Communications with the Board." In accordance with our Bylaws, any person who is a shareholder of record on the record date for the shareholder meeting, on the
date of
the shareholder meeting, and on the date such person provides required notice to the Company may nominate persons for election to the Board if such shareholder complies with the notice procedures set
forth in the Bylaws and summarized in this Proxy Statement under the heading "Proposals for 2021 Annual Meeting." </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_communications_with_the_board"> </A>
<A NAME="toc_de13801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Communications with the Board    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has approved a process for shareholders to send communications to the Board. Shareholders can send communications to the Board and,
if applicable, to the Nominations and Governance Committee or to specified individual directors in writing c/o Ms.&nbsp;Christine Pellizzari, Corporate Secretary, Insmed Incorporated, 700 US Highway
202/206, Bridgewater, New Jersey, 08807. All communications sent to Ms.&nbsp;Pellizzari will be forwarded, as appropriate, to the Board, the Nominations and Governance Committee or any specified
individual directors. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_director_attendance_at_annual_meeting"> </A>
<A NAME="toc_de13801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Director Attendance at Annual Meeting    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our policy is that directors are expected to make reasonable efforts to attend the annual meeting of shareholders absent unusual circumstances.
All directors then on the Board, including Mr.&nbsp;Hayden, attended the 2019 Annual Meeting of Shareholders. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_board_leadership_structure"> </A>
<A NAME="toc_de13801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Board Leadership Structure    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board believes that it is in the best interests of the Company to maintain the flexibility to make determinations about the separation of
the positions of Board Chair and CEO. The Nominations and Governance Committee considers this structure as part of its annual review of the size, organization, structure, composition and operations of
the Board and its committees. In November </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=24,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=49914,FOLIO='19',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2018,
Mr.&nbsp;Hayden stepped down as Chairman of the Board and was succeeded by Mr.&nbsp;Lewis. Mr.&nbsp;Lewis continued as President and CEO of the Company and Mr.&nbsp;Brennan was elected
as Lead Independent Director. The Board believes that its current leadership structure, with Mr.&nbsp;Lewis serving as CEO and Chairman and Mr.&nbsp;Brennan serving as our Lead Independent
Director, is appropriate for the Company at this time. Both Mr.&nbsp;Lewis and Mr.&nbsp;Brennan are actively engaged on significant matters affecting us, such as long-term strategy. The CEO has
overall responsibility for all aspects of our operation, while the Lead Independent Director has a greater focus on governance of the Company, including oversight of the Board. We believe the combined
role of CEO and Chairman balanced with the shared leadership with the Lead Independent Director is a strength for the Company. As our Lead Independent Director, Mr.&nbsp;Brennan calls and chairs
regular and special meetings of the Board and all executive sessions of the independent directors, chairs and presides at annual or special meetings of shareholders, provides meaningful input into the
agenda of Board meetings, oversees the retention of outside advisors, consultants and legal counsel who report directly to the Board, consults frequently with committee chairs and management and has
the right to and often does attend Board committee meetings. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_committees_of_the_board"> </A>
<A NAME="toc_de13801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Committees of the Board    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Bylaws provide that the Board may create one or more committees of the Board. Currently, the Board has four standing committees: the Audit
Committee, the Compensation Committee, the Nominations and Governance Committee and the Science and Technology Committee. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Audit Committee  </B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Composition and Attendance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee consists of Mr.&nbsp;McGirr (Chairman),
Dr.&nbsp;Engelsen, and Mr.&nbsp;Altomari, each of whom
is an independent Board member. During 2019, the Audit Committee held seven meetings. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibilities and Duties.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee assists our Board in fulfilling its oversight
responsibilities relating to the accounting,
reporting and financial practices of the Company as well as overseeing our compliance with applicable legal and regulatory requirements. The Committee reviews and
oversees:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the auditing, accounting, and financial reporting processes, including the audits of our financial statements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our systems of internal controls regarding finance and accounting that we have established; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the qualifications and independence of our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the appointment, retention and performance of our independent registered public accounting firm and the performance of any internal audit
functions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our compliance with legal and regulatory requirements. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee reviews and reassesses the adequacy of its charter at least annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committee Independence.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Board has determined that all three of the current Audit Committee
members, Mr.&nbsp;McGirr, Dr.&nbsp;Engelsen, and
Mr.&nbsp;Altomari, satisfy the heightened independence
requirements of the Nasdaq listing standards and Rule&nbsp;10A-3 under the Securities Exchange Act of 1934, as amended (the Exchange Act). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=25,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=474605,FOLIO='20',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Literacy and Expertise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Board determined that each of the members of the Audit
Committee is able to read and understand fundamental
financial statements, including our consolidated balance sheet, statement of comprehensive income/loss, statement of cash flows, and statement of shareholders' equity. Our Board also has determined
that Mr.&nbsp;McGirr is an "audit committee financial expert," as that term is defined in the rules promulgated by the SEC and has accounting or related financial management expertise as required
under the Nasdaq listing standards. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Compensation Committee  </B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Composition and Attendance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee consists of Mr.&nbsp;Altomari (Chair),
Mr.&nbsp;Brennan, and Mr.&nbsp;Lee, each of whom
is an independent Board member. During 2019, the Compensation Committee held seven meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibilities and Duties.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee develops and oversees the implementation of
our compensation philosophy for our executive
officers and is responsible for our executive and other compensation plans. The Compensation Committee's primary objectives are to develop and maintain an executive compensation program
that:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> creates a direct relationship between pay levels and corporate performance and returns to shareholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provides overall competitive pay levels to effectively attract and retain executive talent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> creates proper incentives to enhance shareholder value; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rewards performance. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee reviews and reassesses the adequacy of its charter at least annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committee Independence and Related Requirements.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Board has determined that all three of the
current Compensation Committee members,
Mr.&nbsp;Altomari, Mr.&nbsp;Brennan, and Mr.&nbsp;Lee satisfy the heightened independence requirements of the Nasdaq listing standards. In addition, all of the members of our Compensation
Committee are "non-employee directors" within the meaning of the rules under Section&nbsp;16 of the Exchange Act and "outside directors" for purposes of Section&nbsp;162(m) of the Internal Revenue
Code of 1986, as amended (the Code and Section&nbsp;162(m)). The Board has determined that Mr.&nbsp;Sharoky also satisfied these independence and related requirements during his tenure on the
Compensation Committee. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Nominations and Governance Committee  </B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Composition and Attendance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominations and Governance Committee consists of Ms.&nbsp;Anderson
(Chair) and Dr.&nbsp;Sharoky, each of whom is an independent Board member. During 2019, the Nominations and Governance Committee held four meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibilities and Duties.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Nominations and Governance Committee identifies and nominates
qualified candidates for directorship and serves in a
leadership role in shaping our corporate </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=26,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=437201,FOLIO='21',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>governance
and overseeing the evaluation of the Board and its committees. The Nominations and Governance Committee:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assists the Board by identifying individuals qualified to become Board members and recommending to the Board the director nominees for election
at shareholder meetings and to fill vacancies on the Board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> makes recommendations to the Board regarding Board and committee organization, structure and composition; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluates the overall effectiveness of the Board and its committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> develops and assesses the Company's corporate governance policies and practices, including risks related to such policies and practices. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominations and Governance Committee reviews and reassesses the adequacy of its charter at least annually. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Science and Technology Committee  </B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Composition and Attendance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Science and Technology Committee consists of Dr.&nbsp;Engelsen
(Chair), Dr.&nbsp;Sharoky, and Mr.&nbsp;Lee,
each of whom is an independent Board member. The Science and Technology Committee was formed in May 2019 and held four meetings. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibilities and Duties.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Science and Technology Committee assists our Board in its oversight
of the Company's preclinical research and
development (R&amp;D) activities and its clinical development activities and decisions. The Science and Technology Committee:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviews with the Company the third-party competitive landscape related to the Company's preclinical R&amp;D and clinical development activities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitors and identifies significant new and emerging trends in science and technology, including R&amp;D, and provides strategic advice to the
Board regarding such issues and trends; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviews with the Company current and planned technology initiatives and provides feedback to the Board regarding such initiatives; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advises the Board on the scientific aspects of business development transactions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assists the Company in reviewing, as requested, the capabilities of the Company's current and prospective key scientific personnel and the
depth and breadth of the Company's scientific resources. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Science and Technology Committee reviews and reassesses the adequacy of its charter at least annually. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="de13801_the_role_of_the_board_in_risk_oversight"> </A>
<A NAME="toc_de13801_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


The Role of the Board in Risk Oversight    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has primary responsibility for overseeing the Company's risk management. The Board administers its oversight responsibility for risk
management directly and through its committees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=27,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=290859,FOLIO='22',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<A NAME="page_de13801_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Each
committee chairman reports to the Board regarding the committee's considerations of management's processes for identifying, evaluating, and controlling significant risks. In addition, the
officers responsible for oversight of particular risks within the Company provide updates and information to our Board. The Board considers specific risk topics, including risks associated with our
strategic plan, our capital structure, our research and development activities, our manufacturing and supply chain, and our operations. Our Board believes that full and open communication between
management and the Board is essential for effective risk management and oversight. The Board and each of its committees have full access to our senior management, as well as the ability to engage
outside advisors and other experts. Management routinely informs the Board of developments that could affect our risk profile or other aspects of our business and development. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for overseeing the Company's program for identifying, evaluating and controlling significant risks. The Audit Committee periodically discusses with
management and the independent auditor the Company's major risk exposures, including financial, legal, regulatory and cybersecurity risk exposures, and the steps taken to monitor, control and minimize
such exposures. The Audit Committee also reviews and evaluates our processes and policies for identifying and assessing key risk areas and for formulating and implementing steps to address such risk
areas. The Audit Committee oversees disclosure controls and procedures, including applicable internal control over financial reporting and meets with the Chief Financial Officer, the Chief Legal
Officer, the Chief Compliance Officer, the Chief Accounting Officer, external audit personnel, and other senior managers as appropriate to review issues regarding compliance with the applicable legal
and regulatory requirements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk taking. Our Compensation Committee
engages an independent consultant to advise it on topics related to Board and executive compensation. In July 2019, the Company selected Willis Towers Watson as its new independent compensation
consultant. In February 2019, the Compensation Committee, with the assistance of Frederic W. Cook&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. (FW Cook), the Company's former independent compensation consultant,
reviewed the executive compensation program and determined that the design of the compensation policies, including the components, weightings and focus of the elements of executive compensation, do
not encourage management to assume excessive or inappropriate risks. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominations and Governance Committee oversees the risks associated with our corporate governance and operating practices, including those relating to the composition of the Board,
the structure and function of Board committees and meeting logistics and policies. The Nominations and Governance Committee regularly reviews the Board's performance, oversees the self-evaluation of
each of the Board's committees, oversees our corporate governance and formulates and recommends corporate governance standards to our Board. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Science and Technology Committee oversees the Company's efforts related to clinical activities, R&amp;D, business development and intellectual property. The Science and Technology
Committee reviews the competitive landscape related to the Company's preclinical R&amp;D and research activities and advises the Board on the scientific aspects of business development transactions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=28,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=1028049,FOLIO='23',FILE='DISK108:[20ZAD1.20ZAD13801]DE13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg13801_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg13801_audit_committee_report_and_independent_auditor_fees"> </A>
<A NAME="toc_dg13801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  AUDIT COMMITTEE REPORT AND INDEPENDENT AUDITOR FEES    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dg13801_report_of_the_audit_committee"> </A>
<A NAME="toc_dg13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Report of the Audit Committee    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee approves the selection of the Company's independent registered public accounting firm and regularly meets with and holds
discussions with management and the Company's independent registered public accounting firm. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee oversees the Company's financial reporting process on behalf of the Board. Management has the primary responsibility for the financial statements and the reporting
process including the systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed the audited financial statements in the Company's Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2019 (the Annual Report) with management, including a discussion of the accounting principles, the reasonableness of significant judgments, and
the quality and clarity of disclosures in the financial statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee reviewed with Ernst&nbsp;&amp; Young, which is responsible for expressing an opinion on the conformity of those audited financial statements with generally accepted
accounting principles, its judgments as to the overall quality of financial reporting, the Company's accounting principles, and such other matters as are required to be discussed with the Audit
Committee by Public Company Accounting Oversight Board (PCAOB) standards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Audit Committee discussed with Ernst&nbsp;&amp; Young its independence from management and the Company, including the matters described in the written disclosures and
letter required by PCAOB standards from Ernst&nbsp;&amp; Young to the Audit Committee regarding the independent accountant's communications with the Audit Committee concerning independence, and
considered the compatibility of non-audit services with the independence of the independent registered public accounting firm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board (and the Board approved) that the audited financial statements be included in
the Company's Annual Report for filing with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>THE AUDIT COMMITTEE</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>David
W.J. McGirr, Chairman<BR>
Alfred F. Altomari<BR>
Steinar J. Engelsen, M.D., C.E.F.A. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=717881,FOLIO='24',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<A NAME="page_dg13801_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dg13801_audit_committee_pre-approval_policy"> </A>
<A NAME="toc_dg13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Audit Committee Pre-Approval Policy    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has adopted an Audit Committee Pre-Approval Policy for the pre-approval of audit services and permitted non-audit services
by the Company's independent registered public accounting firm in an effort to ensure that the provision of such services does not impair the independence of the independent registered public
accounting firm from the Company and is consistent with the rules of the SEC. The policy requires pre-approval by the Audit Committee of the terms and fees of all audit, review and attestation
engagements and related services. The policy also requires the Audit Committee to pre-approve the provision of any audit-related services or non-audit services and determine they would not impair the
independence of our independent registered public accounting firm. The policy prohibits the Audit Committee from retaining our independent registered public accounting firm in connection with a
transaction initially recommended by such firm, the purpose of which may be tax deferral or reduction. The policy delegates pre-approval authority to the Chair of the Audit Committee or, if the Chair
is not available, to any of the Audit Committee's members, but any pre-approval decision must be reported to the Audit Committee at its next scheduled meeting. All of the services performed by
Ernst&nbsp;&amp; Young in the year ended December&nbsp;31, 2019 were pre-approved in accordance with the pre-approval policy. </FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dg13801_independent_registered__dg102462"> </A>
<A NAME="toc_dg13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Independent Registered Public Accounting Firm Fee Disclosure    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee reviewed the aggregate fees billed by Ernst&nbsp;&amp; Young for professional services rendered for the years ended
December&nbsp;31, 2019 and 2018, which were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,196,177</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$975,910</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,995 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,198,172</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$977,905 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit
fees in 2019 and 2018 include fees for services performed to comply with generally accepted auditing standards. These services include the integrated year-end audit of our
consolidated financial statements, attestation services with respect to our internal control over financial reporting, quarterly reviews, accounting consultations on matters addressed during the audit
or quarterly reviews, review of documents filed with the SEC, and $125,000, with respect to 2019, and $115,000, with respect to 2018,
paid to Ernst&nbsp;&amp; Young for consent and comfort letter procedures for registration statements filed in 2019 and 2018, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg13801_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_dg13801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dg13801_review_and_approval_of_related_party_transactions"> </A>
<A NAME="toc_dg13801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Review and Approval of Related Party Transactions    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to our written related party policy, our Audit Committee must review and consider whether to approve or ratify all related party
transactions, as defined in Item&nbsp;404 of Regulation&nbsp;S-K. In determining whether to approve or ratify a related party transaction, the Audit Committee will take into account, among other
factors it deems appropriate, the purpose and potential benefits to us of the transaction, the related party's interest in the transaction, the approximate dollar value involved in the transaction,
whether the transaction was undertaken in the ordinary course of business, whether the related party transaction is on terms no less favorable to us than terms generally available to us from an
unaffiliated third-party under the same or similar circumstances, and whether, under all the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=690157,FOLIO='25',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<A NAME="page_dg13801_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>circumstances,
the transaction is not inconsistent with our best interests. Any transaction which is deemed to be a related party transaction requires the approval of a majority of the disinterested
Audit Committee members. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dg13801_related_party_transactions"> </A>
<A NAME="toc_dg13801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Related Party Transactions    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2019, there were no related party transactions, nor are there currently any proposed related party transactions, which
in accordance with SEC rules, would require disclosure in this Proxy Statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg13801_delinquent_section_16(a)_reports"> </A>
<A NAME="toc_dg13801_8"> </A>
<BR></FONT><FONT SIZE=2><B>  DELINQUENT SECTION&nbsp;16(a) REPORTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires that our directors, executive officers and holders of more than 10% of our Common Stock
report to the SEC their ownership of our Common Stock and changes in that ownership. Directors, executive officers and beneficial owners of more than 10% of our Common Stock are required by applicable
regulations to furnish us with copies of all Section&nbsp;16(a) forms they file. As a matter of practice, members of our staff assist our executive officers and directors in preparing initial
ownership reports and reporting ownership changes and typically file these reports on their behalf. Based solely upon a review of the reports filed pursuant to Section&nbsp;16(a) of the Exchange
Act, we believe that during the year ended December&nbsp;31, 2019, our executive officers, directors and beneficial owners of more than 10% of our Common Stock timely filed all reports required
under Section&nbsp;16, except for the following instances: (1)&nbsp;on May&nbsp;16, 2019, Mr.&nbsp;Lee filed a Form&nbsp;3 that inadvertently omitted 10,000 shares of our Common Stock that
Mr.&nbsp;Lee held at the time of his appointment as a director, which shares were subsequently reported on an amended Form&nbsp;3 filed on March&nbsp;27, 2020, (2)&nbsp;on February&nbsp;27,
2019, Mr.&nbsp;Hayden filed a late Form&nbsp;4 reporting the exercise of options to purchase shares of our Common Stock, and the subsequent sale of such shares, on February&nbsp;15, 2019, due to
a broker error in notifying the Company and Mr.&nbsp;Hayden of the transaction, and (3)&nbsp;on June&nbsp;12, 2019, Mr.&nbsp;Goll filed a Form&nbsp;3 that inadvertently omitted options to
purchase shares of our Common Stock, which options were subsequently reported on an amended Form&nbsp;3 filed on November&nbsp;20, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg13801_security_ownership_of_certain___sec02924"> </A>
<A NAME="toc_dg13801_9"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND MANAGEMENT    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables set forth information about the beneficial ownership of our Common Stock as of the Record Date (except as otherwise
noted), by:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of persons, who beneficially owns more than five percent (5%) of our Common Stock, based on reports filed with the SEC
pursuant to Section&nbsp;13(d) of the Exchange Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all directors and executive officers as a group. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership and percentage ownership are determined in accordance with Section&nbsp;13 of the Exchange Act and related rules and regulations of the SEC. In computing the
number of shares beneficially owned by a person and the percentage ownership of that person, shares of Common Stock subject to options held by that person that are currently exercisable or exercisable
within 60&nbsp;days of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=619418,FOLIO='26',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<A NAME="page_dg13801_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Record
Date and restricted stock units that may vest within 60&nbsp;days of the Record Date are deemed outstanding. Such shares, however, are not deemed outstanding for the purposes of computing the
percentage ownership of any other person. Except as indicated in the footnotes to the following tables or pursuant to applicable community property laws, to our knowledge each shareholder named in the
tables has sole voting and investment power with respect to the shares set forth opposite such shareholder's name. As of the Record Date, there were 89,859,549 shares of Common Stock outstanding. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Beneficially<BR>
Owned(1) </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Greater Than Five Percent (5%) Shareholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FMR&nbsp;LLC(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,401,528</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.9%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>245 Summer Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Boston, Massachusetts 02210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Janus Henderson Group&nbsp;plc(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,667,278</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.0%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 201 Bishopsgate EC2M&nbsp;3AE</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 United Kingdom</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Vanguard Group(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,176,076</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.1%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>100 Vanguard Blvd.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Malvern, PA 19355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 BlackRock,&nbsp;Inc.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,456,517</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.3%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 55 East 52nd&nbsp;Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York, NY 10055</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Palo Alto Investors(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,848,760</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.6%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>470 University Avenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Palo Alto, CA 94301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 T. Rowe Price Associates,&nbsp;Inc.(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,530,775</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 100 E. Pratt Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Baltimore, Maryland 21202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
information in this table, including the footnotes thereto, is derived from third-party filings made with the SEC, as described in the footnotes. We have not
independently verified this information.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2019, FMR&nbsp;LLC (FMR) reported an aggregate beneficial ownership of 13,401,528 shares of our Common Stock, with sole voting power over
421,846 shares and sole dispositive power over 13,401,528 shares.  </FONT>
<BR>

<P style="font-family:times;"><FONT SIZE=2>Members
of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&nbsp;B voting common shares of FMR, representing 49% of the voting
power of FMR. The Johnson family group and all other Series&nbsp;B shareholders have entered into a shareholders' voting agreement under which all Series&nbsp;B voting common shares will be voted
in accordance with the majority vote of Series&nbsp;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement,
members of the Johnson family may be deemed, under the Investment Company Act of 1940 (Investment Company Act), to form&nbsp;a controlling group with respect to FMR.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Neither
FMR nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment </FONT></P>

</DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=113304,FOLIO='27',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<A NAME="page_dg13801_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<UL>

<P style="font-family:times;"><FONT SIZE=2>Company
Act advised by Fidelity Management&nbsp;&amp; Research Company, a wholly owned subsidiary of FMR, which power resides with the Fidelity Funds' Boards of Trustees. Fidelity Management&nbsp;&amp;
Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2019, Janus Henderson Group&nbsp;plc (Janus Henderson) reported an aggregate beneficial ownership of 11,667,278 shares of our Common
Stock, with shared voting and dispositive power over 11,667,278 shares. Janus Henderson has an indirect 97% ownership stake in Intech Investment Management&nbsp;LLC and a 100% ownership stake in
Janus Capital Management&nbsp;LLC (JCM), Perkins Investment Management&nbsp;LLC, Geneva Capital Management&nbsp;LLC, Henderson Global Investors Limited and Janus Henderson Investors Australia
Institutional Funds Management Limited (each an Asset Manager and collectively the Asset Managers). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of
Schedule&nbsp;13G filings. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or
institutional clients (collectively referred to as Managed Portfolios).  </FONT>
<BR>

<P style="font-family:times;"><FONT SIZE=2>As
a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JCM may be deemed to be the beneficial owner of 11,667,278 shares or 13.0% of the shares outstanding of Insmed
Common Stock held by such Managed Portfolios. However, JCM does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and
disclaims any ownership associated with such rights.  </FONT></P>

</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2019, The Vanguard Group and its affiliates named in the Schedule&nbsp;13G/A reported aggregate beneficial ownership of 8,176,076 shares
of our Common Stock, with sole voting power over 185,819 shares, shared voting power over 14,985 shares, sole dispositive power over 7,985,282 shares and shared dispositive power over 190,794 shares.
Vanguard Fiduciary Trust Company, a wholly owned subsidiary of The Vanguard Group,&nbsp;Inc., is the beneficial owner of 175,809 shares as a result of its serving as investment manager of collective
trust accounts. Vanguard Investments Australia,&nbsp;Ltd., a wholly owned subsidiary of The Vanguard Group,&nbsp;Inc., is the beneficial owner of 24,995 shares as a result of its serving as
investment manager of Australian investment offerings.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2019, BlackRock,&nbsp;Inc. reported an aggregate beneficial ownership of 7,456,517 shares of our Common Stock with sole dispositive power
over 7,456,517 shares and sole voting power over 7,225,867 shares, including shares held by a number of its subsidiaries.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2019, Palo Alto Investors&nbsp;LP (Palo Alto), PAI&nbsp;LLC, Dr.&nbsp;Patrick Lee and Dr.&nbsp;Anthony Joonkyoo Yun (together, the
Palo Alto Investors) reported an aggregate beneficial ownership of 6,848,760 shares of our Common Stock with shared dispositive power over 6,848,760 shares and shared voting power over 6,848,760
shares. The Palo Alto Investors filed the Schedule&nbsp;13G jointly, but not as members of a group, and each of them expressly disclaims membership in a group. Each filer disclaims beneficial
ownership of our Common Stock except to the extent of that filer's pecuniary interest therein.  </FONT>
<BR>

<P style="font-family:times;"><FONT SIZE=2>Palo
Alto is a registered investment adviser and investment adviser of investment limited partnerships, and is the investment adviser to other investment funds. PAI&nbsp;LLC is the general partner
of investment limited partnerships. Palo Alto's clients have the right to receive or the </FONT></P>

</DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=653935,FOLIO='28',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<A NAME="page_dg13801_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>power
to direct the receipt of dividends from, or the proceeds from the sale of, our Common Stock.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of December&nbsp;31, 2019, T. Rowe Price Associates,&nbsp;Inc. (Price Associates) reported an aggregate beneficial ownership of 6,530,775 shares of our Common
Stock, with sole voting power over 1,353,471 of the shares and sole dispositive power over the 6,530,775 shares. For the purposes of the reporting requirements of the Exchange Act, Price Associates is
deemed to be a beneficial owner of such securities; however, Price Associates expressly disclaims that it is the beneficial owner of such securities.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Beneficially<BR>
Owned </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Executive Officers</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth M. Anderson(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alfred F. Altomari(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David R. Brennan(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55,221</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarissa Desjardins, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#150;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steinar J. Engelsen, M.D.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>288,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leo Lee(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David W.J. McGirr(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,261</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Melvin Sharoky, M.D.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>258,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,246,512</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.44%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>312,103</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>114,254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>591,545</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>392,707</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paolo Tombesi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#150;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current directors and executive officers as a group (15 persons)(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,320,845</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.63%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Denotes
ownership of less than 1% of the outstanding shares of our Common Stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
6,899 restricted stock units (RSUs) that will vest within 60&nbsp;days of the Record Date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
2,222,143 shares of our Common Stock that are subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of the Record
Date and 12,936 RSUs that will vest within 60&nbsp;days of the Record Date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
294,525 shares of our Common Stock that are subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of the Record Date
and 5,390 RSUs that will vest within 60&nbsp;days of the Record Date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
109,712 shares of our Common Stock that are subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of the Record Date
and 1,078 RSUs that will vest within 60&nbsp;days of the Record Date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
547,729 shares of our Common Stock that are subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of the Record Date
and 6,468 RSUs that will vest within 60&nbsp;days of the Record Date. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=438845,FOLIO='29',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<A NAME="page_dg13801_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
384,010 shares of our Common Stock that are subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of the Record Date
and 3,665 RSUs that will vest within 60&nbsp;days of the Record Date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
3,508,205 shares of our Common Stock that are subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of the Record
Date and 79,986 RSUs that will vest within 60&nbsp;days of the Record Date..  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=35,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=730893,FOLIO='30',FILE='DISK108:[20ZAD1.20ZAD13801]DG13801A.;4',USER='CHE108048',CD='28-MAR-2020;18:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di13801_1_31"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di13801_proposal_no._2_advisory_vote_o__pro03175"> </A>
<A NAME="toc_di13801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2    <BR>    <BR>    ADVISORY VOTE ON THE 2019 COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="di13801_information_regarding_the_advi__inf03721"> </A>
<A NAME="toc_di13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Information Regarding the Advisory Vote on the 2019 Compensation of our Named Executive Officers    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Section&nbsp;14A of the Exchange Act, we are holding a shareholder advisory vote on the compensation of our named executive
officers, as described in the "Compensation Discussion and Analysis" section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure set forth in this Proxy
Statement. At the 2017 Annual Meeting, shareholders voted to hold advisory votes on an annual basis, and the Board subsequently adopted a resolution providing for such an annual vote. At the Annual
Meeting, shareholders will be asked to approve the following resolution: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RESOLVED,
that the shareholders of Insmed Incorporated approve, on an advisory basis, the compensation of the Company's named executive officers, disclosed pursuant to Item&nbsp;402
of Regulation&nbsp;S-K in the Company's Proxy Statement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee oversees and administers our executive compensation program, including the evaluation and approval of compensation plans, policies and programs offered to our
named executive officers. Our executive compensation program is designed to meet the following objectives:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> align management interests with the interests of our shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> emphasize use of "at-risk" and performance-based compensation to motivate executives to advance our interests; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide executive compensation packages that are competitive in order to attract and retain executives whose skills are critical to the current
and long-term success of the Company. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
read the "Compensation Discussion and Analysis" section starting on page 32 of this Proxy Statement for a detailed discussion about our executive compensation programs, including
information about the 2019 compensation of our named executive officers. </FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="di13801_vote_required_for_approval_of_this_proposal"> </A>
<A NAME="toc_di13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Vote Required for Approval of this Proposal    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The advisory vote on the compensation of our named executive officers will be approved by the affirmative vote of the majority of votes
properly cast at the Annual Meeting. Abstentions or broker non-votes will not have an effect on the outcome of this proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
this vote is being conducted on an advisory basis, and is therefore not binding on us, the vote will be carefully considered by the Compensation Committee and our Board. Both our
Compensation Committee and our Board value the opinions of our shareholders and, to the extent there is any meaningful vote against the 2019 compensation of our named executive officers, we will
consider our shareholders' concerns and evaluate what actions, if any, may be appropriate to address those concerns. The outcome of the vote, however, will not be construed as overruling any prior
decision by the Company, the Compensation Committee or the Board. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="di13801_recommendation"> </A>
<A NAME="toc_di13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Recommendation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THE BOARD RECOMMENDS THAT YOU VOTE "FOR" THE APPROVAL, ON AN ADVISORY BASIS, OF THE 2019 COMPENSATION OF OUR NAMED
EXECUTIVE OFFICERS.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=478476,FOLIO='31',FILE='DISK108:[20ZAD1.20ZAD13801]DI13801A.;11',USER='CHE108048',CD='28-MAR-2020;19:31' -->
<A NAME="page_di13801_1_32"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di13801_compensation_discussion_and_analysis"> </A>
<A NAME="toc_di13801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION DISCUSSION AND ANALYSIS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Compensation Discussion and Analysis (the CD&amp;A) explains our compensation philosophy, policies and decisions for 2019 for the following
executives, whom we refer to in this CD&amp;A and in the following tables as our named executive officers: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I><U>William H. Lewis</U></I></B></FONT><FONT SIZE=2>, President and CEO, responsible for developing, in connection with the
Board, our corporate mission and objectives and providing direction and leadership to ensure the execution of our corporate strategy and achievement of our objectives. Mr.&nbsp;Lewis was appointed
as our Chairman in November 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I><U>Roger Adsett</U></I></B></FONT><FONT SIZE=2>, Chief Operating Officer, responsible for oversight of overall business
operations, including marketing, sales and commercial activities, technical operations and supply chain activities.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I><U>John Goll</U></I></B></FONT><FONT SIZE=2>, Chief Accounting Officer, served as our principal financial officer from July
2019 to January 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I><U>Christine Pellizzari</U></I></B></FONT><FONT SIZE=2>, Chief Legal Officer, responsible for oversight of all corporate
and litigation-related legal matters, government affairs and for providing ongoing legal support with respect to regulatory strategy, financing opportunities, business development initiatives, and
intellectual property matters.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I><U>S. Nicole Schaeffer</U></I></B></FONT><FONT SIZE=2>, Chief People Strategy Officer, responsible for all aspects of human
resources and corporate services inclusive of organizational and leadership development, total compensation and employee communications, facilities, environmental health and safety, and information
technology.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I><U>Paolo Tombesi</U></I></B></FONT><FONT SIZE=2>, former Chief Financial Officer, stepped down as our Chief Financial
Officer and his employment with the Company ended on June&nbsp;2, 2019. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="di13801_executive_summary_of_our_2019___exe02479"> </A>
<A NAME="toc_di13801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Executive Summary of Our 2019 Business and Strategic Achievements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial
product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) in September 2018 for the treatment of </FONT><FONT SIZE=2><I>Mycobacterium
avium</I></FONT><FONT SIZE=2> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory
setting, as defined by patients who do not achieve negative sputum cultures after a minimum of six consecutive months of a multidrug background regimen therapy. Nontuberculous mycobacterial (NTM) lung
disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2019, our named executive officers played critical roles in the furtherance of our mission. We successfully completed our first year of commercialization and observed strong
performance in the US launch of ARIKAYCE. In July 2019, we filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for ARIKAYCE for the treatment of patients with
persistent MAC lung infection, and the filing was subsequently validated. In 2019, we also advanced our Japanese new drug application (JNDA), resulting in the submission of the JNDA to Japan's
Ministry of Health, Labour and Welfare (MHLW) in March 2020 for ARIKAYCE for the treatment of patients with MAC lung disease who do not respond sufficiently to prior treatment. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=308249,FOLIO='32',FILE='DISK108:[20ZAD1.20ZAD13801]DI13801A.;11',USER='CHE108048',CD='28-MAR-2020;19:31' -->
<A NAME="page_di13801_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also have a robust pipeline which includes the following product candidates: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Pipeline Stage

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Product Candidate </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Potential Rare Disease Area(s) </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Clinical Stage</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>INS1007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Therapeutic potential in non cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pre-Clinical Stage</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>INS1009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Formulation that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Early Stage</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Various pre-clinical compounds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Opportunities related to multiple rare diseases of unmet medical need, including gram positive pulmonary infections in cystic fibrosis (CF), NTM lung disease and refractory localized infections involving
biofilm</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
complement our internal research and development, we actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2019, we completed enrollment of patients in the WILLOW study, a global randomized, double-blind, placebo-controlled Phase&nbsp;2 clinical study evaluating the efficacy, safety
and pharmacokinetics of INS1007 administered once daily for 24&nbsp;weeks in adults with non-CF bronchiectasis. In February 2020, we announced positive top-line results from the WILLOW study. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;More
broadly from a strategic and operational standpoint, in 2019 we expanded our leadership team with talented executives in key financial, medical, commercial, sales, and clinical
roles. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="di13801_compensation_philosophy_and_principles"> </A>
<A NAME="toc_di13801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Compensation Philosophy and Principles    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We operate in a competitive, rapidly changing and heavily-regulated industry. The long-term success of our business requires us to be
resourceful, adaptable, and innovative, and the skills, talent, and dedication of our executive officers are critical components to this success. Therefore, our compensation program for our executive
officers, including our named executive officers, is designed to attract, retain, and incentivize the best possible talent. The Company's compensation program for named executive officers is
structured to implement the following guiding principles: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alignment with Shareholder Interests.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of our named executive officers'
compensation is in the form of equity awards based on
our belief that equity awards align management's interests with the creation of future shareholder value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of "At-Risk" Compensation to Incentivize Executives.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A substantial portion of our named
executive officers' compensation is based on "at risk,"
or variable, compensation, such as annual cash incentives and stock options. We believe this mix of compensation best aligns the interests of our named executive officers with those of our
shareholders over time and contributes to the achievement of short-term goals and the advancement of our long-term strategy through long-term goals. In 2019, approximately 90% of our CEO's
compensation was "at risk," and 82% of our other named executive officers' compensation was "at risk". The charts below reflecting compensation to our non-CEO named executive officers do not include
compensation paid to Mr.&nbsp;Tombesi, who stepped down as Chief Financial Officer during the first half of 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=38,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=647981,FOLIO='33',FILE='DISK108:[20ZAD1.20ZAD13801]DI13801A.;11',USER='CHE108048',CD='28-MAR-2020;19:31' -->
<A NAME="page_di13801_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2019 CEO Compensation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>Variable Performance-Based vs.<BR>
Guaranteed CEO Compensation for 2019</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g516552.jpg" ALT="GRAPHIC" WIDTH="202" HEIGHT="225">
</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g915412.jpg" ALT="GRAPHIC" WIDTH="255" HEIGHT="198">
<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>2019 Other NEO Compensation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>Variable Performance-Based vs.<BR>
Guaranteed<BR>
Other NEO Compensation for 2019</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g801928.jpg" ALT="GRAPHIC" WIDTH="226" HEIGHT="241">
</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g229816.jpg" ALT="GRAPHIC" WIDTH="255" HEIGHT="184">
<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pay for Performance.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We reward the named executive officers for attaining established
business and individual goals. The attainment of these goals
requires the named executive officer to dedicate his or her time, effort, skills and business experience to the success of the Company and the maximization of shareholder value. A significant portion
of the named executive officers' compensation is based on Company and individual performance, and the compensation program is designed to reward both short-term and long-term performance. Short-term
performance of our named executive officers is principally rewarded through annual cash incentives that reflect the achievement of corporate goals and, with respect to named executive officers other
than our President and CEO, individual goals. Long-term performance of our named executive officers is largely rewarded through stock option and RSU awards that are eligible to vest based on continued
service and have a value tied to share price appreciation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pay competitively to attract and retain skilled executive officers.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The compensation program
is designed to allow the Company to attract and retain
individuals whose skills are critical to the current and long-term success of the Company. Because competition for top talent is intense in our industry, retention is a key objective of the
compensation program. The compensation program is designed to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=39,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=150037,FOLIO='34',FILE='DISK108:[20ZAD1.20ZAD13801]DI13801A.;11',USER='CHE108048',CD='28-MAR-2020;19:31' -->
<A NAME="page_di13801_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>appropriately
compensate our executive officers for the success of the Company from a competitive standpoint, so that they remain with the Company and continue to contribute to the Company's long-term
success. We seek to achieve this objective by granting equity as a combination of stock options and RSU awards. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
our 2019 Annual Meeting of Shareholders, we held an advisory vote on the compensation of our named executive officers. Over 95% of the shares voted were voted in favor of our
say-on-pay proposal.
The Compensation Committee considered these voting results and believes they affirm the Company's compensation philosophy and the principles discussed above. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="di13801_corporate_governance_perspecti__cor02995"> </A>
<A NAME="toc_di13801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Corporate Governance Perspectives on our Executive Compensation Program    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that our executive compensation program reflects our commitment to strong corporate governance practices as evidenced by the
following aspects of our executive compensation program:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Compensation Committee has overall responsibility for executive compensation plans, policies and programs, although our independent Board
members approve recommendations made by our Compensation Committee regarding the compensation of our President and CEO; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Performance metrics that govern incentive compensation are defined by our Compensation Committee at the start of each fiscal year and are
reviewed by our Compensation Committee at the end of the year; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our executive compensation program, in the aggregate, rewards performance in a variety of ways, aimed at a balanced assessment based on the
Company's strategic objectives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Individual and corporate multiplier ranges in our incentive compensation program are developed and implemented such that payouts are capped at
a predetermined maximum amount, irrespective of performance that exceeds objectives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Compensation Committee has the ability to exercise its discretion to reduce or eliminate incentive compensation payouts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have share ownership guidelines in place for our President and CEO, pursuant to which he must hold shares of Common Stock, vested
in-the-money stock options and unvested restricted stock units in an aggregate amount equal to at least three times his base salary within 5&nbsp;years of the adoption of the guidelines or date of
hire, whichever is later. As of the Record Date, Mr.&nbsp;Lewis satisfied these guidelines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We also have share ownership guidelines in place for certain of our other senior executives, pursuant to which they must hold shares of Common
Stock, vested in-the-money stock options and unvested restricted stock units in an aggregate amount equal to his or her base salary within 5&nbsp;years of the adoption of the guidelines or date of
hire, whichever is later. As of the Record Date, Mr.&nbsp;Adsett, Ms.&nbsp;Pellizzari and Ms.&nbsp;Schaeffer satisfied these guidelines. Mr.&nbsp;Goll and Mr.&nbsp;Tombesi are no longer
subject to our share ownership guidelines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Compensation Committee regularly meets in executive session without members of management present; </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=40,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=470627,FOLIO='35',FILE='DISK108:[20ZAD1.20ZAD13801]DI13801A.;11',USER='CHE108048',CD='28-MAR-2020;19:31' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk13801_1_36"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our independent compensation consultant reports directly to the Compensation Committee and meets regularly with the Compensation Committee
without management present; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The employment agreements for our named executive officers do not provide for tax "gross-ups" or severance payments on a change in control
absent termination of the named executive officer's employment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our executive compensation program seeks to balance short-term pay opportunities through annual cash incentives with long-term incentive
opportunities through equity awards and employs both fixed compensation components (base salary) and variable compensation components (annual cash incentives and equity awards); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our insider trading policy prohibits our employees, including officers, and directors from (i)&nbsp;engaging in hedging transactions (whether
through the use of financial instruments such as prepaid variable forwards, equity swaps, collars, exchange funds or otherwise) involving the Company's securities and (ii)&nbsp;pledging the
Company's securities as collateral for loans of any type without the prior approval of the Compensation Committee. No such pledges were approved during 2019. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Compensation Committee annually reviews a compensation risk assessment conducted by management. The Compensation Committee does not believe that our compensation
program is reasonably likely to have a material adverse effect on the Company based on our compensation philosophy and principles and the governance principles described above. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dk13801_executive_compensation_determination_process"> </A>
<A NAME="toc_dk13801_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Executive Compensation Determination Process    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Role of the Compensation Committee and the Board in Making Compensation Decisions.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee has been delegated the authority to
make determinations regarding all elements of compensation for our executive officers, except for Mr.&nbsp;Lewis, our President and CEO. Our Compensation Committee recommends to our independent
Board members the individual elements of total compensation for Mr.&nbsp;Lewis for approval. The independent Board members review this recommendation and determine the compensation for
Mr.&nbsp;Lewis. As discussed in further detail below, in assessing executive compensation, our Compensation Committee engages an outside independent compensation consultant to assess the
competitiveness of our programs and periodically conducts a peer group review. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Role of Management.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, in making executive compensation decisions,
may
solicit input from management as appropriate with respect to individual and Company performance and results. The Compensation Committee receives recommendations and evaluations with respect to the
compensation and performance of our named executive officers from the President and CEO (aside from his own compensation and performance) and Company performance. The Compensation Committee considered
management's assessment along with the input of its independent compensation consultant when making 2019 compensation decisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Role of the Compensation Consultant.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is authorized to select and
retain its own independent compensation consultant and
has routinely sought the advice of an independent compensation consultant regarding our executive compensation practices. During 2019, FW Cook advised the Compensation Committee on its compensation
risk assessment, and provided data and recommendations on executive officer compensation. In December 2019, Willis Towers Watson provided a comprehensive review of long-term incentive guidelines for
all employee levels, an unvested equity analysis to assess the retention power of our compensation program for senior executives, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=208376,FOLIO='36',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>data
and recommendations on executive officer compensation. The Compensation Committee evaluates the independence of its compensation consultant on an annual basis and has concluded that each of FW
Cook, its former compensation consultant, and Willis Towers Watson, its current compensation consultant, was independent during their respective tenure in 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Evaluation Processes and Criteria.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Given the high demand for the experienced
and well-qualified executives we seek to employ, the
Compensation Committee reviews data and information from a variety of sources such as outside surveys of compensation and benefits for executive officers in the biotechnology industry, as well as
public information regarding executive compensation at peer biotechnology companies. The Compensation Committee also draws upon the personal knowledge of its members with respect to executive
compensation at comparable companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the amount and composition of compensation elements (cash and non-cash elements and short- and long-term elements) for our non-CEO named executive officers, our
Compensation Committee reviews the performance of each executive officer holistically. In setting compensation levels for our executive officers for 2019, our Compensation Committee considered many
factors, including, but not limited to, the following factors:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our achievement of certain product development, financial, strategic planning and other goals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each non-CEO named executive officer's individual performance against certain pre-established goals, as discussed in more detail below; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope and strategic impact of each executive officer's responsibilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our past business performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our long-term goals and strategies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the experience of each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> past compensation levels of each executive officer and of the executives as a group; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> relative levels of pay among executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount of each element of compensation in the context of the executive officer's total compensation and other benefits; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for each executive officer other than the President and CEO, the evaluations and recommendations of our President and CEO; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the competitiveness of our compensation relative to selected peer group companies and other survey data, which are described in detail below. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration
of these factors is subjective. No relative weights or rankings are assigned to them except as otherwise discussed in this CD&amp;A. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the President and CEO's compensation, the Compensation Committee reviews and evaluates the performance of the President and CEO and recommends to the Board the individual elements
of his total compensation, considering, among other things, individual performance, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=42,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=919760,FOLIO='37',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>experience,
prior compensation levels, and our general performance objectives, as well as the compensation practices of peer companies and the markets in which we compete for executive talent. The
Board then must approve the President and CEO's compensation. The President and CEO may not be present during voting or deliberations on his compensation. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Selection of Peer Companies and Benchmarking  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, the Compensation Committee, upon advice received from FW Cook, its former compensation consultant, selected the companies
that comprised our 2019 peer group through a screening process that considered publicly traded biopharmaceutical companies similar to us
in number of employees, market capitalization and stage of product development. This review resulted in modifications from our 2018 peer group as described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of employees at the companies in our 2019 peer group ranged from 59 to 520, with a median of 255 employees, and these companies had market capitalizations that ranged from
approximately $1.39&nbsp;billion to $8.60&nbsp;billion, with a median of $2.89&nbsp;billion. Employee numbers were as of the most recently reported fiscal year-end prior to November 2018 and
market capitalizations were as of July&nbsp;25, 2018. The peer group was identified assuming a successful launch of ARIKAYCE in 2019, with an estimated 430 Company employees and an estimated market
capitalization for the Company of approximately $3.00&nbsp;billion. The table below depicts our 2019 peer group: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:75%;margin-left:12%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="201pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="30%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ACADIA Pharmaceuticals&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Corcept Therapeutics Incorporated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sage Therapeutics</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Acceleron Pharma&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Halozyme Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sangamo BioSciences,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Aerie Pharmaceuticals,&nbsp;Inc.*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Heron Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sarepta Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Agios Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Immunomedics,&nbsp;Inc.*</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Spark Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Amicus Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Intercept Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ultragenyx Pharmaceutical&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Array BioPharma&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Loxo Oncology,&nbsp;Inc.*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Clovis Oncology,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Puma Biotechnology,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2019 peer group reflects the following changes from our 2018 peer group: (i)&nbsp;the removal of Keryx Biopharmaceuticals,&nbsp;Inc. and ZIOPHARM Oncology,&nbsp;Inc. and
(ii)&nbsp;the addition of the companies above that are marked by an asterisk. The Compensation Committee concluded that these adjustments to the peer group were appropriate given changes in the
number of employees, market capitalization, stage of development and merger-and-acquisition activity of the Company and historical and potential peer companies. The removal of Keryx
Biopharmaceuticals,&nbsp;Inc. and ZIOPHARM Oncology,&nbsp;Inc. were due to their significantaly smaller market capitalizations as compared to the assumed market capitalization of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FW
Cook provided comparative data regarding cash compensation, long-term equity incentives, and short-term incentives to executive officers at companies in the 2019 peer group. Using
this compensation data and relevant survey data, the Compensation Committee established benchmarks for the purpose of evaluating compensation ranges for base salary, annual cash incentive targets and
long-term equity incentives for each of our named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=43,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=154043,FOLIO='38',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dk13801_components_of_compensation"> </A>
<A NAME="toc_dk13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Components of Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In summary, the compensation paid to our executive officers in 2019 included the following components: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="172pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Component

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Purpose of Component </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Provide our executive officers with a level of stability and certainty each year. </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Annual Cash Incentives</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Motivate and reward executive officers for short term corporate and individual performance. </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term Equity Incentives</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Motivate and reward executive officers for long-term corporate performance.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Align the interests of management and shareholders, thereby enhancing shareholder value.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Attract, motivate, and retain talented employees. </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Health, Welfare and Retirement Programs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Provide market competitive benefits to protect employees' and their covered dependents' health and welfare. Provide a program to foster retirement savings. </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Severance and Change in Control Benefits</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Discourage turnover and mitigate the influence of a potential change in control on an executive officer's decision-making due to concerns regarding job security.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
components of our compensation program and compensation decisions for 2019 for each named executive officer are described in more detail below: </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Base Salary  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee reviews and sets base salaries for executives, other than the President and CEO, on an annual basis during the first
quarter of each year. The Board annually determines the base salary for our President and CEO based on the recommendation of our Compensation Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board and Compensation Committee seek to establish and maintain base salaries for each position and level of responsibility that (i)&nbsp;are competitive with those of executive
officers in our peer group and (ii)&nbsp;reflect individual performance contributions. Our Compensation Committee reviews variances between the salary levels for each of our executive officers and
the executive officers of the companies included in our peer group and determines, in its discretion, individual salary adjustments after considering the factors described above, although no relative
weights or rankings are assigned to these factors. In setting the base salary for our named executive officers other than our President and CEO, the Compensation Committee also considers the
recommendations of our President and CEO. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=44,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=381832,FOLIO='39',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of our named executive officers received merit-based increases to their base salaries in January 2019, which adjustments are reflected in the table below. Ms.&nbsp;Schaeffer's
adjustment also reflected a 3.4% adjustment to better align with salaries in our peer group. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="115pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="115pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base Salaries </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual Rate Approved<BR>
in 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual Rate Approved<BR>
in 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% Increase </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$610,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$640,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.0%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$458,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$472,030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$306,520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$316,480</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.2%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$436,110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$449,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$375,940</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$400,010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.4%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paolo Tombesi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$442,620</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$455,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.0%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
base salaries of Mr.&nbsp;Adsett and Mr.&nbsp;Goll were further adjusted in 2019 to reflect their respective promotions. Mr.&nbsp;Adsett's base salary increased from $472,030
to $500,000, effective in November 2019, in connection with his promotion from Chief Commercial Officer to Chief Operating Officer. The aggregate increase in Mr.&nbsp;Adsett's base salary from 2018
to 2019 was 9.1%. Mr.&nbsp;Goll's base salary increased from $316,480 to $335,000, effective in March 2019, in connection with his promotion from Vice President, Corporate Controller to Senior Vice
President, Chief Accounting Officer. The aggregate increase in Mr.&nbsp;Goll's base salary from 2018 to 2019 was 9.3%. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Annual Cash Incentives  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain an annual cash incentive program for all of our employees to motivate and reward the attainment of annual corporate goals and
individual goals. In establishing targets for the cash incentive awards for our executive officers, the Compensation Committee (and the Board, in the case of our President and CEO) considers target
annual cash incentive opportunities extended to executive officers in similar positions at companies included in our peer group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2019, there were no changes to target cash incentive award percentages that were set in 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target Cash<BR>
Incentive Award<BR>
Opportunity as a<BR>
Percentage of Base<BR>
Salary </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paolo Tombesi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2019, the Compensation Committee determined that the cash incentive award for our named executive officers other than Mr.&nbsp;Lewis would be determined by reference to both
corporate and individual goals, with 75% tied to corporate goals and 25% tied to individual goals. The Compensation Committee believed that including the achievement of individual goals as a component
of our 2019 cash incentive award payouts was important to incentivize our non-CEO named executive officers, and reflect their actual individual performance. Given Mr.&nbsp;Lewis's substantial
influence on the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=45,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=1001771,FOLIO='40',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>overall
performance of the Company, the Compensation Committee believed it was appropriate and in the best interests of our shareholders to continue to have Mr.&nbsp;Lewis's cash incentive award be
based solely upon the achievement of corporate objectives, and the Board concurred in this view. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payouts
for corporate goals were based upon the product of each named executive officer's respective target award and an overall corporate multiplier (ranging between 0% and 200%),
which was determined based on Company performance during 2019. For our non-CEO named executive officers, payouts for individual objectives were based on the product of each named executive officer's
respective target award times an individual multiplier (ranging between 25% and 150%), which was determined based on achievement of individual goals for 2019. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Corporate Goals  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the beginning of each year, management recommends annual corporate objectives to the Compensation Committee for approval. These objectives
serve as the basis for determining our performance against key strategic and operating parameters for the year. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee (and the Board, with respect to our President and CEO) approved the following corporate objectives and weightings for 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Corporate Objectives

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighting (% of<BR>
Corporate<BR>
Objectives) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance ARIKAYCE franchise</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance future pipeline</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Improve corporate operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
objective had at least two goals associated with it, such as net revenue, patient start rate or pipeline milestones. At that time, the Compensation Committee believed that the
goals associated with these corporate objectives were challenging but attainable, and that attainment was uncertain. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=46,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=730960,FOLIO='41',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
the specific goals are not disclosed for each objective given their potential commercial sensitivity, the following achievements in 2019 were factors taken into consideration when
assessing Company performance: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="24%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Corporate Objective

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Key Achievements </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance ARIKAYCE Franchise</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Achieved target net revenue goal and goals related to certain patient metrics, including enrollment forms, patient start rate and adherence rate</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:14pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:14pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continued dialogue with the Food and Drug Administration (FDA) on protocol for post-marketing requirement and advanced additional life-cycle
management plans</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:14pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:14pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced international filings (filed MAA with EMA and advanced Japanese submission with MHLW)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:14pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:14pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ensured adequate supply to cover forecast and built inventory reserve </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance Future Pipeline</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Completed enrollment in the WILLOW study during 1H 2019 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Improve Corporate Operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Stayed within timeline and budget for the building of new corporate headquarters</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Enhanced internal communication, transparency and culture of feedback at all employee levels</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table provides a breakdown of how the Board, with respect to our President and CEO, and the Compensation Committee, with respect to our remaining named executive officers,
determined that we performed against each of these corporate objectives during 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Corporate Objectives

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighting<BR>
(% of<BR>
Corporate<BR>
Objectives) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual<BR>
Performance </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual % of<BR>
Corporate<BR>
Objectives<BR>
Earned </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance ARIKAYCE franchise</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance future pipeline</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Improve corporate operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Individual Goals  </I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consultation with our named executive officers, Mr.&nbsp;Lewis established individual goals for each of our other named executive officers
at the beginning of 2019 that (i)&nbsp;were specific to each named executive officer's area of responsibility and (ii)&nbsp;were intended to support our corporate objectives for 2019. These
individual goals were then recommended to and approved by our Compensation Committee. At the time these goals were established, the Compensation Committee </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=47,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=294394,FOLIO='42',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_43"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>believed
they were challenging but attainable, and attainment was uncertain. The individual goals for each named executive officer, other than Mr.&nbsp;Lewis, for 2019 included the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="24%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Named Executive Officer

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Individual Goals </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Achieve target net revenue for ARIKAYCE</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Operationalize life-cycle management plan for ARIKAYCE</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Ensure adequate supply to cover forecast and build inventory reserve for ARIKAYCE</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Advance international filings</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Implement global expansion plans</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Advance future pipeline </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>John Goll</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Support pre-commercial international growth and global tax structuring</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Maintain financial forecasts to support external financial guidance, accessing capital and corporate defense purposes</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Ensure and monitor a cost-disciplined approach to investments consistent with strategic priorities of the organization</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Ensure timely and accurate financial statement preparation and filings in compliance with the Sarbanes-Oxley Act of 2002 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Continue to support ARIKAYCE launch in the US and launch preparedness in the European Union and Japan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Advance company growth through successful identification, diligence and execution of strategic acquisitions</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Effectively manage Board interactions and be responsive to Board needs</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Complete successful public financings to provide capital necessary for continued operations </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Continue to drive leadership and collaboration of executive leaders</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Provide tools and measurement to hold executive committee accountable for 2019 company survey commitments</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Increase pipeline and talent strategies for hiring</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Hire key senior executive and executive level positions for 2019 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Paolo Tombesi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Improve corporate operations by making our financial planning and analysis team a trusted and valuable business partner</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Ensure timely and accurate financial statement preparation and filings in compliance with the Sarbanes-Oxley Act of 2002</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Raise company profile across media, public opinion and employees through corporate communications</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Advance strategic procurement function</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=48,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=1043403,FOLIO='43',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
input from Mr.&nbsp;Lewis, the Compensation Committee made a qualitative determination following the end of the year as to the level of achievement by each of our named executive
officers other than our President and CEO with regard to his or her respective individual performance objectives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
upon our achievement of the corporate goals summarized above, as well as the achievement of individual goals set by the Compensation Committee, our named executive officers earned
the following cash incentive awards for 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Allocation of Bonus </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual Bonus Achievement </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base<BR>
Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
Bonus % </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Goals </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Individual<BR>
Goals </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Goals </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Individual<BR>
Goals </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 Cash<BR>
Bonus </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$640,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$472,700</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$476,692</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$237,900</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$335,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$140,500</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$449,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$224,200</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$400,010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$196,900</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paolo Tombesi(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$455,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$89,627</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Effective
in November 2019, Mr.&nbsp;Adsett was promoted from Chief Commercial Officer to Chief Operating Officer and his base salary increased to $500,000.
Mr.&nbsp;Adsett's base salary was prorated for purposes of the calculation of his cash bonus.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Effective
in March 2019, Mr.&nbsp;Goll was promoted from Vice President, Corporate Controller to Senior Vice President, Chief Accounting Officer and his base
salary increased to $335,000. Mr.&nbsp;Goll's cash bonus was based on his increased base salary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Tombesi
stepped down as our Chief Financial Officer, and his employment with the Company ended in June 2019. Mr.&nbsp;Tombesi's 2019 cash bonus was
prorated and paid as severance according to the terms of his separation agreement.  </FONT></DD></DL>
 </DIV>
 <UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Long-term Equity Incentives  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of the guiding principles of our compensation program is pay for performance, and we believe that a significant portion of our executives'
compensation should be performance-based to create appropriate incentives and rewards for achieving strategic goals that are critical drivers of shareholder value. We also believe that stock ownership
by management aligns our executives' interests with those of our shareholders, and equity incentive compensation rewards our executives for their contributions to the long-term success of the Company.
The Compensation Committee believes that equity-based compensation is a vital part of our compensation program as it creates an ownership culture that rewards our executives for maximizing shareholder
value over time and aligns the interests of our named executive officers and other key employees with those of our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee believes that the combination of stock option and RSU awards to our named executive officers and other employees encourages retention and aligns the interests
of employees and our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the equity compensation awards to grant to our named executive officers in 2019, the Board, with respect to our President and CEO, and the Compensation Committee, with
respect to our remaining named executive officers, considered each named executive officer's role, as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=49,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=778714,FOLIO='44',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<A NAME="page_dk13801_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>described
above, along with the advice of FW Cook, our former compensation consultant, including information regarding comparative equity compensation awards received by the executives in our peer
group. Individual performance prior to the grant date was also considered. Generally, 75% of the award value is made in the form of stock options and 25% of the award value is made in the form of
RSUs. The Board, with respect to our President and CEO, and the Compensation Committee, with respect to our remaining named executive officers, may also grant equity awards from time to time in
recognition of a named executive officer's expanded duties and responsibilities or continuing contributions to the Company's performance. Based on these considerations, our named executive officers
received the following equity incentive awards in 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:60%;margin-left:20%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="91pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="108pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of Grant </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Options<BR>
Granted(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Restricted<BR>
Stock Units Granted(2) </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>555,140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,741</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>231,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,559</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/18/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,863</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,760</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,311</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,870</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,660</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paolo Tombesi(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:20%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Options
granted on January&nbsp;3, 2019 had an exercise price of $13.91, the per-share closing price of our Common Stock on that date. Shares of our Common Stock
underlying these options vest over a four-year period, with 25% of the shares vesting on the first anniversary of the date of grant and 12.5% of the shares vesting every six months thereafter until
the fourth anniversary of the date of grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
restricted stock units vest and become available as follows: 25% on each anniversary of the date of grant through the fourth anniversary date of the grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>On
November&nbsp;18, 2019, Mr.&nbsp;Adsett received an award of RSUs in connection with his promotion to Chief Operating Officer.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Compensation Committee determined that an increase to Ms.&nbsp;Pellizzari's award of restricted stock units was appropriate given her individual performance
contributions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Tombesi
stepped down as our Chief Financial Officer, and his employment with the Company ended in June 2019. He forfeited this option grant in its
entirety at the time of his termination.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=50,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=687956,FOLIO='45',FILE='DISK108:[20ZAD1.20ZAD13801]DK13801A.;21',USER='JFUSS',CD='29-MAR-2020;17:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dm13801_1_46"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Other Benefits  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain several other benefit programs that are offered to all employees including executives on an equivalent basis, which include
coverage for health insurance, dental insurance, life and disability insurance, and a 401(k) plan. With respect to our 401(k) plan, the Company will deposit a matching contribution of 100% of
deferrals up to 4% of an employee's eligible compensation (subject to any maximum applicable limits under the Internal Revenue Service regulations). We also maintain an Employee Stock Purchase Plan
whereby eligible employees, including executives, are given the opportunity to purchase Common Stock at a discounted price through payroll deductions. We do not have any defined benefit plans or
non-qualified deferred compensation plans. From time to time, we may also provide employees with certain other limited perquisites. For instance, in 2019, we paid certain legal fees on
Mr.&nbsp;Lewis' behalf, including in connection with his sale of shares of our Common Stock in a registered offering. </FONT></P>

<UL>
<UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Severance and Change in Control Benefits  </I></B></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed in further detail below, we have entered into employment agreements with each of our named executive officers that, in addition to
other items, provide for certain severance and change in control payments. We believe that the existence of these potential benefits will discourage turnover and mitigate the influence of a potential
change in control on an executive officer's decision-making due to concerns regarding job security. The employment agreements with our named executive officers do not provide for single-trigger
vesting on a change in control or tax gross-up payments. In connection with the termination of Mr.&nbsp;Tombesi's employment, we entered into a separation agreement providing for certain cash and
other benefits. See "Potential Payments Upon Termination" for additional information. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_compensation_committee_report"> </A>
<A NAME="toc_dm13801_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


COMPENSATION COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee has reviewed and discussed the CD&amp;A required by Item&nbsp;402(b) of Regulation&nbsp;S-K with management and
based on the review and discussions with management of the CD&amp;A, the Compensation Committee recommended to the Board that the CD&amp;A be included in this Proxy Statement and incorporated by reference in
the Company's Annual Report. </FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_the_compensation_committee"> </A>
<A NAME="toc_dm13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


THE COMPENSATION COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Alfred
F. Altomari, Chairman<BR>
David R. Brennan<BR>
Leo Lee </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_summary_compensation_table"> </A>
<A NAME="toc_dm13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Summary Compensation Table    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation earned by the named executive officers in 2019, 2018, and 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=51,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=465726,FOLIO='46',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
improve readability, the following columns have been removed from the table as there is no reportable information with respect to these items: "Change in Pension Value" and
"Nonqualified Deferred Compensation Earnings." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(5) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William H. Lewis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$640,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,499,972</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$4,499,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$472,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$61,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$7,175,094</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>President and CEO</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$610,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,174,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$3,524,964</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$622,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$5,943,159</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$566,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$3,200,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$577,830</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$8,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$4,352,433</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Roger Adsett</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$475,741</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,124,990</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,874,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$237,900</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$14,773</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$3,728,403</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Operating Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$458,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$474,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,425,015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$300,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$14,662</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$2,673,150</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$436,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,612,615</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$281,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$8,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$2,338,765</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John Goll</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$330,584</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$124,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$225,023</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$140,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$832,283</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Former Principal Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$306,520</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$68,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$206,264</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$171,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$763,632</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$297,590</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$274,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$161,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$8,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$842,148</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Christine Pellizzari</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$449,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$749,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,274,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$224,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$2,709,564</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Legal Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$436,110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$324,978</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$975,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$283,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$2,030,589</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$415,340</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,284,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$270,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$8,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,977,865</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 S. Nicole Schaeffer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$400,010</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$424,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,274,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$196,900</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$15,701</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$2,312,597</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief People Strategy Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$375,940</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$324,978</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$975,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$244,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$14,529</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,934,848</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$348,090</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,219,612</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$226,300</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,805,402</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Paolo Tombesi(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$189,958</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$974,990</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$362,384</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,527,332</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Former Chief Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$442,620</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$324,978</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$975,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$270,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$2,023,828</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$253,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,300,046</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$277,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12,087</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,883,283</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
a retention bonus paid to Mr.&nbsp;Goll in 2017 and a sign-on bonus compensation paid to Mr.&nbsp;Tombesi upon commencement of employment in 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
in this column reflect grant date fair values of RSUs granted in 2018 and 2019, calculated in accordance with FASB ASC Topic 718, except the assumption of
forfeitures is not made. Amounts are based on the closing price of our common stock on the Nasdaq Global Market on the date of grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
in this column reflect grant date fair values of stock option awards granted each year, calculated in accordance with FASB ASC Topic 718, except the
assumption of forfeitures is not made. The stock options expire 10&nbsp;years from the date of grant, and the exercise price equals the closing price of our Common Stock on the date of grant. See
Note&nbsp;10, "Stock-Based Compensation" of the consolidated financial statements in the Company's Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, regarding
assumptions underlying valuation of all equity awards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
in this column represent annual cash incentive awards paid to each executive officer under our annual cash incentive program. For further information, see
"Components of Compensation&#151;Annual Cash Incentives."
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts in the "All Other Compensation" column consist of the following amounts:</FONT><FONT SIZE=2>
<BR><BR></FONT>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2017, 2018 and 2019, Mr.&nbsp;Lewis received $8,100, $11,000 and $11,200, respectively, pursuant to our 401(k) plan. In 2019, we also paid
$50,462 in legal fees on Mr.&nbsp;Lewis' behalf, including in connection with his sale of shares of our Common Stock in a registered offering. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2017 and 2018, Mr.&nbsp;Tombesi received $7,200 and $11,000, respectively, pursuant to our 401(k) plan. In 2017, Mr.&nbsp;Tombesi
received an additional $4,887 as reimbursement for legal fees in connection with his entry into an employment agreement with the Company. In 2019, Mr.&nbsp;Tombesi earned $362,237 as compensation
pursuant to the terms of his separation agreement, as described in more detail under "Potential Payments Upon Termination" below. </FONT></DD></DL>
</UL>
</DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=52,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=403735,FOLIO='47',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2017, 2018 and 2019, Mr.&nbsp;Adsett received $8,100, $11,000 and $11,200, respectively, pursuant to our 401(k) plan. In 2018 and 2019,
Mr.&nbsp;Adsett also received an additional $3,300 per year in health savings account (HSA) contributions pursuant to his participation in a tax qualified HSA. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2017, 2018 and 2019, Ms.&nbsp;Pellizzari and Mr.&nbsp;Goll each received $8,100, $11,000 and $11,200, respectively, pursuant to our
401(k) plan. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2017, 2018 and 2019, Ms.&nbsp;Schaeffer received $8,100, $11,000 and $11,200, respectively, pursuant to our 401(k) plan. In 2017, 2018 and
2019, Ms.&nbsp;Schaeffer also received an additional $3,300 each year in HSA contributions pursuant to her participation in a tax qualified HSA.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</UL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Tombesi's
2017 salary covers the period from his date of hire on June&nbsp;1, 2017 through December&nbsp;31, 2017. Mr.&nbsp;Tombesi's annual salary
as of his hire date was $435,000. Mr.&nbsp;Tombesi stepped down as our Chief Financial Officer and his employment with the Company ended on June&nbsp;2, 2019. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_2019_grants_of_plan-based_awards"> </A>
<A NAME="toc_dm13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


2019 Grants of Plan-Based Awards    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the annual cash incentive awards and equity grants made to our named executive
officers during the year ended December&nbsp;31, 2019. No other plan-based awards were granted to any of our named executive officers during 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=4 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares of<BR>
Restricted<BR>
Stock<BR>
Units<BR>
(RSUs)<BR>
(#)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
ecurities<BR>
Underlying<BR>
Options<BR>
(#)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Possible Payouts Under<BR>
Non-Equity<BR>
Incentive Plan Awards(1) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base<BR>
Price of<BR>
Option<BR>
Awards<BR>
($/Sh) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair Value<BR>
of Stock<BR>
and Option<BR>
Awards<BR>
($)(4) </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Threshold<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum<BR>
($) </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$384,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$768,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>555,140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$4,499,965</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>51,741</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$1,499,972</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Roger Adsett</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$375,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>231,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$1,874,999</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>21,559</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$624,995</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11/18/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,863</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$499,995</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$7,328</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$117,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$219,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>27,760</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$225,023</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4,311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$124,976</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$11,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$179,680</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$336,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>157,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$1,274,993</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>25,870</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$749,971</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$160,004</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$300,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>157,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$1,274,993</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5/15/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>14,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$424,993</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Paolo Tombesi.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$11,398</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$182,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$341,925</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>120,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$974,990</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Constitutes
threshold, target and maximum award opportunities for our named executive officers under our annual cash incentive program. See "Compensation Discussion
and Analysis&#151;Components of Compensation&#151;Annual Cash Incentives" for information regarding the criteria applied in determining the amounts payable under the awards. The actual
amounts paid with respect to these awards are included in the "Non-Equity Incentive Plan Compensation" column in the Summary Compensation Table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts shown in this column reflect RSUs granted to our named executive offivers pursuant to our equity incentive plans. The vesting schedule for these grants
is as follows: 25% on each anniversary of the date of grant through the fourth anniversary date of the grant. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=53,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=758011,FOLIO='48',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts shown in this column reflect stock options granted to our named executive officers pursuant to our 2017 Incentive Plan. The vesting schedule for these
grants is as follows: 25% on the first anniversary of the date of grant and 12.5% of the shares vesting on each six-month anniversary thereafter until the fourth anniversary of the date of grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Reflects
grant date fair values of RSU and option awards granted during the applicable year, calculated in accordance with FASB ASC Topic 718, except the assumption
of forfeitures is not made. See Note&nbsp;10, "Stock-Based Compensation" of the consolidated financial statements in the Company's Annual Report on Form&nbsp;10-K for year ended
December&nbsp;31, 2019 regarding assumptions underlying valuation of all equity awards.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_narrative_disclosure_to_summar__nar03501"> </A>
<A NAME="toc_dm13801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Narrative Disclosure to Summary Compensation Table and 2019 Grants of Plan-Based Awards Table    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The employment agreements for our named executive officers generally provide for no fixed termination or other expiration dates. See "Potential
Payments Upon Termination" for information regarding the terms of these agreements that would be relevant in the event of the executive's termination or upon a change in control. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_outstanding_equity_awards_at_2019_fiscal_year-end"> </A>
<A NAME="toc_dm13801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Outstanding Equity Awards at 2019 Fiscal Year-End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the equity awards held by each of our named executive officers as of
December&nbsp;31, 2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=9 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=7 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive Plan<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That Have<BR>
Not Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That Have<BR>
Not Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive Plan<BR>
Awards:<BR>
Number of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights That<BR>
Have Not<BR>
Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive Plan<BR>
Awards:<BR>
Market or<BR>
Payout<BR>
Value of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights That<BR>
Have Not<BR>
Vested<BR>
(#) </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William H. Lewis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>430,630</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$3.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>09/10/2022(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>186,170</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$4.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>09/28/2022(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>83,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/23/2023(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>166,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/23/2023(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>250,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$14.24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10/31/2023(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$20.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/10/2024(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>06/02/2024(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>150,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$22.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/21/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>142,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/07/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>215,206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$10.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/19/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>109,706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,824</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/05/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>88,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>53,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$17.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/17/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>75,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,181</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$30.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/04/2028(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>555,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/03/2029(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>80,672(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,926,447(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=54,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=410821,FOLIO='49',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=9 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=7 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive Plan<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That Have<BR>
Not Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That Have<BR>
Not Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive Plan<BR>
Awards:<BR>
Number of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights That<BR>
Have Not<BR>
Vested<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive Plan<BR>
Awards:<BR>
Market or<BR>
Payout<BR>
Value of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights That<BR>
Have Not<BR>
Vested<BR>
(#) </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Roger Adsett</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>22,015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$14.56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10/03/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,855</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/05/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$17.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/17/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,364</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>50,606</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$30.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/04/2028(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>231,310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/03/2029(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>58,117(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$1,387,834(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John Goll</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/08/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>37,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$22.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/21/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,062</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,438</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/07/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,135</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$10.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/19/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/05/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$17.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/17/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,395</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$30.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/04/2028(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,760</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/03/2029(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,003(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$143,352(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Christine Pellizzari</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>150,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$11.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>07/30/2023(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$20.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/10/2024(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>06/02/2024(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/08/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>45,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$22.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/21/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/07/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>65,756</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,394</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$10.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/19/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>41,137</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>24,683</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/05/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>37,987</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>22,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$17.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/17/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$30.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/04/2028(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>157,290</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/03/2029(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>33,871(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$808,839(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 S. Nicole Schaeffer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,226</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$6.96</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/02/2023(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/23/2023(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/23/2023(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$20.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/10/2024(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$12.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>06/02/2024(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/08/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>41,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$22.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/21/2025(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$16.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/07/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,181</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,394</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$10.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/19/2026(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25,712</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,428</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/05/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>23,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$17.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>05/17/2027(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$30.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/04/2028(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>157,290</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$13.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>01/03/2029(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>22,661(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>$541,145(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Paolo Tombesi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
stock options have a vesting schedule of 25% on the first anniversary of the date of grant and 12.5% on each six-month anniversary thereafter until the fourth
anniversary of the date of grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>One-half
of the shares subject to the option vested upon receipt of the written acceptance of our MAA filing for ARIKAYCE by the EMA in February 2015, and one-half
of the shares subject to the option vested upon FDA approval of ARIKAYCE in September 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=55,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=1045148,FOLIO='50',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
RSUs have a vesting schedule as follows: 25% on each anniversary of the date of grant through the fourth anniversary date of the grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Reflects
the closing price of $23.88 per share of the Company's common stock on the Nasdaq Global Market on December&nbsp;31, 2019. </FONT></DD></DL>
 </DIV>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_option_exercises_and_stock_vested_during_2019"> </A>
<A NAME="toc_dm13801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Option Exercises and Stock Vested During 2019    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information with respect to stock options exercised and stock vested during the year ended December&nbsp;31,
2019. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Exercise (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized on<BR>
Exercise<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Vesting (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized on<BR>
Vesting<BR>
($) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>277,684</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,275,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,644</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>143,213</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,899</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,900</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,539</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>565</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,390</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,620</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>195,319</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,620</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Paolo Tombesi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>79,475</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,241</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,620</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dm13801_potential_payments_upon_termination"> </A>
<A NAME="toc_dm13801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Potential Payments Upon Termination    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our named executive officers are entitled to payments and other benefits under their employment agreements in connection with their termination
under certain circumstances. We believe that the existence of these potential benefits will discourage turnover and mitigate the influence of a potential change in control on an executive officer's
decision-making due to concerns regarding job security. On June&nbsp;2, 2019, Mr.&nbsp;Tombesi stepped down as our Chief Financial Officer and his employment with the Company ended. Pursuant to a
separation agreement, Mr.&nbsp;Tombesi received the following severance benefits: (i)&nbsp;12&nbsp;months' salary at his 2019 base salary, paid semi-monthly over a 12-month period; (ii)&nbsp;a
pro-rata portion of his annual bonus based on actual Company performance during 2019, payable within two and one-half months following December&nbsp;31, 2019; (iii)&nbsp;accelerated vesting of any
of his options and RSUs that would have otherwise vested within six months of June&nbsp;2, 2019; and (iv)&nbsp;payment for the cost of COBRA coverage equivalent to his current coverage through no
later than May&nbsp;31, 2020 (minus certain employee contributions), in each case less applicable tax withholding. As of December&nbsp;31, 2019, Mr.&nbsp;Tombesi had earned $362,237 under this
arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Mr.&nbsp;Lewis's employment is terminated by us without cause or by Mr.&nbsp;Lewis for good reason within two years after a change in control of the Company, Mr.&nbsp;Lewis
will receive payment of accrued obligations, a lump sum severance payment equal to two times the sum of his then applicable annual base salary plus two times his annual target bonus plus a pro-rata
portion of his annual target bonus (calculated as the target bonus for the year of termination multiplied by the following fraction: (i)&nbsp;the number of days that the Executive was employed by
the Company during that fiscal year, divided by (ii)&nbsp;365), full vesting of all equity awards, and continuation for up to 18&nbsp;months of health benefits provided he elects continued
coverage under COBRA. Should Mr.&nbsp;Lewis's employment be terminated by us without cause
or by Mr.&nbsp;Lewis for good reason prior to the date of a change in control or more than two years after a change in control, he would be entitled to receive all of the foregoing benefits provided
that his severance payment would instead be limited to one and one-half times his then applicable annual base salary and one times his target bonus (payable over an 18-month period) for the year of
termination, his pro-rata bonus would be based on actual performance for the year of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=56,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=589421,FOLIO='51',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>termination,
and his accelerated vesting would be limited to full vesting of all time-based equity awards granted at least one year prior to his termination date. Should Mr.&nbsp;Lewis's employment
be terminated due to his death or disability, Mr.&nbsp;Lewis or his estate would receive payment of accrued obligations, a pro-rata portion of his annual target bonus based on actual performance for
the year of termination, and any insurance benefits to which he and his beneficiaries were entitled as a result of his death or disability. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Mr.&nbsp;Adsett's employment is terminated by us without cause or by Mr.&nbsp;Adsett for good reason within two years after a change in control of the Company, Mr.&nbsp;Adsett
will receive payment of accrued obligations, a lump sum severance payment equal to one and one-half times his then applicable annual base salary plus one and one-half times his annual target bonus
plus a pro-rata portion of his annual target bonus (calculated as the target bonus for the year of termination multiplied by the following fraction: (i)&nbsp;the number of days that the Executive
was employed by the Company during that fiscal year, divided by (ii)&nbsp;365), full vesting of all equity awards, and a continuation of up to 18&nbsp;months of health benefits provided he elects
continued coverage under COBRA. Should Mr.&nbsp;Adsett's employment be terminated by us without cause or by Mr.&nbsp;Adsett for good reason prior to the date of a change in control or more than
two years after a change in control, Mr.&nbsp;Adsett would be entitled to receive all of the foregoing benefits provided that his severance payment would be limited to his then applicable annual
base salary and instead be payable over a 12-month period, his pro-rata bonus would be based on actual performance for the year of termination, and his equity award vesting would be limited to
accelerated vesting of all time-based equity awards that would otherwise have vested within 12&nbsp;months following his termination date. Should Mr.&nbsp;Adsett's employment be terminated due to
his death or disability, Mr.&nbsp;Adsett or his estate would receive payment of accrued obligations, a pro-rata portion of his annual target bonus based on actual performance for the year of
termination, and any insurance benefits to which he and his beneficiaries were entitled as a result of his death or disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Mr.&nbsp;Goll's employment is terminated by us without cause or by Mr.&nbsp;Goll for good reason within one year after a change in control of the Company, Mr.&nbsp;Goll will
receive payment of accrued obligations, a lump sum severance payment equal to his then applicable annual base salary plus a pro-rata portion of his annual target bonus (calculated as the target bonus
for the year of termination multiplied by the following fraction: (i)&nbsp;the number of days that the Executive was employed by the Company during that fiscal year, divided by (ii)&nbsp;365),
full vesting of all equity awards, and a continuation of up to 12&nbsp;months of health benefits provided he elects continued coverage under COBRA. Should Mr.&nbsp;Goll's employment be terminated
by us without cause or by Mr.&nbsp;Goll for good reason prior to the date of a change in control or more than one year after a change in control, Mr.&nbsp;Goll would be entitled to receive all of
the foregoing benefits provided that his severance payment would be limited to one-half of his then
applicable annual base salary and instead be payable over a six-month period, his pro-rata bonus would be based on actual performance for the year of termination, his equity award vesting would be
limited to accelerated vesting of all time based equity awards that would otherwise have vested within six months following his termination date, and he would be entitled to receive a continuation of
up to six months of health benefits provided he elects continued coverage under COBRA. Should Mr.&nbsp;Goll's employment be terminated due to his death or disability, Mr.&nbsp;Goll or his estate
would receive payment of accrued obligations, a pro rata portion of his annual target bonus based on actual performance for the year of termination, and any insurance benefits to which he and his
beneficiaries were entitled as a result of his death or disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Ms.&nbsp;Pellizzari's employment is terminated by us without cause or by Ms.&nbsp;Pellizzari for good reason within two years after a change in control of the Company,
Ms.&nbsp;Pellizzari will receive payment of accrued obligations, a lump sum severance payment equal to one and one-half times her then applicable annual base salary plus one and one-half times her
annual target bonus plus a pro-rata portion of her annual target bonus (calculated as the target bonus for the year of termination </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=57,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=234196,FOLIO='52',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<A NAME="page_dm13801_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>multiplied
by the following fraction: (i)&nbsp;the number of days that the Executive was employed by the Company during that fiscal year, divided by (ii)&nbsp;365), full vesting of all equity
awards, and a continuation of up to 18&nbsp;months of health benefits provided she elects continued coverage under COBRA. Should Ms.&nbsp;Pellizzari's employment be terminated by us without cause
or by Ms.&nbsp;Pellizzari for good reason prior to the date of a change in control or more than two years after a change in control, Ms.&nbsp;Pellizzari would be entitled to receive all of the
foregoing benefits provided that her severance payment would be limited to her then applicable annual base salary and instead be payable over a twelve month period, her pro-rata bonus would be based
on actual performance for the year of termination, and her equity award vesting would be limited to accelerated vesting of all time-based equity awards that would otherwise have vested within
12&nbsp;months following her termination date. Should Ms.&nbsp;Pellizzari's employment be terminated due to her death or disability, Ms.&nbsp;Pellizzari or her estate would receive payment of
accrued obligations, a pro-rata portion of her annual target bonus based on actual performance for the year of termination, and any insurance benefits to which she and her beneficiaries were entitled
as a result of her death or disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Ms.&nbsp;Schaeffer's employment is terminated by us without cause or by Ms.&nbsp;Schaeffer for good reason within two years after a change in control of the Company,
Ms.&nbsp;Schaeffer will receive payment of accrued obligations, a lump sum severance payment equal to one and one-half times her then applicable annual base salary plus one-and-one-half times her
annual target bonus plus a pro-rata portion of her annual target bonus (calculated as the target bonus for the year of termination multiplied by the following fraction: (i)&nbsp;the number of days
that the Executive was employed by the Company during that fiscal year, divided by (ii)&nbsp;365), full vesting of all equity awards, and a continuation of up to 18&nbsp;months of health benefits
provided she elects continued coverage under COBRA. Should Ms.&nbsp;Schaeffer's employment be terminated by us without cause or by Ms.&nbsp;Schaeffer for good reason prior to the date of a change
in control or more than two years after a change in control, Ms.&nbsp;Schaeffer would be entitled to receive all of the foregoing benefits provided that her severance
payment would be limited to her then applicable annual base salary and instead be payable over a 12-month period, her pro-rata bonus would be based on actual performance for the year of termination,
and her equity award vesting would be limited to accelerated vesting of all time-based equity awards that would otherwise have vested within 12&nbsp;months following her termination date. Should
Ms.&nbsp;Schaeffer's employment be terminated due to her death or disability, Ms.&nbsp;Schaeffer or her estate would receive payment of accrued obligations, a pro-rata portion of her annual target
bonus based on actual performance for the year of termination, and any insurance benefits to which she and her beneficiaries were entitled as a result of her death or disability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the employment agreements, the term "cause" generally includes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
conviction of the executive, or a plea of nolo contendere, to a felony involving moral turpitude;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>willful
misconduct or gross negligence by the executive resulting, in either case, in material economic harm to the Company or any related entities;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
willful failure by the executive to carry out the reasonable and lawful directions of the Board and failure by the executive to remedy such willful failure within
30&nbsp;days after receipt of written notice of same, by the Board;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>fraud,
embezzlement, theft or dishonesty of a material nature by the executive against the Company or any related entity, or a willful material violation by the
executive of a policy or procedure of the Company or any related entity, resulting, in any case, in material economic harm to the Company or any related entity; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
willful material breach by the executive of his or her employment agreement and failure by the executive to remedy the material breach within 30&nbsp;days after
receipt of written notice thereof from the Board. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=58,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=793193,FOLIO='53',FILE='DISK108:[20ZAD1.20ZAD13801]DM13801A.;21',USER='CHE108048',CD='28-MAR-2020;19:19' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_do13801_1_54"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of the employment agreements, the term "good reason" generally includes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
material diminution in the executive's base compensation;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
material diminution in the executive's authority, duties, or responsibilities;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
material diminution in the authority, duties, or responsibilities of the supervisor to whom the executive is required to report;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
Company's or related entity's requiring the executive to be based at any office or location outside of 50 miles from the location of employment or service as of
the effective date of his or her employment agreement, except for travel reasonably required in the performance of the executive's responsibilities; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>any
other action or inaction that constitutes a material breach by the Company of the executive's employment agreement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the employment agreements, the term "change in control" generally includes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>the
acquisition by another person of beneficial ownership of 40% or more of our Common Stock;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
proxy contest that results in the replacement of a majority of the members of our Board;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>a
merger after which our shareholders own less than 60% of the surviving corporation's stock; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>approval
by our shareholders of a complete liquidation or dissolution of our Company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
protect our business and goodwill, for a period of 12&nbsp;months after the termination of an executive's employment with us, each executive has agreed that he or she will
not: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>engage
in any activity in material competition with the business in which we engaged while the executive was employed by us;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>directly
or indirectly recruit or solicit any person who is then our employee or was our employee at any time within six months prior to such solicitation; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>solicit,
divert or take away, or attempt to divert or to take away, the business or patronage of any of our clients or customers, or prospective clients or
customers. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
severance benefits that executives may be entitled to receive under these agreements and other benefits that the executives are entitled to receive under other plans may constitute
parachute payments that are subject to the "golden parachute" rules of Section&nbsp;280G of the Code and the excise tax of Code Section&nbsp;4999. If these payments are determined to be parachute
payments, as calculated by our independent registered public accounting firm, the parachute payments will be reduced if, and only to the extent that, a reduction will allow the executives to receive a
greater net after tax amount than the executives would receive absent a reduction. All severance benefits are also subject to the execution and non-revocation of a general release of claims against
the Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=59,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=556822,FOLIO='54',FILE='DISK108:[20ZAD1.20ZAD13801]DO13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:34' -->
<A NAME="page_do13801_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table below summarizes the hypothetical payments that could have been incurred by us with respect to each of the named executive officers below, assuming that a qualified
termination under the applicable agreement had occurred on December&nbsp;31, 2019 as a result of termination without cause or for good reason during the two-year period immediately following a
change in control. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro-Rata<BR>
Bonus(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefits </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Equity(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$2,049,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$384,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$39,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$9,049,187</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$11,522,103</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,050,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$22,606</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$4,407,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$5,679,842</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$335,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$117,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$26,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$547,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,025,809</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$943,320</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$179,680</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$39,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$2,952,857</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$4,114,873</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$840,021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$160,004</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$13,922</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$2,534,019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$3,547,966</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
payments would be payable to the executive upon a qualified termination under the applicable agreement. The cash severance figure for Mr.&nbsp;Lewis includes
salary for two years plus two times the target bonus. The cash severance figures for Mr.&nbsp;Adsett, Ms.&nbsp;Pellizzari and Ms.&nbsp;Schaeffer include one and one-half times their salary and
one and one-half times their target bonus. The cash severance figure for Mr.&nbsp;Goll includes one year's salary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value used in the table assumes the full target bonus for the year.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value represents the acceleration of all applicable equity awards outstanding as of December&nbsp;31, 2019. The value realized upon the accelerated vesting of
(i)&nbsp;stock options is calculated by multiplying the number of stock options subject to accelerated vesting by the difference between $23.88, the closing price of our Common Stock on
December&nbsp;31, 2019, and the exercise price of the options, and (ii)&nbsp;RSUs is calculated by multiplying the number of shares of RSUs subject to accelerated vesting by $23.88. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the hypothetical payments that could have been incurred by us with respect to each of the named executive officers below assuming that a qualified
termination under the applicable agreement had occurred on December&nbsp;31, 2019 as a result of termination without cause or for good reason prior to the date of a change in control or following
the one- or two-year period, as applicable, after a change in control. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro-Rata<BR>
Bonus(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefits </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Equity(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William H. Lewis</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,345,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$384,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$39,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$2,278,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$4,047,232</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Roger Adsett</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$15,071</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,630,501</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$2,345,572</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Goll</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$167,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$117,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$13,006</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$176,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$474,578</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christine Pellizzari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$449,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$179,680</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$26,011</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,246,972</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,901,863</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>S. Nicole Schaeffer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$400,010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$160,004</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$9,281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,079,287</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$1,648,582</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
payments and other benefits would be payable to the executive upon a qualified termination under the applicable agreement. The cash severance figure for
Mr.&nbsp;Lewis consists of one and one-half times his base salary plus target bonus for one year, while the figures for Mr.&nbsp;Adsett, Ms.&nbsp;Pellizzari and Ms.&nbsp;Schaeffer consist of
their respective base salaries for one year. The cash severance figure for Mr.&nbsp;Goll consists of six months of his base salary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value used in the table assumes the full target bonus for the year. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=60,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=16185,FOLIO='55',FILE='DISK108:[20ZAD1.20ZAD13801]DO13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:34' -->
<A NAME="page_do13801_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
Mr.&nbsp;Lewis, the value represents the acceleration of all time-based vesting equity outstanding as of December&nbsp;31, 2019 granted at least one year
prior to the termination date. For Mr.&nbsp;Adsett, Ms.&nbsp;Pellizzari, Ms.&nbsp;Schaeffer and Mr.&nbsp;Goll, the value represents accelerated vesting of all time-based equity that would have
otherwise vested within 12&nbsp;months following the termination date. The value realized upon the accelerated vesting of (i)&nbsp;stock options is calculated by multiplying the number of stock
options subject to accelerated vesting by the difference between $23.88, the closing price of our Common Stock on December&nbsp;31, 2019, and the exercise price of the options, and (ii)&nbsp;RSUs
is calculated by multiplying the number of shares of RSUs subject to accelerated vesting by $23.88.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do13801_compensation_committee__do102484"> </A>
<A NAME="toc_do13801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is comprised entirely of independent directors, and none of our executive officers served on the Compensation
Committee or on the board of any company that employed any member of our Compensation Committee or our Board during the year ended December&nbsp;31, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do13801_dodd-frank_mandated_ceo_pay_ratio"> </A>
<A NAME="toc_do13801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DODD-FRANK MANDATED CEO PAY RATIO    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As required by Section&nbsp;953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item&nbsp;402(u) of
Regulation&nbsp;S-K, we are providing the following information about the relationship of the median annual total compensation of our employees and the annual total compensation of Mr.&nbsp;Lewis,
our President and CEO. Registrants may identify the median employee once every three years unless there has been a change in their employee population or employee compensation arrangements that the
registrant reasonably believes would result in a significant change in pay ratio disclosure. The pay ratio included in this section is calculated in a manner consistent with Item&nbsp;402(u) of
Regulation&nbsp;S-K. </FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In 2019, we determined the median of the annual total compensation of all employees of our company (other than Mr.&nbsp;Lewis) for 2019 was
$237,800. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> For 2019, the annual total compensation of Mr.&nbsp;Lewis, as reported in the Summary Compensation Table, is $7,175,094. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on this information, the ratio of the median of the annual total compensation of all employees (other than Mr.&nbsp;Lewis) to the annual total compensation of Mr.&nbsp;Lewis
was 1 to 30.17. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
identify the median of the annual total compensation of all of our employees (other than Mr.&nbsp;Lewis), as well as to determine the annual total compensation of our median
employee, we took the following steps: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
determined that, as of December&nbsp;31, 2019, our employee population, excluding Mr.&nbsp;Lewis, consisted of approximately 434 individuals working either at
Insmed Incorporated or one of our consolidated subsidiaries. This population consisted of our full-time, part-time and temporary employees and, as permitted by SEC rules, excluded independent
contractors or similar non-employee workers during 2019. We did not exclude any non-US employees from these calculations.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
identify the "median employee" from our employee population, we compared the sum of each employee's wages, aggregate fair value of equity awards and target cash
bonus for 2019. In doing so, we annualized the compensation of all permanent </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=61,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=389830,FOLIO='56',FILE='DISK108:[20ZAD1.20ZAD13801]DO13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:34' -->
<A NAME="page_do13801_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>employees
who were hired in 2019 but did not work for us the entire fiscal year. The fair value of option awards granted during 2019 was calculated using the Black-Scholes valuation model pursuant to
the assumptions described in Note&nbsp;10, "Stock-Based Compensation" of the consolidated financial statements included in our Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2019. We did not make any cost-of-living adjustments in identifying the median employee.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>After
identifying the median employee, we calculated annual total compensation for the employee using the same methodology we use for our named executive officers,
as set forth in the Summary Compensation Table. This process resulted in a median employee with annual total compensation of $237,800 for 2019. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC's rules for identifying the median employee and calculating the pay ratio based on that employee's annual total compensation allow companies to adopt a variety of methodologies,
to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. As a result, the pay ratios reported by other
companies may not be comparable to our pay ratio, reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions,
estimates and assumptions in calculating their own pay ratios. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do13801_director_compensation"> </A>
<A NAME="toc_do13801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board determines the compensation of our non-employee directors based in part on recommendations made by the Compensation Committee. The
Compensation Committee evaluates the form and amount of compensation for non-employee directors at least annually and recommends changes to our Board when appropriate. Our Board is currently
compensated through a combination of cash retainers and equity awards in the form of RSUs. Our approach to Board compensation is intended to align our non-employee director compensation practices with
the interests of our shareholders. For example, we have share ownership guidelines in place for our non-employee directors, with a target share ownership of three times the amount of each director's
annual retainer that should be achieved within five years after the adoption of the guidelines or first appointment to the Board, whichever is later. As of the Record Date, all of our non-employee
directors who had been on the Board for at least five years exceeded the share ownership guidelines. Mr.&nbsp;Lewis is a director and an executive officer of the Company. He receives no additional
compensation for serving on the Board. Our share ownership guidelines for Mr.&nbsp;Lewis are described under "Compensation Discussion and Analysis&#151;Corporate Governance Perspectives on
our Executive Compensation Program" above. No other director is an employee of the Company. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="do13801_fees_earned_or_paid_in_cash"> </A>
<A NAME="toc_do13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Fees Earned or Paid in Cash    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our non-employee directors are paid quarterly retainer fees for their service on the Board. Our non-employee directors are not compensated for
attending individual meetings of the Board on a per-meeting basis. During 2019, each non-employee director was paid a retainer totaling $50,000 annually. Mr.&nbsp;Brennan, the Lead Independent
Director, was paid an additional retainer totaling
$25,000. The Chair of the Nominations and Governance Committee was paid an additional annual fee of $10,000; the Chair of the Compensation Committee was paid an additional annual fee of $15,000; the
Chair of the Audit Committee was paid an additional annual fee of $20,000; the Chair of the Science and Technology Committee was paid an additional annual fee of $15,000. Annual retainer fees for
non-chair committee members were paid as follows: members of the Nominations and Governance Committee, $5,000; members of the Compensation Committee, $7,500; members of the Audit </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=62,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=417447,FOLIO='57',FILE='DISK108:[20ZAD1.20ZAD13801]DO13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:34' -->
<A NAME="page_do13801_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Committee,
$10,000; and members of the Science and Technology Committee, $7,500. Retainers are paid on a quarterly basis. </FONT></P>


<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="do13801_grant_of_restricted_stock_units"> </A>
<A NAME="toc_do13801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Grant of Restricted Stock Units    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2019, each non-employee director, other than Mr.&nbsp;Hayden and Dr.&nbsp;Desjardins, received an annual equity-based grant with a
grant date value of approximately $200,000 in the form of RSUs. Mr.&nbsp;Hayden resigned from the Board in May 2019 and did not receive an equity-based grant as a result, while
Dr.&nbsp;Desjardins's compensation was prorated to reflect her appointment as of November&nbsp;12, 2019. The RSUs vest on the first anniversary of the date of the award, provided that the director
attends at least 75% of the meetings of the Board during the year in which the award is made. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="do13801_other"> </A>
<A NAME="toc_do13801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Other    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We reimburse all of our directors for expenses incurred in connection with their attendance at Board or committee meetings. We also provide
director and officer insurance for all directors. In 2019, we made a payment to Mr.&nbsp;Hayden in recognition of his service to the Board, as described further below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth a summary of the compensation we paid to our non-employee directors in 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
improve readability, only the columns "Fees Earned or Paid in Cash," "Stock Awards," "All Other Compensation" and "Total" have been included in the table. All other columns have been
removed as there is no reportable information with respect to those compensation items. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="131pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned<BR>
or Paid<BR>
in Cash ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards ($)(1)(2)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation ($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Alfred F. Altomari</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$75,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$275,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth M. Anderson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$55,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$255,000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David R. Brennan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$82,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$282,500</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steinar J. Engelsen, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$72,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$272,500</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarissa Desjardins, Ph.D.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$6,794</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$100,552</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$107,346</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald Hayden</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$27,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$77,500</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leo Lee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$57,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$257,500</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David W.J. McGirr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$70,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$270,000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Melvin Sharoky, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$62,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$262,500</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amounts
in this column reflect grant date fair values of stock awards granted during 2019, calculated in accordance with FASB ASC Topic 718, except the assumption of
forfeitures is not made.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Altomari,
Ms.&nbsp;Anderson, Mr.&nbsp;Brennan, Dr.&nbsp;Engelsen, Mr.&nbsp;Lee, Mr.&nbsp;McGirr, and Dr.&nbsp;Sharoky each received a grant of
6,899 RSUs in May 2019. Dr.&nbsp;Desjardins received a grant of 5,295 RSUs in November 2019. As of December&nbsp;31, 2019, each of our directors held 6,899 RSUs except for Dr.&nbsp;Desjardins,
who held 5,295 RSUs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>No
option awards were granted to our directors in 2019. None of our other non-employee directors held options as of December&nbsp;31, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Fees
earned by Mr.&nbsp;Hayden in 2019 include $50,000 paid in connection with Mr.&nbsp;Hayden's retirement, in recognition of his service to the Board.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Desjardins's
compensation was prorated to reflect her appointment as of November&nbsp;12, 2019.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=63,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=67799,FOLIO='58',FILE='DISK108:[20ZAD1.20ZAD13801]DO13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:34' -->
<A NAME="page_do13801_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do13801_proposal_no._3_ratification_of__pro03758"> </A>
<A NAME="toc_do13801_7"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 3<BR>  <BR>    RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><A NAME="do13801_information_relative_to_ratifi__inf04252"> </A>
<A NAME="toc_do13801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Information Relative to Ratification of the Appointment of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has appointed Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the year ending
December&nbsp;31, 2020. Shareholder ratification of the appointment of our independent registered public accounting firm is not required under Virginia law, our Articles of Incorporation or our
Bylaws. However, the Board is submitting the appointment of Ernst&nbsp;&amp; Young to our shareholders for ratification as a matter of good corporate governance. A representative of Ernst&nbsp;&amp; Young
is expected to attend the Annual Meeting and will have an opportunity to make a statement and respond to appropriate questions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
principal function of Ernst&nbsp;&amp; Young is to audit our consolidated financial statements and attest on the effectiveness of our internal control over financial reporting and, in
connection with these audits, to review certain related filings submitted to the SEC and to conduct limited reviews of the consolidated financial statements included in each of our quarterly reports.
The aggregate fees billed for each of the
last two years for professional services rendered by Ernst&nbsp;&amp; Young, as well as information relating to the Audit Committee's pre-approval policies and procedures, are detailed under "Audit
Committee Report and Independent Auditor Fees." </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="do13801_vote_required_for_approval_of_this_proposal"> </A>
<A NAME="toc_do13801_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Vote Required for Approval of this Proposal    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ratification of the appointment of Ernst&nbsp;&amp; Young as the Company's independent registered public accounting firm for the year ending
December&nbsp;31, 2020 requires the affirmative vote of a majority of the votes properly cast at the Annual Meeting. Abstentions are not considered votes cast and, therefore, will have no effect on
the voting outcome. If your shares are held in street name, your broker or agent has discretionary authority to vote shares held through it in the absence of your instruction regarding how your shares
should be voted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that this proposal is not approved, the Audit Committee plans to consider the vote and the reasons therefore in future decisions on the selection of our independent
registered public accounting firm. Even if the appointment is ratified, the Audit Committee may engage different independent auditors at any time during the year if it determines that such a change
would be in our best interests and those of our shareholders. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="do13801_recommendation"> </A>
<A NAME="toc_do13801_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Recommendation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THE BOARD RECOMMENDS THAT YOU VOTE "FOR" THE RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG AS OUR INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2020.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=64,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=985925,FOLIO='59',FILE='DISK108:[20ZAD1.20ZAD13801]DO13801A.;5',USER='CHE108048',CD='28-MAR-2020;19:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dq13801_1_60"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="PROPOSAL_NO4"></A>PROPOSAL NO. 4  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> AMENDMENT NO. 1 TO THE INSMED INCORPORATED 2019 INCENTIVE PLAN  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Incentive Plan was approved by our shareholders at the 2019 Annual Meeting of Shareholders. The Board of Directors adopted on
March&nbsp;30, 2020, subject to shareholder approval, Amendment No.&nbsp;1 to the 2019 Incentive Plan (the Amendment) to provide for the issuance of 4,500,000 additional shares of Common Stock
under the 2019 Incentive Plan. No other changes to the 2019 Incentive Plan are proposed or recommended. The Amendment is attached hereto as Appendix&nbsp;A. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_background_and_purpose"> </A>
<A NAME="toc_dq13801_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Background and Purpose    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Amendment is not approved, we will have remaining only 736,091 shares available for future grant under the 2019 Incentive Plan (plus any
shares that might be returned to the 2019 Incentive Plan as a result of future cancellations, terminations, expirations, forfeitures and lapses), based on awards outstanding as of the Record Date, and
thereafter we will have limited ability to grant additional equity incentives under the 2019 Incentive Plan. We continue to focus on the successful commercialization of ARIKAYCE in the US for
appropriate patients, are seeking regulatory approvals for ARIKAYCE outside the US, such as in Europe and Japan, and expect to design and conduct a Phase&nbsp;3 program for INS1007 through which we
will seek to confirm the positive results seen in the WILLOW study. We expect these activities to result in continued increases in our employee headcount and to ensure that we have sufficient equity
plan capacity to compensate and incentivize our employees, the Board adopted the Amendment and strongly recommends that our shareholders approve the Amendment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity-based
compensation is a vital part of our compensation program for our employees, including our named executive officers, and our non-employee directors. We believe equity-based
compensation creates an ownership culture that rewards our executives for maximizing shareholder value over time and aligns the interests of our employees and directors with those of our shareholders.
We have traditionally granted stock options to new hires in connection with their commencement of employment and stock options, as well as other forms of equity-based compensation, to key employees as
part of their ongoing compensation packages. In 2018, we began granting RSUs to our employees. We believe that providing these equity awards incentivizes employees, including management, to create
long-term shareholder value and aids in retention efforts, as awards generally vest over a number of years. In addition, we grant RSUs to non-employee directors annually as part of their compensation
for service on the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board currently intends that the 4,500,000 shares requested under the Amendment, in addition to the 736,091 shares available for future grant under the 2019 Incentive Plan (plus any
shares that might be returned to the 2019 Incentive Plan as a result of future cancellations, terminations, expirations, forfeitures and lapses), will be sufficient to fund the Company's annual stock
option and RSU grants to current employees as well as equity grants to new hires for at least the next year, which it believes appropriate taking into account the Company's planned growth. Upon a
review of the remaining shares available for grant under our 2019 Incentive Plan and the anticipated need for future equity award issuances, the Board approved the Amendment and the share pool
authorized for issuance thereunder to ensure that we have sufficient equity plan capacity to continue to provide our eligible employees and directors with appropriate equity-based incentives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=65,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=231594,FOLIO='60',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_key_considerations_for_requesting_additional_shares"> </A>
<A NAME="toc_dq13801_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Key Considerations for Requesting Additional Shares    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In determining the number of shares to be authorized under the 2019 Incentive Plan, as proposed to be amended, the Board considered the
following principal factors: </FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Number of Shares Available for Grant under Existing Plan:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;As of the Record
Date, 736,091 shares remained available for issuance under the 2019 Incentive Plan. There were no shares available to grant under prior incentive plans.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Number of Outstanding Awards Under All Plans:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;As of the Record Date, there
were 13,155,696 outstanding stock options, which had a weighted average exercise price of $17.96 and a weighted average remaining contractual life of 7.30&nbsp;years, and there were 931,384 RSU
awards outstanding.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Burn Rate:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Burn rate measures our usage of shares for our stock plans as a
percentage of our outstanding shares. For 2019, 2018, and 2017, our burn rate was 3.42%, 1.95%, and 2.88%, respectively, resulting in an average annual burn rate of 2.75% over a three-year period. The
rates were calculated by dividing the number of shares subject to awards granted during the year net of forfeitures and cancellations by the weighted average number of shares outstanding during the
year. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_new_plan_benefits"> </A>
<A NAME="toc_dq13801_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


New Plan Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards under the 2019 Incentive Plan, as proposed to be amended, are discretionary and the administrator has not yet determined to whom future
awards will be made and the terms and conditions of such awards. As a result, no information is provided concerning the benefits to be delivered under the plan to any individual or group of
individuals. Information about awards granted to our named executive officers and directors during 2019 can be found under the heading "Compensation Discussion and Analysis&#151;2019 Grants of
Plan-Based Awards" and "Director Compensation&#151;Grant of Restricted Stock Units," respectively. During 2019, awards covering 1,429,355 shares of Common Stock were granted to our executive
officers, awards covering 66,985 shares were granted to our non-employee directors and awards covering 2,447,499 shares were granted to our other employees. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_2019_incentive_plan_summary"> </A>
<A NAME="toc_dq13801_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


2019 Incentive Plan Summary    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of the material features of the 2019 Incentive Plan, as proposed to be amended. The following discussion is
qualified in all respects by reference to the full text of (i)&nbsp;the plan, attached as Exhibit&nbsp;10.5 to the Company's Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2019 and (ii)&nbsp;the Amendment, attached hereto as Appendix&nbsp;A. The term "employees" in the following discussion is used to refer to officers and directors and other
employees of the Company and its affiliates, where applicable. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Purpose and Eligibility  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the 2019 Incentive Plan is to advance the interests of the Company by aligning the individual interests of employees, officers,
non-employee directors and other service providers, in each case who are selected to be participants, with the interests of Company shareholders, and by providing such individuals with an incentive to
continue working toward and contributing to the success and progress of the Company. Employees of the Company and its affiliates, members of the Board, and other non-employee advisors or service
providers are eligible to be considered for the grant of awards </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=66,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=141320,FOLIO='61',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>under
the 2019 Incentive Plan. As of the Record Date, approximately 8 nonemployee directors, 7 executive officers and 432 other employees of the Company were so eligible. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Shares Subject to the 2019 Incentive Plan and to Awards  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Amendment is approved, the maximum number of shares of Common Stock authorized under the 2019 Incentive Plan is 8,000,000, including the
4,500,000 shares that would be added to the 2019 Incentive Plan under the Amendment, plus any shares of Common Stock subject to outstanding awards under the 2017 Incentive Plan, the 2015 Incentive
Plan or the 2013 Incentive Plan, as of the effective date of the 2019 Incentive Plan, that, after such date, are canceled, terminate unearned, expire, are forfeited or lapse for any reason or are
settled in cash without the delivery of shares. Shares of Common Stock issued under the 2019 Incentive Plan may either be authorized and unissued shares or previously issued shares acquired by the
Company, including shares purchased in the open market. The number of shares of Common Stock available for issuance under the 2019 Incentive Plan will be reduced by (i)&nbsp;one share for each share
of Common Stock subject to a stock option or stock appreciation right (SAR) with an exercise or strike price of at least 100% of the fair market value of the underlying Common Stock on the date of
grant, and (ii)&nbsp;1.25 shares for each share of Common Stock subject to a full value award (</FONT><FONT SIZE=2><I>e.g</I></FONT><FONT SIZE=2>., restricted stock or RSUs). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of Common Stock available for issuance under the 2019 Incentive Plan will be increased to the extent that an award under the 2019 Incentive Plan (or any award under
the 2017 Incentive Plan, the 2015 Incentive Plan or the 2013 Incentive Plan that is outstanding as of the effective date of the 2019 Incentive Plan) is canceled, terminates unearned, expires, is
forfeited, or lapses for any reason, or such an award is settled in cash without the delivery of shares to a participant, such that any shares of Common Stock subject to any such award will again be
available for the grant of an award pursuant to the 2019 Incentive Plan. Shares will not again be available for issuance under the plan if they are tendered in payment of an option exercise price or
delivered or withheld to satisfy any tax withholding obligation. Additionally, shares covered by a stock-settled SAR that are not issued upon full settlement will also not again be available for
issuance under the plan. The payment of dividend equivalents in cash in conjunction with any outstanding awards under the 2019 Incentive Plan will not be counted against the shares available for
issuance under the 2019 Incentive Plan. Any shares of Common Stock with respect to awards issued under the 2019 Incentive Plan (or an award issued under the 2017 Incentive Plan, the 2015 Incentive
Plan or the 2013 Incentive Plan) that again become available for future grants will be added back to the share pool (i)&nbsp;as one share for each share of Common Stock subject to a stock option or
SAR, and (ii)&nbsp;as 1.25 shares for each share of Common Stock subject to a full value award, provided, that awards issued under the 2017 Incentive Plan, the 2015 Incentive Plan or the 2013
Incentive Plan will be considered full-value awards if they would have
been full-value awards if issued under the 2019 Incentive Plan and added back to the share pool as one share in all other cases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Amendment is approved, the aggregate number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options (ISOs) granted under the 2019
Incentive Plan will not exceed 8,000,000, including the 4,500,000 that are added to the 2019 Incentive Plan under the Amendment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards
granted or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, by a
company acquired by the Company or with which the Company combines will not reduce the shares authorized for issuance under the 2019 Incentive Plan. In addition, in the event that a company acquired
by the Company, or with which the Company combines, has shares available under a shareholder-approved, pre-existing equity compensation plan, not adopted in contemplation of such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=67,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=221642,FOLIO='62',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>acquisition
or combination, the shares available for grant pursuant to such pre-existing plan (as adjusted in connection with such acquisition or combination) may be used for awards under the 2019
Incentive Plan and will not reduce the shares authorized for issuance under the 2019 Incentive Plan, provided that the awards using such available shares will not be made after the last day awards
could have been made under the terms of the pre-existing plan absent the acquisition or combination and will not be granted to individuals who were employed by the Company or its subsidiaries at the
time the acquisition or combination was consummated. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Administration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Incentive Plan is administered by the Compensation Committee, or, in the absence of the Compensation Committee, the Board itself. Any
power of the administrator may also be exercised by the Board. To the extent that any permitted action taken by the Board conflicts with action taken by the administrator, the Board action will
control. The Compensation Committee may by resolution authorize one or more officers of the Company to perform any or all things that the administrator is authorized and empowered to do or perform
under the 2019 Incentive Plan; provided, however, that such authorization must specify the total number of awards (if any) such officer or officers may award pursuant to such delegated authority, and
provided further that in no event may an officer of the Company be delegated the authority to grant awards to, or amend awards held by, the individuals who are subject to Section&nbsp;16 of the
Exchange Act or report directly to such officer. Additionally, no such officer may grant any awards to himself or herself. The administrator may also
delegate any or all aspects of the day-to-day administration of the 2019 Incentive Plan to one or more officers or employees of the Company or any subsidiary, and/or to one or more agents. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the provisions of the 2019 Incentive Plan, the administrator has the authority to select the participants to receive awards and to grant such awards and to determine the
terms and conditions of awards and the number of shares to be issued pursuant thereto, including conditioning the receipt or vesting of awards upon achievement of performance conditions. All
decisions, determinations and interpretations by the administrator are final and binding on all participants and all other persons holding or claiming rights under the plan or any award granted
thereunder. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Awards  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Incentive Plan authorizes the grant of awards of stock options, SARs, restricted stock and RSUs. Any award may be subject to
performance conditions as determined by the administrator. The terms of awards will be determined by the administrator and set forth in an award agreement. The terms of any awards may vary among
participants. Subject to the provisions of the 2019 Incentive Plan, the administrator will specify before, at or after the time of grant the provisions governing the effects upon an award of a
separation from service or other termination of service. Unless otherwise provided in an award agreement or another agreement, including an employment agreement, unvested awards will be forfeited
immediately if a participant terminates his or her employment with the Company for any reason. Participants will not have any rights as a shareholder with respect to shares covered by an award until
the date the participant becomes the holder of record of such shares. Awards granted under the plan are subject to a minimum vesting period of one year, except in the case of substitute awards issued
in connection with acquisitions or awards that vest in connection with certain acceleration events. Additionally, the administrator has the authority to grant awards covering up to 5% of the plan's
share pool that are not subject to this minimum vesting requirement. With respect to awards that entitle a participant to dividends or dividend equivalents, in no event may such dividends or dividend
equivalents, if any, be paid to the participant prior to the vesting of the portion of the award to which such dividends or dividend equivalents relate. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=68,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=537325,FOLIO='63',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Options.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock options granted under the 2019 Incentive Plan may be either
non-qualified stock options or ISOs under Section&nbsp;422 of the
Code. The exercise price of any stock option granted, other than substitute awards, may not be less than 100% of the fair market value of a share of our Common Stock on the date of grant (provided
that the exercise price of an ISO granted to a participant who owns stock possessing more than 10&nbsp;percent of the combined voting power of all classes of the
Company's stock (a 10% Shareholder) will be at least 110% of the fair market value on such date). The option exercise price is payable in cash or such other method as determined by the administrator,
including an irrevocable commitment by a broker to pay over such amount from a sale of the shares issuable under an option, the delivery of previously owned shares of Common Stock or withholding of
shares of Common Stock deliverable upon exercise. Vesting may be based on continued employment, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance
conditions. The term of a stock option will in no event be greater than ten years (or, for an ISO granted to a 10% Shareholder, five years), provided that the term of a non-qualified stock option will
be automatically extended if, at the time of its scheduled expiration, the participant holding such option is prohibited by law or by the Company's insider trading policy from exercising such option.
Any such extension will expire on the 30<SUP>th</SUP>&nbsp;day following the date such prohibition no longer applies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
than in connection with a change in the Company's capitalization, at any time when the exercise price of an option is above the fair market value of a share of Common Stock, the
Company may not, without shareholder approval: (i)&nbsp;reduce the exercise price of such option, (ii)&nbsp;exchange such option for cash, another award or a new option or SAR with a lower
exercise price or (iii)&nbsp;otherwise reprice such option. Options may not be granted under the 2019 Incentive Plan in consideration for, and will not be conditioned upon the delivery of shares to
the Company in payment of the exercise price and/or tax withholding obligation under, any other option. Holders of a stock option will have no voting rights or rights to receive dividends or dividend
equivalents with respect to their stock option until they become the holder of record of the underlying shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the Record Date, the fair market value of a share of our Common Stock, determined by the last reported sale price per share on that date as quoted on the Nasdaq Global Select
Market, was $14.39. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock and Restricted Stock Units.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The grant, issuance, retention, vesting and/or
settlement of any restricted stock or RSU award will
occur at such time and be subject to such terms and conditions as determined by the administrator or under conditions established by the administrator, which may include conditions based on continued
employment, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance conditions. Participants who receive restricted stock will be entitled to receive all
dividends and other distributions paid with respect to those shares unless determined otherwise by the administrator. The administrator will determine whether such dividends or distributions will be
automatically reinvested in additional restricted stock and/or subject to the same restrictions as the underlying restricted stock, or whether such dividends or distributions will be paid in cash.
Unless otherwise set forth in the award agreement, prior to the time shares are issued to a participant under an RSU, the Company will pay or accrue dividend equivalents on each date that dividends
are paid, and such dividend equivalents will be paid at the time specified in the award agreement. As described above, no dividends or dividend equivalents may be paid with respect to an award of
restricted stock or RSUs prior to the vesting of the portion of the award to which such dividends or dividend equivalents relate. Unless otherwise determined by the administrator, participants holding
shares of restricted stock may exercise full voting rights with respect to those shares during the period of restriction. Participants holding RSUs will not have voting rights with respect to the
underlying shares until they become the holder of record of the underlying shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=69,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=128660,FOLIO='64',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A SAR entitles the participant, upon settlement, to receive a
payment based on the excess of the aggregate market price
of a specified number of shares of Common Stock at the time of the exercise over the exercise price of the right. SARs may be granted on a stand-alone basis or in tandem with a related stock option.
The exercise price may not be less than the fair market value of a share of our Common Stock on the date of grant. A SAR granted in tandem with a stock option will have an exercise price equal to the
exercise price of the stock option to which it relates. The administrator will determine the vesting requirements and the payment and other terms of a SAR, including the effect of termination of
service of a participant. Vesting may be based on continued employment, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance conditions. Other than in
connection with a change in the Company's capitalization, at any time when the exercise price of a SAR is above the fair market value of a share of Common Stock, the Company may not, without
shareholder approval: (i)&nbsp;reduce the exercise price of such SAR, (ii)&nbsp;exchange such SAR for cash, another award or a new option or SAR with a lower exercise price or
(iii)&nbsp;otherwise reprice such SAR. Holders of a SAR will have no voting rights or rights to receive dividends or dividend equivalents with respect to their SAR until they become the holder of
record of the underlying shares. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Adjustment and Change in Control  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number and kind of shares of Common Stock available for issuance (including under any awards then outstanding), and the number and kind of
shares of Common Stock subject to the limits set forth in the 2019 Incentive Plan, will be equitably adjusted by the administrator to reflect any reorganization, reclassification, combination of
shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that
affects the number or kind of shares of Common Stock outstanding. Such adjustment may be designed to comply with Section&nbsp;424 of the Code or may be designed to treat the shares available under
the 2019 Incentive Plan and subject to awards as if they were all outstanding on the record date for such event or transaction or to increase the number of such shares to reflect a deemed reinvestment
in shares of the amount distributed to the Company's security holders. The terms of any outstanding award will also be equitably adjusted by the administrator as to price, number or kind of shares
subject to such award, vesting, and other terms to reflect the foregoing events, which adjustments need not be uniform as between different awards or different types of awards. No fractional shares of
Common Stock will be issued pursuant to such an adjustment. In the event there is any other change in the number or kind of outstanding shares of Common Stock, or any stock or other securities into
which such Common Stock will have been changed, or for which it will have been exchanged, by reason of a change in control, other merger, consolidation or otherwise, then the administrator will
determine the appropriate and equitable adjustment to be effected, which
adjustments need not be uniform between different awards or different types of awards. In addition, in the event of such change, the administrator may accelerate the time or times at which any award
may be exercised, consistent with and as otherwise permitted under Section&nbsp;409A of the Code, and may provide for cancellation of such accelerated awards that are not exercised within a time
prescribed by the administrator in its sole discretion. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise expressly provided for in an award agreement or another agreement, including an employment agreement, in the event of a change in control, unless provision is made in
connection with the change in control for (i)&nbsp;assumption of awards previously granted or (ii)&nbsp;substitution for such awards, (A)&nbsp;the administrator will make an adjustment to any or
all awards as the administrator deems appropriate to reflect such change in control or (B)&nbsp;(1) in the case of an option or SAR, the participant will have the ability to exercise such option or
SAR, including any portion of the option or SAR not previously exercisable, and the unexercised portion of such option or SAR will be cancelled upon on the consummation of the change in control;
(2)&nbsp;in the case of an award </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=70,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=40159,FOLIO='65',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>subject
to performance conditions, the participant will have the right to receive a payment based on performance through a date determined by the administrator prior to the change in control (unless
such performance cannot be determined, in which case the participant will have the right to receive a payment equal to the target amount payable); and (3)&nbsp;in the case of outstanding restricted
stock and/or RSUs not subject to performance conditions, all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable to, such award will
immediately lapse. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise expressly provided for in an award agreement or another agreement, including an employment agreement, or under the terms of a transaction constituting a change in
control, the following will occur upon a participant's involuntary termination of employment or other service within 24&nbsp;months following a change in control, provided that such termination does
not result from disability, cause or gross misconduct: (i)&nbsp;in the case of an option or SAR, the participant will have the ability to exercise such option or SAR, including any portion of the
option or SAR not previously exercisable, and the option or SAR will remain exercisable for a period of three years following such termination (or until expiration, if earlier), (ii)&nbsp;in the
case of an award subject to performance conditions, the participant will have the right to receive a payment based on performance through a date determined by the administrator prior to the change in
control (unless such performance cannot be determined, in which case the participant will have the right to receive a payment equal to the target amount payable), and (iii)&nbsp;in the case of
outstanding restricted stock and/or RSUs not subject to performance conditions, all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable
to, such award will immediately lapse. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Transferability  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No award may be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated other than by will or the laws of
descent and distribution, and each option or SAR is exercisable only by the participant during his or her lifetime. Notwithstanding the foregoing, outstanding options may be exercised following the
participant's death by the participant's beneficiaries or as permitted by the administrator. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Duration of the 2019 Incentive Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards may not be granted under the 2019 Incentive Plan after the tenth anniversary of the adoption by the Board of the 2019 Incentive Plan.
Notwithstanding the foregoing, the 2019 Incentive Plan may be terminated at such earlier time as the Board may determine. Termination of the 2019 Incentive Plan will not affect the rights and
obligations of the participants and the Company arising under awards granted prior to such termination. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Amendment and Termination  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to limitations imposed by law, the Board may amend or terminate the 2019 Incentive Plan at any time and the administrator may amend or
alter any agreement or other document evidencing an award made under the 2019 Incentive Plan. However, no such amendment may deprive the recipient of an award previously granted under the 2019
Incentive Plan of any rights thereunder without his or her consent, unless the administrator determines that the amendment (i)&nbsp;is required or advisable to satisfy any law or regulation or avoid
adverse financial accounting consequences, or (ii)&nbsp;is not reasonably likely to significantly diminish the benefits provided under the award, or that any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=71,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=18788,FOLIO='66',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_67"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>diminishment
has been adequately compensated. Notwithstanding the foregoing, no such amendment shall, without the approval of the shareholders of the Company: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>increase
the maximum number of shares of Common Stock for which awards may be granted under the 2019 Incentive Plan;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>reduce
the price at which options may be granted below the price provided for in the 2019 Incentive Plan;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>reprice
outstanding options or SARs;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>extend
the term of the 2019 Incentive Plan;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>change
the class of persons eligible to be participants; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(f)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>otherwise
amend the 2019 Incentive Plan in any manner requiring shareholder approval by law or the rules of any stock exchange or market or quotation system on
which the Common Stock is traded, listed or quoted. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Recoupment Policy  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The administrator has the authority to cause a participant or an award under the plan to be subject to the Company's recovery, recoupment,
clawback and/or other forfeiture policies, as maintained by the Company from time to time. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_federal_income_tax_treatment"> </A>
<A NAME="toc_dq13801_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Federal Income Tax Treatment    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion summarizes the material U.S. federal income tax consequences to the Company and the participants in connection with
the 2019 Incentive Plan under existing applicable provisions of the Code and the accompanying regulations. The discussion is general in nature and does not address issues relating to the income tax
circumstances of any individual participant. The discussion is based on federal income tax laws in effect on the date of this Proxy Statement and is, therefore, subject to possible future changes in
the law. The discussion does not address the consequences of state, local or foreign tax laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonqualified Options</I></FONT><FONT SIZE=2>&#151;An employee will not recognize any income upon receipt of a nonqualified stock option, and the
Company will not be entitled to a
deduction for federal income tax purposes at the time of grant. Ordinary income will be realized by the holder at the time the nonqualified stock option is exercised and the shares are transferred to
the employee. The amount of such taxable income, in the case of a nonqualified stock option, will be the excess, if any, of the fair market value of the shares on the date of exercise over the
exercise price. The Company will generally be entitled to a tax deduction in an amount equal to the ordinary income that an employee recognizes upon exercise. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive Stock Options</I></FONT><FONT SIZE=2>&#151;An employee who receives an ISO will not recognize any income for federal income tax purposes
upon receipt of the ISO, and
the Company will not realize a deduction for federal income tax purposes. The holder generally will not be taxed upon exercise, but the excess, if any, of the fair market value of the stock on the
date of exercise over the option exercise price may subject the holder to the alternative minimum tax. If the holder does not dispose of the ISO shares within two years from the date the option was
granted or within one year after the shares were transferred to him on exercise of the option, then that portion of the gain on the sale of the shares that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=72,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=69835,FOLIO='67',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>is
equal to the difference between the sales price and the option exercise price will be treated as a long-term capital gain. The Company will not be entitled to a deduction either at the time the
employee exercises the ISO or subsequently sells the ISO shares. However, if the employee sells the ISO shares within two years after the date the ISO is granted or within one year after the date the
ISO is exercised, then the sale is considered a disqualifying sale, and the spread on exercise will be taxed as ordinary income. The balance of the gain will be treated as long- or short-term capital
gain depending on the length of time the employee held the stock. If the shares decline in value after the date of exercise, the compensation income will be limited to the difference between the sale
price and the amount paid for the shares. The tax will be imposed in the year the disqualifying sale is made. The Company will be entitled to a deduction equal to the ordinary income recognized by the
employee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to both nonqualified stock options and ISOs, special rules apply if an employee uses shares already held by the employee to pay the exercise price or if the shares received
upon exercise of the option are subject to a substantial risk of forfeiture by the employee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock</I></FONT><FONT SIZE=2>&#151;Employees receiving restricted stock will not recognize any income upon receipt of the restricted
stock. Ordinary income will be
realized by the holder at the time that the restrictions on transfer are removed or expire. The amount of ordinary income will be equal to the fair market value of the shares on the date that the
restrictions on transfer are removed or expire. The Company will be entitled to a deduction at the same time and in the same amount as the ordinary income the employee is deemed to have realized.
However, no later than 30&nbsp;days after an employee receives the restricted stock, the employee may elect to recognize taxable ordinary income in an amount equal to the fair market value of the
shares at the time of receipt. Provided that the election is made in a timely manner, when the restrictions on the shares lapse, the employee will not recognize any additional income. If the employee
forfeits the shares to the Company, the employee may not claim a deduction with respect to the income recognized as a result of the election. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
when an employee disposes of shares acquired under the 2019 Incentive Plan, the difference between the sales price and his or her basis in such shares will be treated as
long- or short-term capital gain or loss depending upon the holding period for the shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units</I></FONT><FONT SIZE=2>&#151;Employees who are granted RSUs do not recognize income at the time of the grant. When the award
vests or is paid, participants
recognize ordinary income in an amount equal to the fair market value of the units at such time, and the Company will receive a corresponding tax deduction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights</I></FONT><FONT SIZE=2>&#151;Upon exercise of a SAR, an employee will recognize taxable income in the amount of the cash
received. An employee who
receives unrestricted shares upon exercise of a SAR will recognize ordinary income in the year of exercise equal to the fair market value of the shares received. In either such case, the Company will
be entitled to an income tax deduction in the amount of such income recognized by the employee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential Limitation on Deductions</I></FONT><FONT SIZE=2>&#151;Section&nbsp;162(m) of the Code places a limit of $1,000,000 on the amount the
Company may deduct in any one
year for compensation paid to each of the Company's "covered employees." The definition of "covered employee" includes anyone who was the Company's CEO or CFO at any time during the year, as well as
the Company's three other most highly-compensated executive officers during the year. Any individual who is or became a covered employee after December&nbsp;31, 2016 will always be treated as a
covered employee, even after termination of employment. Accordingly, awards granted to the Company's covered employees under the 2019 Incentive Plan may not be fully deductible. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=73,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=942434,FOLIO='68',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal Income Tax Consequences to the Company</I></FONT><FONT SIZE=2>&#151;To the extent that a recipient recognizes ordinary income in the
circumstances described above, the
Company will be entitled to a corresponding deduction provided that, among other things, the income meets the test of reasonableness, is an ordinary and necessary business expense, is not an "excess
parachute payment" within the meaning of Section&nbsp;280G of the Code and is not disallowed by the $1,000,000 limitation on certain executive compensation under Section&nbsp;162(m). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding</I></FONT><FONT SIZE=2>&#151;To the extent required by applicable federal, state, local or foreign law or practice, a participant
will be required to satisfy, in
a manner satisfactory to the Company, any withholding tax obligations that arise by reason of the award. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;409A</I></FONT><FONT SIZE=2>&#151;Section&nbsp;409A of the Code applies to any awards under the 2019 Incentive Plan that are deemed to
be deferred compensation.
If the requirements of Section&nbsp;409A of the Code
are not met, the recipient may be required to include deferred compensation in taxable income, and additional taxes and interest may be assessed on such amounts. If any awards are subject to
Section&nbsp;409A of the Code, we intend to have the awards comply with Section&nbsp;409A of the Code. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_equity_compensation_plan_information"> </A>
<A NAME="toc_dq13801_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Equity Compensation Plan Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2019, we made stock-based awards from our 2019 Incentive Plan and our 2017 Incentive Plan, and have outstanding grants under our 2015
Incentive Plan, 2013 Incentive Plan and 2000 Stock Incentive Plan (together with the 2019 Incentive Plan, 2017 Incentive Plan, 2015 Incentive Plan and the 2013 Incentive Plan, the Plans). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2019 Incentive Plan was adopted by the Board and approved by our shareholders on May&nbsp;16, 2019. Under the terms of the 2019 Incentive Plan, we are authorized to grant a
variety of incentive awards based on our Common Stock, including stock options (both incentive stock options and non-qualified stock options), performance options/shares and other stock awards, such
as RSUs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents information as of December&nbsp;31, 2019, with respect to the Plans. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="91pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan Category

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
to be Issued<BR>
Upon Exercise<BR>
of Outstanding<BR>
Options and Rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted Average<BR>
Exercise Price<BR>
of Outstanding<BR>
Options and Rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Remaining Available<BR>
for Future Issuance<BR>
Under Equity<BR>
Compensation Plans </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;border-bottom:solid #000000 1.0pt;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Compensation Plans Approved by Shareholders:</FONT>&nbsp;</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019 Incentive Plan(1)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>106,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>$19.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,868,698</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017 Incentive Plan(2)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,345,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>$18.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015 Incentive Plan(3)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,481,442</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>$15.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2013 Stock Incentive Plan(4)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,496,326</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>$14.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2000 Stock Incentive Plan(5)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>677,467</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>$3.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;border-bottom:solid #000000 1.0pt;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Compensation Plans Not Approved by Shareholders:</FONT>&nbsp;</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Individual Compensation Arrangements(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>887,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>$21.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,993,768</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,868,698 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD VALIGN="TOP" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="TOP" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
shares of Common Stock issuable upon the exercise of outstanding stock options and vesting of outstanding RSUs granted under our 2019 Incentive Plan. </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=74,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=622763,FOLIO='69',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
shares of Common Stock issuable upon the exercise of outstanding stock options and vesting of outstanding RSUs granted under our 2017 Incentive Plan. To
the extent that awards granted under the 2017 Incentive Plan terminate unearned, expire, or are canceled, forfeited, lapse for any reason, or are settled in cash without the delivery of shares, the
shares of Common Stock underlying such grants will again become available for purposes of the 2019 Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
shares of Common Stock issuable upon the exercise of outstanding stock options granted under our 2015 Incentive Plan. To the extent that awards granted
under the 2015 Incentive Plan terminate unearned, expire, or are canceled, forfeited, lapse for any reason, or are settled in cash without the delivery of shares, the shares of Common Stock underlying
such grants will again become available for purposes of the 2019 Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
shares of Common Stock issuable upon the exercise of outstanding stock options granted under our 2013 Stock Incentive Plan. To the extent that awards
granted under the 2013 Incentive Plan terminate unearned, expire, or are canceled or, forfeited, lapse for any reason, or are settled in cash without the delivery of shares, the shares of Common Stock
underlying such grants will again become available for purposes of the 2019 Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
shares of Common Stock issuable upon the exercise of outstanding stock options granted under the 2000 Stock Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
outstanding inducement grants of stock options we made in connection with the hiring of various employees. The vesting schedule for the shares of Common
Stock subject to these options is as follows: 25% on the first anniversary of the date of grant and 12.5% of the shares vesting on each six-month anniversary thereafter until the fourth anniversary of
the date of grant.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_vote_required_for_approval_of_this_proposal"> </A>
<A NAME="toc_dq13801_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Vote Required for Approval of this Proposal    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval of the Amendment requires the affirmative vote of a majority of the votes cast at the Annual Meeting. Abstentions and broker non-votes
will not have an effect on the outcome of this proposal. </FONT></P>

<P style="font-family:times;;margin-left:17.0pt;text-indent:-17.0pt;"><FONT SIZE=2><A NAME="dq13801_recommendation"> </A>
<A NAME="toc_dq13801_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:17.0pt;text-indent:-17.0pt;" -->


Recommendation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>THE BOARD RECOMMENDS THAT YOU VOTE "FOR" THE APPROVAL OF THE AMENDMENT TO THE 2019 INCENTIVE
PLAN.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=75,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=274211,FOLIO='70',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<A NAME="page_dq13801_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dq13801_proposals_for_2021_annual_meeting"> </A>
<A NAME="toc_dq13801_9"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSALS FOR 2021 ANNUAL MEETING    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder proposals intended for inclusion in our proxy statement for the 2021 Annual Meeting of Shareholders must be received at our offices
no later than the close of business on December&nbsp;1, 2020. All such proposals must comply with Rule&nbsp;14a-8 under the Exchange Act and must
be submitted to the Corporate Secretary, Insmed Incorporated, 700 US Highway 202/206, Bridgewater, New Jersey 08807. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our Bylaws, any shareholder (as defined in our Bylaws) who wishes to present other business or nominate a director candidate at the 2021 Annual Meeting of Shareholders must give
timely written notice of any such business or nomination to our Corporate Secretary in advance of the meeting. Such written notice must comply with the requirements in our Bylaws and must be given,
either by personal delivery or by United States registered or certified mail, postage prepaid, to our Corporate Secretary at the address given above no later than 120&nbsp;days nor more than
150&nbsp;days before the anniversary of the immediately preceding year's annual meeting. Accordingly, for the 2021 Annual Meeting of Shareholders, our Corporate Secretary must receive such written
notice no earlier than December&nbsp;13, 2020 and no later than January&nbsp;12, 2021. If the date of the 2021 Annual Meeting of Shareholders is more than 30&nbsp;days before or more than
60&nbsp;days after May&nbsp;12, 2021 (the anniversary of this year's Annual Meeting), then the written notice must be received no later than the 120th&nbsp;day prior to such Annual Meeting or,
if later, the 10th&nbsp;day following the day on which public disclosure of the date of such Annual Meeting was first made. If a shareholder fails to meet these requirements or fails to satisfy the
requirements of Rule&nbsp;14a-4 under the Exchange Act, the named proxies may exercise discretionary voting authority under proxies that we solicit to vote on any such business or nomination in
accordance with their best judgment. Our Bylaws are available on our website at www.insmed.com under the heading "Investor Relations&#151;Corporate Governance" or by submitting a written
request to the Corporate Secretary, Insmed Incorporated, 700 US Highway 202/206, Bridgewater, New Jersey 08807. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dq13801_annual_report_on_form_10-k"> </A>
<A NAME="toc_dq13801_10"> </A>
<BR></FONT><FONT SIZE=2><B>  ANNUAL REPORT ON FORM 10-K    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>We will provide without charge to each person to whom this Proxy Statement has been made available on the written
request of such person, a printed copy of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, including the financial statements and financial statement schedules.
Requests should be directed to Ms.&nbsp;Christine Pellizzari, Corporate Secretary, Insmed Incorporated, 700 US Highway 202/206, Bridgewater, New Jersey, 08807, (908)&nbsp;977-9900. In connection
with any such request, we will provide a list of exhibits to the Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, and will provide copies of any such exhibit upon the
payment of a reasonable fee.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dq13801_separate_copies_for_beneficial_holders"> </A>
<A NAME="toc_dq13801_11"> </A>
<BR></FONT><FONT SIZE=2><B>  SEPARATE COPIES FOR BENEFICIAL HOLDERS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Institutions that hold shares in street name for two or more beneficial owners with the same address are permitted to deliver a single set of
proxy materials to that address. Only one set of proxy materials will be delivered to such address unless they receive contrary directions from one or more of such beneficial owners. Any such
beneficial owner can request a separate copy of these
proxy materials by contacting our Corporate Secretary as described above, and we will promptly provide a separate copy. If you are the beneficial owner, but not the record holder, of the Company's
shares and wish to receive only one copy of our proxy materials in the future, you will need to contact your broker, bank or other agent to request that only a single copy of each document be mailed
to all shareholders at the shared address in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=76,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=304201,FOLIO='71',FILE='DISK108:[20ZAD1.20ZAD13801]DQ13801A.;7',USER='CHE108062',CD='28-MAR-2020;18:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_la13801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A NAME="la13801_appendix_a"> </A>
<A NAME="toc_la13801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix&nbsp;A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="la13801_amendment_no._1_to_the_insmed___ame02168"> </A>
<A NAME="toc_la13801_2"> </A></FONT> <FONT SIZE=2><B>  AMENDMENT NO. 1<BR>  TO THE<BR>  INSMED INCORPORATED 2019 INCENTIVE PLAN    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>March&nbsp;31,
2020 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Insmed Incorporated (the "</FONT><FONT SIZE=2><I>Company</I></FONT><FONT SIZE=2>") sponsors and maintains the Insmed Incorporated 2019 Incentive Plan (the
"</FONT><FONT SIZE=2><I>Plan</I></FONT><FONT SIZE=2>"); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Section&nbsp;18 of the Plan reserves to the Board of Directors of the Company (the "</FONT><FONT SIZE=2><I>Board</I></FONT><FONT SIZE=2>") the right to amend the Plan from
time to time; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
the Board desires to amend the Plan in the manner hereinafter provided, subject to approval by the Company's shareholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, the Plan is amended as follows, effective as of the date of approval by the Company's shareholders: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
reference to "3,500,000" in Section&nbsp;5(a) of the Plan is hereby amended and replaced with "8,000,000".
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
reference to "3,500,000" in Section&nbsp;5(c) of the Plan is hereby amended and replaced with "8,000,000".
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
Amendment shall be and is hereby incorporated in, and forms&nbsp;a part of, the Plan. All other terms and provisions of the Plan shall remain unchanged except
as specifically modified by this Amendment. The Plan, as amended by this Amendment, is hereby ratified and confirmed. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>[</FONT><FONT
SIZE=2><I>Signature page follows</I></FONT><FONT SIZE=2>] </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=77,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=366302,FOLIO='A-1',FILE='DISK108:[20ZAD1.20ZAD13801]LA13801A.;6',USER='CHE108062',CD='28-MAR-2020;19:16' -->
<A NAME="page_la13801_1_2"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg13801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the undersigned officer hereby certifies that the foregoing amendment to the Plan was duly adopted by the Board. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>INSMED INCORPORATED</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;CHRISTINE PELLIZZARI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Name: Christine Pellizzari<BR>
Title: Chief Legal Officer<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=78,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=712302,FOLIO='A-2',FILE='DISK108:[20ZAD1.20ZAD13801]LA13801A.;6',USER='CHE108062',CD='28-MAR-2020;19:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET Before the Annual Meeting - www.proxyvote.com Use the Internet to   transmit your voting instructions and for electronic delivery of information   through 11:59 P.M. Eastern Time on Monday, May 11, 2020. Have your proxy card   in hand when you access the web site and follow the instructions to obtain   your records and to create an electronic voting instruction form. During the   Annual Meeting - www.virtualshareholdermeeting.com/INSM2020 You may attend   the meeting via the Internet and vote during the meeting. Have your proxy   card in hand when you access the web site and follow the instructions. VOTE   BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your   voting instructions through 11:59 P.M. Eastern Time on Monday, May 11, 2020.   Have your proxy card in hand when you call and then follow the instructions.   VOTE BY MAIL Mark, sign and date your proxy card and return it in the   postage-paid envelope we have provided or return it to Vote Processing, c/o   Broadridge, 51 Mercedes Way, Edgewood, NY 11717. Votes must be received by   11:59 P.M. Eastern Time on Monday, May 11, 2020. ELECTRONIC DELIVERY OF   FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our   company in mailing proxy materials, you can consent to receiving all future   proxy statements, proxy cards and annual reports electronically via e-mail or   the Internet. To sign up for electronic delivery, please follow the   instructions above to vote using the Internet and, when prompted, indicate   that you agree to receive or access proxy materials electronically in future   years. C/O BROADRIDGE P.O. BOX 1342 BRENTWOOD, NY 11717 TO VOTE, MARK BLOCKS   BELOW IN BLUE OR BLACK INK AS FOLLOWS: D00234-P36864 KEEP THIS PORTION FOR   YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID   ONLY WHEN SIGNED AND DATED. INSMED INCORPORATED For Withhold For All   AllAllExcept To withhold authority to vote for any individual nominee(s),   mark &quot;For All Except&quot; and write the number(s) of the nominee(s) on   the line below. The Board of Directors recommends you vote FOR Item 1: !! !   1. Election of Class II Directors Nominees: 01) 02) 03) Clarissa Desjardins,   Ph.D. David W.J. McGirr Elizabeth McKee Anderson For Against Abstain The   Board of Directors recommends you vote FOR Items 2, 3 and 4: ! ! ! ! ! ! ! !   ! 2. Advisory vote on the 2019 compensation of our named executive officers.   3. Ratification of the appointment of Ernst &amp; Young LLP as the   independent registered public accounting firm for Insmed Incorporated for the   year ending December 31, 2020. Approval of an amendment to the Insmed   Incorporated 2019 Incentive Plan. 4. Other business may be considered as may   properly come before the meeting or any adjournment or postponement thereof.   Please sign exactly as your name(s) appear(s) hereon. When signing as   attorney, executor, administrator, or other fiduciary, please give full title   as such. Joint owners should each sign personally. All holders must sign. If   a corporation or partnership, please sign in full corporate or partnership   name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature   (Joint Owners) Date </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1305" src="g19382bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=79,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=223422,FOLIO='',FILE="DISK114:[20ZAD2.20ZAD13802]1938-2-BG_ZAD13802.CHC",USER="DSLOAN",CD='Mar 30 21:04 2020' -->

<div style="page-break-before:always;"></div>
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Annual Report on Form 10-K and Notice and Proxy Statement are available   at www.proxyvote.com. D00235-P36864 INSMED INCORPORATED Annual Meeting of   Shareholders May 12, 2020 at 9:00 AM Eastern Time This proxy is solicited by   the Board of Directors The undersigned hereby appoints David R. Brennan,   William H. Lewis and Christine Pellizzari, or any of them, with full power of   substitution in each, as proxies (and if the undersigned is a proxy,   substitute proxies) to vote all shares of Common Stock of Insmed Incorporated   that the undersigned is entitled to vote at the Annual Meeting of   Shareholders to be held on May 12, 2020 at 9:00 AM Eastern Time. In their   discretion, the proxies are authorized to vote upon such other business as   may properly come before the meeting or any adjournment or postponement   thereof. This proxy, when properly executed, will be voted in the manner   directed herein. If no such direction is made, this proxy will be voted in   accordance with the Board of Directors' recommendations or, in the absence of   such recommendations, in the judgment of the proxy holders. Continued and to   be signed on reverse side </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1302" src="g19382bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=80,EFW="2241179",CP="INSMED INCORPORATED",DN="1",CHK=39391,FOLIO='',FILE="DISK114:[20ZAD2.20ZAD13802]1938-2-BG_ZAD13802.CHC",USER="DSLOAN",CD='Mar 30 21:04 2020' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g962448.jpg
<DESCRIPTION>G962448.JPG
<TEXT>
begin 644 g962448.jpg
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M$=PY6-I,V;$:MGLQ#ST5*L2RR""+= TG'>PKO4$DR2)7BB:*R6R41 H"(CP
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MJ&%*;D8QHF<W4#6.B72S!FU2 /HE(1- 53@4  ZZRJI@%10PCT5,S)2 8 ,
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M,^OS]=:86GV6T_EC/\;1U9J1_P!@L_Y*V_J$]5E;3[+:?RQG^-HZLR2F,6$
MQ1$I@C $#%$0$!!CR @(=P$! ! 0[@(<AJ6?:([MT@/]/_LV37#:?2?\8_V/
MKZO4'?\ 3=OB0P!^$2@&O17EHMLBJX<2+%!! AE%EEGC5))%,@<F45446*1,
MA0[F.<Q2E#N(AJMLLN4\IVB1=NK#D[)=B7!\^.#B8R%<Y=0#BL9 QBJ/9QQT
M&%%%)$PD$O*:2:8\E(4 X HX<J%.FJX=*$4 2J)JN7*A#E-^F*HFHJ8ARF[]
M13E$H^\!USA^SQ.RJ9NJXD8A3QCV9I1WQRPS;I$2 #V/#)]P/0AW8>T!/XR
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M=^<1LLH=5$I#J',:F9O#^1/$'^H./=$>0R1HNYO4,:\9-I7=N1J+8D((1O)
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M=]39[;O?V>T61/$6W<[@F#E$CJIKQSO*%1.]:JH@05$G;=K)N5&JI?,+^=N
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M-5#@#(8Y&&!'8CZ?QZ_JG^J)_P <O](-3Z_"X_:_=J/W(X7\>E-0%$_U1/\
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M<A@V"""07VT6%:8KZ^6WZB,$_H&=0X_7@   ]       #L   <   '   <
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MQYWPF("C5.<QO= ! I1.4YB/5HQ'K$I#@4S9,3B4..J(1[?_ ,O_ $_#JZ_
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MJ\=W<:Z1026FDCKATM5YSYCQ132*"D3@%8GRQ .!EM5Y2N)7M0S2%RD;$N%
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M Y6BD)W&.185TJNBVEZ)<(MPLU,D5RDA(5R39K*-S+HN$2KIIKF.B*R"R0*
M45$E" 8AFFJ(J=K=7']\0_RBZ?9/S&_ Z@X-?"YP>FU:)AD;-P@FT:I@(R^,
MN1 C=,H"/&*0#D0#D>  .?0 #MK^WYEYA#_A&S;_ (7QE_W5:::^B7WZ[_?E
MK_K$W^_JNQ''V_<T]OX*_P#-_365^Q?P]<28RW@;=\@PEYRU(RU1R0SF(]C-
M2= 5B73A.%G&P)2"4;CF+?G;B1R<PE:2+-;K*006 H&*:37O9V_T[<]M;ROA
M.^REGAJM:H:*=OY*GO8IA8FRU3L$1;HP6+J:A;!&$*I)P3-)X1U$.RK,CN$4
MP154(NDTUG'Q5LV3XB]$S&Q.9HEVEHI3+(98F3?)71HY.7-"K_$I4@JWQ#![
MZD6U(GY.NKQ7BPEY+Q'$_P#D\8[C&#V[=]5W.Y3!];PM=G]:K<Y:)=DV?N6J
M:]C<02[P4TEWJ13&/#0$&W$XE;$$P@V HB8_!0#H F+PJ' 1#GT'CU'_ "Z:
M:V9MC,].%G9G8HI+.2S$D=R2223V'?/MJ%S !FP /7T&/==9O[']LU*W.97B
MZ->+#=(*(>+MDUG%->5QG(B59-4Y@(M8:Q9FQ! 2 !1!ISQSR(CP(3L-H7AF
M;.]F)F<YA[&"3K(0QGLSG+%]?J7/(ZZ+DO#E-G-2":;&M(.2F%-RUIT37&;E
M+\Z7;J)_1TTUE_[1>Z;G6BV^E6W&]7IVV*6JD%NQ%6LH(LA+$$<BQ3+D \9$
M89 .,ZE73D,3-([11LZ=T=D4LARO=6()4_4$'6P7T]----9'U+]8P;U:5&Y'
MVE;BZ',/))A%6[#]YK\@]AU&24HU:2<*X;+KQZDBQDV)':9#B9$SN/>-P. "
MJW5+R48;!O"\P@)C#^6-FWU'_P!KXS^/W*M--:B\!;%B'9-]$,\T0.ZPDB.5
MT!/W1!DA6 )QVR=1;?E5K%<LJL?*/J ?^5'S&M_?@G[9:5MNKFXAG3K#=)].
MW63'+V0/<7=;=*-5(B#L[5N2/&NU>LD(FJ1ZH9P#LCPYCD3%$Z)0.4^\O335
M/>*CO)U]U"\CM([2T>3NQ9CC:Z(&68DG   R>P &G?: !MU8   "3  P/WZ3
MV&FHWGC.;/<>;BL^8IM5OM60H%]!8?6KS5K4'U1:L%FAKQ.R8KNB6&F61T9W
MY[I1,#(.V[?R2D 6PJ 94[33CX.221==[>\4CQN*>Y /&S(P!IR@@,I! (['
MOW'8Z\;R U%P0"/,A[$ C]\'L=:@6_A>X1*X;F_+%S8/2X0-P:6QF)3=*R9N
MDP?E5AR4W'!@Y#DHB'(<\ZG;L4B(LVB1 X(DV;ID#@ X*FB0A0X*!2AP4H=B
M@ ![@ .VFFISX_3SSMTMYTTLW#\M</-D>3CR&T\N/-CQY8&<8S@9]!I!T\JJ
M+?%57/W?. !G"RXSC7M:X#E:*0G<8Y%A72JZ+:7HEPBW"S4R17*2$A7)-FLH
MW,NBX1*NFFN8Z(K(+) H!1424(!B&::SY4[6ZN/[XA_E%U(9/S&_ Z@X-?"Y
MP>FU:)AD;-P@FT:I@(R^,N1 C=,H"/&*0#D0#D>  .?0 #MK^WYEYA#_ (1L
MV_X7QE_W5:::^B7WZ[_?EK_K$W^_JNQ''V_<T]OX*_\ -_365^Q?P]<28RW@
M;=\@PEYRU(RU1R0SF(]C-2= 5B73A.%G&P)2"4;CF+?G;B1R<PE:2+-;K*00
M6 H&*:8L0."E /0"@'X TTUE?QXFEFZCV=II9)6&R*H:1VD(7[_<. 6)(&23
M@=LDGWU*=@55KRA0%!ER0  "?*B[]M<(R/C;'^6Z;.T')],K5^I-A9J,YNK6
MR'93D))MQ 1*#E@_161%5$_"K5TF5-VR7*1PS707(10L3KQ5?"&VE;=:=^6Q
MA53*-$6DW;KFBM[C'V"C,021\T"1J=OK=AMS5$QQ'AO^2]1ND7@C=)$H &FF
MDO@?N>Y5^KX*%?<+T%&RCR6*4-NQ%4GD4QA7FKI(L,KJ.RLZ,P'8$#7O?(HF
MJ-(T<;2*0%=D4NHSZ*Q!8#\"-1<711;KG2*8QBD$0 3B F'@1#OT@4/=[BAK
MW(5H63DFK)959)-=8B9E$!("I0,/ B05DUD^0]0ZDS!SZ@(=M--;\;M&2.QX
MCO[^WO\ H'ZM5Y_"Q[<O3V]=27O#7\';:QN:@G=PRW9LV2WS=Y"H5R(N-8KD
M$[ZCCU)NEX6BL[,"9@+P(-+&U/P(\' >^I2VW+:=MTVG5N0J>WK$M4QE&2JC
M(\\ZA6SAS8+.O&E<D8.;3:)9Q(6.QKL@>//8CS,H\!D#QT5F5 BZA3--82\<
MMXW>3?VVQ]TW%]M(\P[>]ZRU$NGE,CFH937YHWQ*WEY4]P0=6!L4$ KB40Q"
M7T\T1H),$$$<\<L$=B,^FLC-=1YNP3B'<7C^5QCFW']<R/1Y@ ,Y@[&Q*Y(V
M=E(=)O+0[U,4I*!G6(+*&CIZ$>1\Q'J&,=F]1$QN6FJ.KSS5IX;%::6O8AD2
M2&>"1XIHI$8%)(Y8RKQNI *NK!E(R"#I]95=2K*&5@0RL RL#Z@@Y!!]P1C4
M$;Q8]A>&]DN5VE<P[.Y&>P,R1-X2,O$[!3Y8DKE)=<&D<_95>&EUFR'05)$\
MS(RSTR8<N7CA815'49'I^V/F;10YR$<.$43G3$ 4*50X%$Q!.50G4 #R'40Y
M>?4HAVTTU]-^B[$]KI?:+%J>:S8EH0O+//(\TTCL@)=Y9&9W8GN69B2>Y.JN
MNHB6I51551(0%50H Y+V   'Z-3.O"/\*7:"?&5#W/W>L3^6LD.7QW4,PR;)
M1$U1JG(QSDBC.5A*9%U^#B'TFW4 JK5[;2696/733=1HLW1"K!G7XQ>%*[GO
M:[5L>VB:LT%#GS14Y]1Y5%X-"55<PM;NAFC8RUA@;&S!H=1T*JX)L2.CG12*
M1TFEYR:K36/=XW'<+/C?3%F]<L"COU>*D)[4\HIQA1((ZHD=A702$N$AX*'^
M+'+OJ8P11IL4A2-%,D#&3BBKS.<9? '(X[9;)QV]-1F_S+S"'_"-FW_"^,O^
MZK68V!?! VL9*1K"]DR;N-#YX^>O:TXVT8L9IA[ >0(W\DWY3JJR?V*D8_YZ
M;K-U /!3=(--:(WO<]RAHL\.X7HGYXYQVYT;'ER'')9 ?4 ^OJ ?4#4?AAB,
MH!BC(SZ%%(]8_8C&MVFWSPA]INWFE/ZC3766I=C.V ]ND'EKOB+Z1-+.X"OP
M*P(GB(&#9(-!9UUBH5NFQ#H<J.CE.":B:233360][WC=Y=WOR2[IN,LC6&+/
D)>LN[']S&69I2Q[=NY/;MJ80P0K%&%AB "C $: #\ !C7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g516552.jpg
<DESCRIPTION>G516552.JPG
<TEXT>
begin 644 g516552.jpg
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M,T%8F++8"CEA<WAYMQ@C,I/2)"4H.$)B<8&1H;'P&28G-T=2=Y*UP='A_\0
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M-P(6/];?H*.0RN)3&K,BT0 1TU6%L!&T;0?B!3Z%39F*3?BBLLFLC&Y"]/\
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M_*T/.#+C.K(2!F1R00*2$\H#8O9CB1$Q\0UU.>>N\9LR#-V/(-&A >0:.&!
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MJV<:IZ>RFGA5RJ@@K/%ZTD;>1CJ?Z*L,<I.-7\6Z<6Y$%D76Z676KJ.]F9@
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M2R/I-D ,FDL,CAR0!461/0TR2$F28UT2')LS&FA9JFT<HZ-R>NK]'71UC"O
MC)E_?/L;#8V8LPE1];/JPK:_.PU4V\7%V&_0R &UQ:@*OJXT'$Y!I'W"QJ7
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MG1,E(2$/7WVUTSI-HV<CZ&FVWC&-LE<,WP#*>OG\M74QE/&-=LYVQC'-O/\
MDK$QUL#IYVYF2"F%1IWOQ8:X#?&N-/:C3.B>O8J/JYQC[_C!@]N0QMGY[:/-
M<[?E>>:!L>,H' K-1D4'DR"P9FJ_2$/&JZFKU<8BH[U49LUU56OEQNIC+=;7
M79'\UMCSKSZ#O\E*IXQ6GI-Q2:FFNS7?L'<EEV^'U4RMJLI%V#>,4_'7>Z"N
M<823)M:J7+-=M$]<.63YJYQLKJKJIL//TW^-/ELI\<<<!QQQP'''' <<<<!Q
MQQP'()_7DH A-.O$'[,1QFZ>%>J<D-G9RDS2]\OB@K#'L 5L%<)I:8<[I5^0
M#P6UG^4U-_= (-(=]&J[C9'*<['/2)#1Y@>^$EF+(F+)LW(\B-(M47P\@P>H
M*-GC%\R<Z*-W;)XV55;.VJZ>Z+ANJHBKILGOMKD/G>TY=Q;K"=)I+L#,JH>5
MG534HC(3"A8Q3QPFLLYD%CUP"9I+.)!"I [5W-617(3"A-,IN[L&OFC\F_DL
M:.R\1:51F<1P),(9( TKBDD8)E(_)8\1;%@9H<KG.-'8TBTW4;N4L;XV26UQ
MMA=HYT59O$6[Q%9NGACZC/0"5^GU8BCJ.BC);IM-"V/LCL;;9=^THXJ6(^Y'
M=?+3*J946#AF+APT&4/8YUQ@?)PZC"KY$3;SP#'W$]CKB<GL.E9(3E%,RS,+
M?%WZC^70HP.5D%4SDCMG?W[^507XX6J)DZNWG5Q.804BLO6VQ_OX[D22>K+(
M; /'(Z*\]1JN7.J(V^(J<I(OIIKJXEK?5]8-,/%?.-??-YJ '?66)I+9VQMH
MUL.&1]%KCVD]C[_5++M3/6'S")6&&0D=?RF-SN/N=/>('(6>%2H2IK^.2 %V
M_;)[8^[=-91-5//Y*B>F^,ZX"HN.<>UKG/C&V/./EG'G'G&?P\<YX#CCC7\O
M;&FF,[[YSC&NFF,[[[9S]V-=-?.V<Y_1C&,YSP''+3VS?%*T.,V+7/:L"K%I
M[C=PBC,9*.$EWR:?RS@3'-E5)*:5VV_S:2(<._655SA)/393/L\A<[->N;"8
MXR?@^K-=DIZ;SJN@E9-J#R$/@C'/L;:Z/@D'U60G<MWUW_SK;4]F"#%/8URM
M\<COLALY3+*8RY6Z2;VIANQ'9.FNJ];D;3NV9,HG&FF5&PQKC&KV2RXUJGE1
M&-0J.IJIOI)('/R\-6OL-!Z.=GYM\+&)+/4]%WNKW.O7U,^Q<8$#(X7U$.)(
MA7W7RBH^KDPZ9D9B39 QC3'PR:.LEL*;%=Q:!8KJCKA=Q\$'$IM0P]FARTG9
M&]+?["S5S8%V6$?L.5[>RT;$3BZ*(X$,5]IQ]"Q8 P2:@HG']%U,[)" ;%HW
MVWSIN[V>N_\ =.^\?_)@_0)D]*FH[ZE/<Z(+ K&?"UB'5FEY(P4;FH",D3)P
MW5N>P1#U+587-3 )ZHTKR*/4]7T2#DGDH/-V\H? VL;TRP[<<;;OEX])I[^O
MAQT^I.I.[&7MWTM\\?CW^S:%0]-7J!;-%U3!NSW4_KW9TPC-55Q$I&:DE:P\
MS(VYN+P@)'B?T9.VHQK*4O<O&+A-N_'FF^^Z>B:R.VF/=YUS@K:N(+3]?PNJ
MZQBH6#UW7<8"PR$Q".LM!X.-1B.L$1@4*+9IYSA%D/8MTD$==ME%-L:YW545
M5WW4VK;&,8QC&/EC&/&,?AC'',VAQQQP'''' <<<<#7=M/U'>P-*58^O<E)&
M4MN^*SKL'I=WI]D!\19L:5K. B)HN).$9W$8$2M<.RA"(:L) [MPT]ED'N9O
M9VX^O(KJXEE=M@OOR;U6KU V++_:@L%F<0KD>4<A(_3QTP4=7=M#V?<1K*;#
MBQXM$)&^,T<B]J>O!)]Q$P>2\-G#$MJSF<L'+-X[)9YYO!8E9$5-PB<@6,EB
MDC:? &P1/511@2:871=8;N=$U$M\IX<-T5<8T4TSC=/&<9QYSC-3?#H^\PM[
MK3WN-%$\*^SCWNJ:N^JJFFJG^GKINIIIOMIKMC7.^FFV<9SIKG 0^5CZBUV3
MBQ@L>4IFNB=>C[,KBL9%9L.F\U+ [!3M6Y[8J*-V=2:[F$IB#M<C?LWP:,DB
M9APBN0W-@ A5^Q&LI21I.\/4 ORFNRUOS%."F9;T]KR.2>I&#-G%QS?!>^:=
MA@;L5;LC$2MML^GY9XK3B%O5U%HDC$\PPK9-1LA[21Y+2G=/2]MN=\)O%>P%
MC4M"HK &WU/D,1IZ/E[:?SN$1*5W58=.-;LC35*UF8(G 1;5C&'VB.T$)X:2
M*5[BS>@:5B9 I#HC,;%@_5%MY+5J6F]&Q..5V^L&>4:)L\O(I1%L$[6@UI2Z
MOW"Y>K"(@O9<+W=LHBL3<5 Z82&SF#LH$9C'<BU.@<E MN3]9*UV-0O[#*=9
MQD(DH"=R&&/X),93+$G<@(5_&0$^G#*.F]XB%"(:[0ZR:HVC[YZ^>&BQHQ+&
M<:@\T^IAQ(=V]D^IMV,:*PI0+7]20W5_8 $XRCY&?'%Y-:]6JW1V7KI<'&=S
M%=K,A+EF#Z_ Y+;<M9,2[2M0UMQ]V.4>I#AI&7SA0J91*QXE'IU!CXR4Q"5B
MFAV.R .ZPZ'%1;]/"K5VV6U\9Q[6GG15)35-=LOHNU<)I+I+):U3[./E\ON^
M6/&<X\8^?RQXS\OO_1^&/PQX#"#JK< KO3UG+%K9KF$O@<H)3*NIE"'"2<W@
MDH"MTVK=\T=?2C,I#98%*L26&CM>*R.PX(5U2W5$RXEG=TQ%0(]V/04L2 KD
M9UT*>I6! ,86<K=7K E&H^:15+*WM:L*/MV5/MAQX U14]R,KBY23)R+;(:L
MP-O-!B0^,M]LQ---+35-+35-/3&-=---<:Z::XQXQKIKCQKKKC'RQKKC&,?H
MQS]\#Y@,Q9'8/,G]<SV-2VL+/%8W^D:VLF.EH#83/7'G&RZ,;/H,WA@;M_I(
MGXNH>C+U+;1<><>MU$UM[-/HV&:%LFQK)2.R'"F%=I#$WQ2%27#C3/M854/Q
M!Z"-*+Z[8QM[3AZKM[6/RL9^[GT^+PZWT'V6B:D&O^G:XN**;>\V1"V+$ DJ
M;#W"NNNN7P=0JT7=@B2?L:;($PKD>0;J::*H.DU--=L0JW-_)P.FDS<+D*5L
M6^NNKC*6=&D<"3%E;=>-]_84\;:QRZALRE#)O[W*?ED L $U3;:;-FB33VM%
M4@TZQO93M##M,HQSLM<6$--M=DFLL*1FRFJ>-%,*82Q]HT4DY+*&_C":B?TK
MC;9'.R>%=?;VVSWB_J!]T6*6B2=QQ=S[I/73WY"C:U<.UML>?:5<+-4!S?=3
M?.?G[ABV3UUQC7"?G&=MIR+$_DR/:1BLIBL>U] 3IOE3_-XL*K;*JY[[K.=?
M:RN[BLMMEALMKKMMM_F12"2FR>$]=$<+^\:XO23^3=>I:S:KKCWW4F1KX>:H
M-V8Z\;%&*JM=LK>7ZJIOK\V;M\:XT1SEIJJX6\K^SJIM[G;;8(H#?J-=W5D-
MD-+H #/GM_ND'2M8,'OC9/=/;7"Y$6=1U]GV\*);IM$U$E]$U/;4TUV1VQEL
M'MKVNG*#II+.S%V$&+C&R+@8)F.((*62WQ^6CN.K8=#$MDM\><;)[;;8VQ\L
M_+&,8GO'_P F%]1HZGJH4L'I[%?>#V[G5)U9-NR1=)\KE/+@8YU$T>P;ZX;:
M[*>"#9VY1643QKHAC13"FN15:?R2NP"JZ#J]>[L9#,_>)[O =)T>^?D5D_>;
M852;2ZSYRL/;;92QIE-PK7SO&%-]O::[:IXRJ&EB8:H[/')#W67!-3WV7!1S
MNL_+JZ>=E-LN"SU1R46TSMNHIM[]XIK[6ZF^?GOOG-W^LG1?MMWREFD-ZFT9
M-K@5U?Z#C4Q$LM1540U17*V=UYQ;AO+. QS1NGHJLH.W-/9*YU142%1XF\]V
MU4^BUUZ_DU/I;T@[9&IE64Q[025ENU<)$.R4T7F$;T=H;8445TJR+L(75*Z2
MBNN-M43$.,Y2UUUTPKM^7LI.M$89$*_C@F'P6+1V%Q( VU9 HM$P8N-QP*ST
MVWWT:" 05JQ%#6VFV^^VJ#)HBGC.VV?9\[9SEPYRQF4RQO&5G'I-/XU@?24_
MDQE#=+CD8[!]OB,9[-]H ;QJ=BH1L/=*4#3)UEG78>5B $\T:D['FPM37XEC
M/IV-8L@[SX=[$H-'2S! ZOM18QC7&,8QXQC_ *_O^><YSGYYSG/G.<YSG.<Y
MSG.<YSSGCEMMWMU7'''&3'&22;23_?OFG'''(IQQQP'''' <<<<!QQQP+/RS
MK[1L\D)>6S6H:VEDG/Q->"&STBA<>,%B\-=)N$EXR2?/V"Z[T,HB[=H99.-U
M$]4'3E#3V$5U4]_6_P G*A/JB/@'V.UM]1Q0B2@QL2^IP+ZNLADQ-#9+*F[<
M1\%\$GO(9&(&R PZPC\:_.,T2[ARH1QESM>GC@=1'X^#B@03&HT(&@(^"'M!
M(4('9-QPH4,8HZ-V; >P:)I-FC1LAIHD@W02T23TUQKKKC'.WXXX#CCC@...
M. XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.1\VIV:[/_P"5#-.MW6OK
M]25D[UM1]/W)-)=<O8^:4OKC-SS>ZX?'X[&PD/ZXW=DK]&:TF8(EBI(H#QC)
M@>T:,'&4EU^2#<CUK?\ G1^W7]B'H7_C3W]X#[2/5'_5%Z0_MZ73_ %Q]I'J
MC_JB](?V]+I_@"Y(5QP(]?M(]4?]47I#^WI=/\ 7.-K*]477'G;J/T@UQ]WG
M;OK=&,>?P\YZ!<D+Y!Q_*"37J#@NAXQ[Z:B-VK]AMK\K1N0TH$"M(IY]FRHB
M;YDVV1[<<4<:@\%M(S]*N46V,(YRUPX5T:;N,;!EYBRO5%VQYUZC](-L>?'G
M'?6Z,X\^?'CSCH%]_GY>/QYS]I'JC_/_ ((O2'Y?+/\ P]+I^6?PS_P N1!]
M*G?J$RWT3RFG?F4=HX!V6(]@5V,JD,\K:Q2UB-:K2N*%J,F%@1.M3E9W(WHV
M11](E';"D]3R(+-XY794](P;IP-'/FZQ#MIVYH2KZWCM8P2V B(RR[CD"31.
MO+D[!TW:<3AULTL)6'59/['@Z]^A:S*1636B?C=7F(Z*E 9&/RR4QN_=ZDA4
M48S )?/M(]4?]47I#^WI=/\  %Q]I'JC_JB](?V]+I_@"Y$^=[B]UZ2*5["8
M2)N0TR#H2E^>$S/K_-9LTE@RQK?[;-1,D:SE*.R25E5(6D"I9IA-5_6T6@.A
M@ *,)6:VG@MC$LW:VN[NR+[1=:^LEA2@3+MK6I*&]HY_83*GF$19QB)0@/+X
M]?U79%:%'" ,@5MZ==;!E>;D7A*3#8B4L#+]Z:* MB&X9!_:1ZH_ZHO2']O2
MZ?X N/M(]4?]47I#^WI=/\ 7)"<>?&/.?.?&/.?'CSG].?'Z//X<YX$>OVD>
MJ/\ JB](?V]+I_@"X^TCU1_U1>D/[>ET_P  7)"N.!'K]I'JC_JB](?V]+I_
M@"X^TCU1_P!47I#^WI=/\ 7)"N.!'K]I'JC_ *HO2']O2Z?X N/M(]4?]47I
M#^WI=/\  %R0KC@1Z_:1ZH_ZHO2']O2Z?X N/M(]4?\ 5%Z0_MZ73_ %R0KC
M@1Z_:1ZH_P"J+TA_;TNG^ +C[2/5'_5%Z0_MZ73_  !<D*XX$7DG[9]V*;FE
M",>P'5OK2 K^Z[_KV@%I#5/;VR;%F$;,60UDFP:0(P^4=/ZQ"FAC!Z T;E6R
MLV#O-$'VCEEJ\W040Y*#IM[>FNWCQ[6NNWC[_'M8QGQY^7GQY_#D:_J/_G>A
MW]Y%U7_>G_))D?S27]7I^[C@>3CCC@.1ZUO_ #H_;K^Q#T+_ ,:>_O)"N1ZU
MO_.C]NO[$/0O_&GO[P)"N... YZ[ERU:I96>+H-T<;:ZY5<JI(I8VVSXUQG=
M7;33&=L_+7'GSG.?&.>QR(KUH.F%Q=Y>KD$JFE =?R>21GL' K,,QVRI3O$8
MV7B\>B=BA'R&2F(K,452#8I*0Q%FR=!=T%O@E5-7+=P@AMD)5R\FC("/DI2=
M/A L7#,G1,O(BA8>-!"A[+391X0(F';E <P9M---]W+QTZ10;ZZ[;*JZ8USG
M'AB\LBDV!"Y/#9*!E<;--MW@>0QHX./!"S1-;9KNZ'%Q+MXP(M]'&F[?9=JY
M72T6TW2SOJIIG7$ 76#TZ[OH?TNI7UFM6L6L@F+WM1I=3*O^O%FP%T0C492N
M. SH$9ARMQ5TVI>P#\/<QK::O*?M&)-JVG^K1W%#+[5P1;NLT$CU0[L1IZ(F
M8*N[;%2AP'[1QS4A3,QKR@9G*ZOF?9CI;/I*1F4)A=C[=>*L[57G4$+[ "8C
M-8.D(C^QH'!)(7+TU8I71Q&0V4GCQB/:.B#]XW8L639P[>O';I-JT:-&J>Z[
MITY<+*)H(-VR*:BJ[A;?1-%)/?=3?5/3.<4>,@%>)3@K;PJ,QS:?2J)1V(DY
M^V9M7$@+0J.O2YR-Q[Z<Q[U?>.L",B+EV0]LMHQW>DW!#9-5=31;6 >6TAZB
MDHA\OB$EA_;&51>45Q9<?ZWQMKV>J8:5K!M*;FNC+P!W>/&YZ;'W.[)]>2U2
M1.-I_1=_NAC=C(@F)O'K16<7*XRMAM;=_8MT$O:C":6\@[7&U&]<0"X6$D&A
MX(G'[=!0.(M[3A,+<S8DXJT%U:BD@.M2E5M9$^?RB0TV0E,9-RTW9Z95V$N
M(^#DX@?((X9%'P15OJ[&&0I%D6$D6N^V=='+ D/7<LGC??;7;&B[9=5+;.,X
MUWSG&>=M[6OGQ[6//X><>?N\_P#AC.?^C'GFLHYZ6^I]UP@HGKKU)((A*MKF
MR;3WA!&L)4.JFO6]/^('W(JN+1& 3&TIQ(X^N]OZ"69TEEOTX;+NE*D[ ,I(
MX?+P\&2P![<Q5GJ[_6("\;#;^2DCBGY"TDQ\-V'BI2"_7:W.I-UF2#09'BUZ
MQR)QK[&NWT^A$-C*>M+V#+V\?K>.3L'=@^O5=*S8ALBO2PL=LQT($F#'<F^1
M&#='CQLUV($G"2ZZ ]EJNJGEV]60:N5D6C?"CA1)NNIHGMHDIMK[^,XSCSC.
M,X_'&?./^W'-;7L5U8[WHV&(;0;'<>T$*RN&$S"KIXVOZLSH(12K+I#/(O*5
MW4;MNSPPF1]FF?;Z3227@S)J'ZZ[##,'CH2;Q:KQ&@6+2T^GV$OB-T(L$[ B
M9L+E#"QI[K&%K"G1B<2DU7JY-!U$SS_64V!<4UA>A)-=]LUKZ:W9<<DBC=/1
MHXGSIBJ.!@0SBXXXX#CCC@.... XXXX$:OJ/_G>AW]Y%U7_>G_))D?S27]7I
M^[CD;/J/_G>AW]Y%U7_>G_))D?S27]7I^[C@>3CCC@.1ZUO_ #H_;K^Q#T+_
M ,:>_O)"N1ZUO_.C]NO[$/0O_&GO[P)"N... Y9^[+_I?KA$6L\O2RXA5D0?
M'QT68GYD62$,'\C+(OG(T&QW4QNH\*/&HPB[19-DE5]F@]ZZSIANU74TO!S"
M?O-U6EW:Z 5I'H'9@.JY96%R@K;$'I)!RT_!D-AD)L*"O0+\&#G==%4M7@VP
MGCQN1:21++5X.;Z+,WC==9/4*X'=S^L!VD#O8V-7%%)A3D>.;Q0A,(5DG,M5
MYC].#8NU@P<%&QI.2R">%I.:#1D!" 04C*9#(C D($$OR1)FV6[2L^UE%VJ-
ME[X'+EHT^KR1C8E/HK:T9D]+SN$'SP=I((\QE,%MD/#96&2E )ZV+Q4DX$X$
MRD=LJZ /R6C5W\/A+#/3UM: =7I+7#*Z*_EE[X[6B>X<-FQ6L9*#JQ.P8M-(
M7+ ,-DD)S8TNESB)OF$0WCI8RQFVQX>L9^LH9OJ[#,Q3G&CL)T0[0VQ>]<W7
M-83U>MFPYK)B\9E$+E<4F4FZU5G4<!ZTWQ"(-]-KE&2<ME<_/SZ[9674ESN*
MLT$Q[T;70P8,1;*S5T$R8_L-3QB:GZ_#S-D9D<0)3 )--1#,F2#00U!8Y");
M(P\[D[1DK&X84;QRQ(H69,)(5&N"[1\ZR*T>*!S28^X24VAJZX)LC*HTJXE*
M"+J-H)GA&ZTA;+M5WS=P#2U>94+H+,FSAXBL.U<IJ-4%G">^R*2F^L$PWT>;
M$ QL_%V=@5#)L,V48=H'YY%#IK3L.9!P7T\1YX3V8B0QN(T?Q">RCI9,!LR8
MM9;-GIJ)VPB]?[/20<V&D=S*E])OZHG%K!E?V#[V#O;_ %QMJ)9B-;N&82C&
M-7]O;?[)SVJ:2>%TG!N+08P!M#>'"=Q68XF8+YD9PU'@@8VWC8X)/["[+4?5
M5N4K1=@3X;&[3[#_ &@_9#%WC(NKM+<5=&TY9-MLEVH]P! Z"0*NKI#>2DP^
MAA;VQX38B135:Z764E<7206<K2$$DV;)^]774+C=$$$L!]Y#E197=UA-)/4#
MIN:SNIMKKJ)UV)YSACKEQB+3M#Z<4U[(7A-K_=W+L!E$8;]=A_7.&M67_L\'
M"Z8F!"RI8QN4:L*?EY,G9\IE4PC!WZHE 6F:]5"C'R9-RV72S@['/1"NB',)
M^JR["5S-'\DK]\+&@[&KM>4Q96>1N8Q"J*LDA!A)6<K"M]XYZ>M<PWK(@_>Q
M"6I@IWDM;*4:E#;.(L^#8?S/8/\ !,B7UPBVP\D*6.#GVLA#;-'X5NS>$7!5
MDYU>Y1=C$1X]^^6?M]U&B;-D\=;K:H-EU$Z7A%X518BBR$/FX,HNC,9K 46V
MSCZ.<DY37;G1K,AX%J2U9N)$B"552W=$P21$7NV43>(/%6BFB^T*D=]'24MZ
MQFXF5E*%D=@X0BC>M%GD1-/HJRC03OS9O=R755)-WH?5XPKRW1\]9TK9B$7"
MIM3D:%N22T:<!WFL)1\]4^E%<5>6Y4D^:NNL$=%P_L//+K?LHK$S1)E#(C->
MT=DW\[IZ#0J8P<I&MD60B:L@T*M.!O\ KY.8%)T3Y0KK9\-) X)&PGZXYQKC
MQC&/PQC'R_H_ZL?^&/\ HQ]W.> XXXX#CCC@....!&KZC_YWH=_>1=5_WI_R
M29'\TE_5Z?NXY&SZC_YWH=_>1=5_WI_R29'\TE_5Z?NXX'DXXXX#D>M;_P Z
M/VZ_L0]"_P#&GO[R0KD>M;_SH_;K^Q#T+_QI[^\"0KCCC@.6%[!]BX%UMC46
MD<Z'SHWM-YP.KJ(1RN()([%ETAEA(%))0F/'1R,-';_9)M'8A(S+Y\MJBS9L
MA2^RJV%=T$E;]<QK[.=;!G9>-P(.YL.=5<:K2RQEJ1"85\V@;\PRD0^)S.$*
M-G8RR(9/(L1$OXY/9"U<MW0#=RDX49O63MJX::[;A;AOWSJ C1LHNX-&[9(?
M5NUVM"I52_KU_#;B/W@7D4=B<:JX1#IX[C#=N=DIV61Y)@6/&0L08"WZDDD$
MC#1L:5*LOVQ[UU'%H6E).S;0MTYD&DR+P9U"NPY")AGK@H$ AY22.Q*5Q*0R
MR!V!7[2-'Q9@E8D,DQ:)QK15Z)FA",2(,:##Z-;>G\'%4',ZD$WE:V\^DE],
M.T >^#(NL%YI%[O R>)2N-'VL4CD&B5;$(R/<PP4#*PYW%DF,CBST\))/,.2
MN2C>S5\^F1/.Q<%<QJR.Z5R$3,L4M]"R%4 0YG7A4/:==Q:MAP:#5.PD;$#
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M%41Z;>'02-C]V[+1%!==FJ06TW>O'2REP_>:_AO_ *M3_9X'[XY^/>:_AO\
MZM3_ &>/>:_AO_JU/]G@1L>H_P#G>AW]Y%U7_>G_ "29'\TE_5Z?NXY&QZCV
MV-E>AWCVOYR+JO\ ?KMK_P JP/\ YL8\_=^C^C'WYQR2='\TE_5Z?NXX'DXX
MXX#FM]W1_G1+A_L.=0?\;^Y_'' HCCCC@.... XXXX#CCC@.... XXXX#CCC
M@.... XXXX#CCC@6TE7_ +[.AO\ >#]</_P]J\VOT?S27]7I^[CCC@>3CCC@
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g915412.jpg
<DESCRIPTION>G915412.JPG
<TEXT>
begin 644 g915412.jpg
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MY6E0C0\^#8KSG&/'G.,>?ACSGYY_-C\_//*>.UMUR-'L/=D3.]WW72>-==*
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MB>T1+[!TA(BHYBYNC2KX-- U &^PJ,B=T\*RZ?F5[%Q*IT^@VX[9S4$:E;4
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MR#EZKZC=^MK@ZI'NP2]O6H:K2]>OMA&+,=]AA.*FBM*Q;IO-()-(!,J9TLG
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M1 ?+3><F).R>:+-I 5SDB72>/<_3\X\93E2!0I>-B*PKL5'CPA<"=!#H/%V
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MGH6$]DXQWF,Q.;V(Y8N;E36B\U QJKNMPJ[9M7"EH4-5"=46N='*N!)$I.%
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M252?N=5$*N"42-.G4H8THM6I'XBQ^T<%+QY%^Z=#4Y!7<^KBJJ[=RIR\,B;
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DX3:]?.Q;I3794?)"[C&^R;?;&F,-<ZYWSKKMG7&V=]'' __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g801928.jpg
<DESCRIPTION>G801928.JPG
<TEXT>
begin 644 g801928.jpg
M_]C_X  02D9)1@ ! 0$!;P%O  #__@ ^1$E32S$P.#I;,C!:040Q+C(P6D%$
M,3,X,#$N3U544%5473$Y,SA?,5]/5$A%4E].14]?2U]0244N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@ \0#B 0$1 /_$ !\  0 !! ,! 0$
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M[1R&L.W*_.MLAUM!?=7H2([Q,Y;8=QV;(Y?VS(1@.!A'8,^Q:B!,%8QAX6+
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M,Q;?&+]-=0NLLBG9^S#=)5X3G$HW*N)!(70!#=V6(G(8M71@X\1QMJQ4DA*
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MT68%!)88]269D1A)BX<,G[!VBJV>-%UFZZ>Z2F^N?DY_A%'@_/>,2]5+HI(
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MMNB\NC747&MJ4L@E[S7JU+Y(B*G-<-TLJ;J,NMUJR9QD62BVFNVNHFC;E*L
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M@/;-'+MF)R](Y&-'*Z*B[8?D@^RQ14T:Y>.O<^_4KG''''''(%^4W^33[_\
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M%H83AT2<'I4A))5%17S-LZDX'0A41W?+J,6WC^HR\X<_1DT7VEXY^SU..!*
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MQDD0?J$GON-$$62K+33;V\>N?&W(2]8N*UE'=/L]*&X"'0JN*L)NWD! )PZ
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K<<<<<<<<<<B]W=_$T[7_ *NUO?\ !);GL$!?Q*)_HP?_ '-#E5XXXY__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g229816.jpg
<DESCRIPTION>G229816.JPG
<TEXT>
begin 644 g229816.jpg
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M>C9LFFW;Z[>NJ*&FB*6-$M==,!O>... XXXX#CCC@.... XXXX#CCC@....
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MA<7^)_R&9^7C*^7PS_;L4/\ #/YO[W./Q/\ D,]?3^EE?'Y^GXV*']?3\_\
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M$NB)&M.NLXKM7C^LI-ZU$F<JW;G,Y/"HWDI',/W+Q'.O2NN02W:.[FUC9PE
MG=>GG>GR!BQD&E$<A+CI,.3'84S:2D+-1CK7=N^CG[;?=%TV6URFJGMG7;'.
M<,>JWCFZ94/=BNG5BIQNL[E;! #9-> E4-B*9O:9E"+86JFMFP>Q0=/S8HES
M0SUAP.)TREEA/SVTDF]B$TW<NS#$])=X3JO)^P*8OXA?7":A)Y8,4R+]Z7E.
MN!6@*B5$%EXM7!R$3#^:#I=*?;@Y%'@QU6TSI!$4$I'OY\;&7[%54AX D\Q
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D7VR:=!=AE5-]6D9(.W&=$TT]]]]L)^FNFNV^?377;.'' __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g19382bgi001.gif
<DESCRIPTION>G19382BGI001.GIF
<TEXT>
begin 644 g19382bgi001.gif
M1TE&.#=A\ ,9!7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M0(D+$ (*2MH%3%RA"0K@@1.ZL <NSM0$7>#G4E&@TD:2804-=2A<%* $!Z*
M#PLX2 *&D#H(2"&M8HTK<]:0BT<-) $6L( 4!H()(V# F F0P ?\X$RY&O8X
M$MB$_$[@ &,21 H72%T,BGG8R@Y'"A!(70Y0<8*]%H0/*(B!_%)W1SW9C0;$
M(H@,,K")(DADDN3"J4-\ ,B+_RS "1:@Y!IJVTO8*L29:^CI5M:P@+#VC0:H
M J04]A&#&* B #FP0&T%DH#,BC84^&ALGG@0A2&4E'0% <,0P N1!5R!=%>P
M@' 1(@)$O/$B/+" N 0BA"JH82 1:(,5$[*&8X03#%DPKE46X $5Y-1.@97
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ME 6*@(-@X6 !(!QO#?".<11<H 03L(&E<'!""GK* A5@H!"&=($%/+!F)$
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MTP-^8'9$H#(, #L=>24;UES2=IJ9)3\7_^ \-/ W#C!M!P$*R:11&E!842$
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M-!'0 +D6 5# *6MP!3^P U7:!QJP B6@93RP:%+U V.04S[09@.1K?[5*4(
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MY@"-JP&-^P:-ZP":N[B(&[B::P*,4 5V, 0- +C$ZE(:@ *9&[BK2ZR-:[B
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M2A ^@ <N4)1MT(?4W@!)@/@AL/A+8+ 2< 95F0(D%62KYP/CZP'-GCFW%6#
MIP<_0&X!Y@%QH#[@C@3Q=F \ &X$=@8LH 'HEP6YH =U_[ $"2!['. +[48*
M1+ '0?: MC80L;<"C2#^[D8$E$ %,58"7@ $%  )OH"@0. X0J +N: $ -%
M@H07%]P0X>"IQ8<02DPPZ-.&BA,",,!HL, %P,:-/%Y(R.!F&PJ,)FSP<$)%
MB9DI"C@N$"(Q@9(Q2CXTX3'*11.7'"]:"-&%A8H%+# V6"%BAX6!'GQQ\6'"
M!91M.^ H:<!%1"<J%AJ<8>&)AE$+70YP!%"F@84,F\+L6?OA3(L?7 Y]&JH
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MLCX^  6(=,8$ -X5?H] !1A@M0R,,<J@(A?F-_U$S IDV.&,A/X<0P<2476
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ML< -U$U:Y2@P*BZ4 "F5&4H"6L>@=!R#$3, @PK8==T$" $(1.C=JX[D7PP
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MY ,9. )<E \>T(4FD#G_EWD@7/0 "(!(>R$$R&F[MH" 1]D(O]D$R!$L .
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M5[3P@2@@!>QSNR"@@3Z0!![#,)50E6/R!!MQ.C?0 XSB$20@@(&H &\RHRG
MA".X):[J ZI;5QW(@!E8$.*%D9DBOTN@C V8!2FX@"4X4@]&@B; %2Y!AUO:
M'R&*DR19@1,)VQ&! C+@EHFQE3WP-PD3 D,8 ?,4 A68$SK0D(J# ZY=@)X4
M00:1@@:!$27P@B5QKQ;&!"\@@F-P@).T6I$DE&4$6 ]3U_\RFJ L@"AI8BL>
M.0054 (EP(,E+8X(( 4C2)P/Z +ITSYL K\&R5<6R*$>"0L=<@+ !0:C_=U7
M--WO8$#6X U_.%,]ZJP<T,D\:E/EN($3. %DZZQJY%PFQ--Y5"U44 (^S4=.
M0(480%VL28"O 9D8D.7^\XY0"I!\_(X $#?O" #<18U>/H%L6^1A_D!-#:(0
MIJ@6<(!;@@0X> ,V:30="B"47-(7<( C  8N 0+$\ 2U[(-<B:@-(863I!/P
M'05:,1(:P(+=^:]W\C0%4*HE8*LC50,R" '\\2>.N%9</%6(7( 2D  +V $8
MP(0B^X!."$A0:0@N6(T/Z3PR4(/_Q!!!RM& @1B!-7B!$!B%2B "HS"+ SJ
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M S!\L71U%S1\" !\Q_F _^QB%-B'_E/\?2 D(U#$!4@ =-@$<+-D%' V_;N
MV7_8M7C$M\?]_S9*.*V8!2&Z@M#2[P@X@DT@!/5&!VX1@=[_QR4Q$GN!@(!"
M%#-0@1>8@3_42MJ!)@=Q;RJ%A"_0@2BH@ ]3@WZF5ZTL6X#URO>9(*]L QU
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MC6@BH)'4V:18)<#="51 EO[-  R(L$,3/- &#1Y!1\4"0!EZHX$/H$$14+!
M$V@ B>;8#0P:0 1(1@ &+VPB"'/R0!V H84^]&9KC2E#)]JPM0@PPB(0X((>
MZK"/3VQN$RY8@0Q& 8.FM.$$_$(;(A.IR$4RTDHB\ )Q]@ $(D3!#0< 0PH4
ML 83;&\4/W  !5*VNIK(X @MB8A2>'"$=%02,5[_2((,\!"$$ G!9.'PQ +*
MX(!F]8$1V\L 1-0S!Q40P0-34, PC3"*M$#"<Q$!PQA&P((ZQ&$-+] !$J8P
M K51P E04  +W*"'(;!PF1*AA!J80H5U_6T,N7B(2UIF$_7PX ,Z\-J</G"5
M/32  2)(P18*<2H1 &%D+'/97 Y0D!8X  :"D=&S[D8(-RR #%U @D&N8($]
M]&!@5V!31#:0%)<8@@@;&(/M=-."#\BH,G^C @4XH,T(:( "C5@,&""@E8A<
MP2QYV8T3X, !3:2F"$%50 FAX( E\, ,=&# 'BS0(Q&\@86'.&8?')  ,GQB
ME([Q0!Q80,X%C&()3F@"_V/>-9H45*"4P&G$#%IPA&W5P@9,:0(+QI*:,[#
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M>!-B3/^;VI14&4B"W=B$"(C9 AQ"OMS!!W !^%6'<95 -+60#3C(S'  17D
MJ,224.!!7,F!I;30=*V)$T %G9Q!&7B"<K1AIOD<I!7""D3 !Z3%#.Y634'1
M&.Q!Z?R-!E36]@B:6I""J:W 62G A1$!S;B>)$XB)59BBH@ "FQ$YL!0>BV
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M!9A Z.:S &"?#)"!"[@7MI@ DZ] "<0Y 61!O!B:$US &XPL&3B O3%&+_T
M(VB $5#"TCCM"D">!M11DOC *) "!HB?"2C8G)@  6B 'RPT#7B !J! J7G
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MD2!$2(.>&12H!9LD]I!$D0M2&(&%-$*9(MY# J G"R$N8*2*CY$FI(T3=,@
M D9B<*$"B"%H QB#_<UK Q7XH$& 1B@%8 XJ4%R C";V^$*))L*=18$7#.*#
M)A:@$$B ",:0@ H*6*"4!PNL[=OTTMQD;@TG&"?E@#6.85P#1%QX'!,4+FBC
M:X<@@  %J%+* !%%NLB@C=Y1:O^!D394V'"!**AP .0YYAZ"B@/F<($1"*[O
M@Q0%>(@=C+REE&$'+F;:@Q$7F!- "$:FH !I"&)J 8L+5,C%@SKV4<.), B2
M-ZCL*F@FJ%E-5'*"%6#"8V>0@<=T-P(.5&$*Z>G$)A3(0$4X<!13D$D"40(Q
M.$3"$D0P P0V484<!, .*L@ (6#  RRD@ @>0$0,?)$$,$CB>Y"H0@^HP($8
M0* *A%B"G6ZXP4T1@A&&X(()T*"((^*!'BD,U:G,4 4[.)!3*Y !'GKP!41L
MC 4_/$@?3C $1)#"!'F+00I,4(44T H)9AP!RJ+(N#98(12U0X0GP' "" RO
M"PK !!C_-="&(- @3V6XX11J>,.N^< ,F]A$#T@QBABH@#DRP$4<P/"T/:0A
M (K0 A*NAH08S& -:V#8(E#QL0[@HFQ%H,$MA3B#,JJA:$$@ @T6< @[A $2
MBE@!&!;!AFN=SE"0<)DKP2 V3%B "32(B@C&P 5,%$("8R!"5I8@A#'D8@<
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MR '44H@0&D"?:>:F#U!XST)HE0$'_( B *#!%8A +#A8P&0@-O)DQ.2P6F4
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M!HZ! !K ! S!"&(*8VR1!W"A2\#@!XC@5S("!KZN ;Y,3!CA#"#A$PIOZ6:
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MI01:)O; HBZ!.>X[7#Z8G%L/$*DC 3@ DCR@" :911*@S&P@%@=B"FB #$*
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M#!DT8 (-?,8#0S !(X+ DM)E1D2:*(%S3'"B->"A?;#+  HT8 8;\" **:"
M"#I!!2Y$ 89J@ U'L$2##%1*$D5B"1B^$ +_)<P+,GLH40.LU)$U5.E&"IB#
MYY P!!2$@ )"")4#5H($#8R$#4)8$T5L@ DRH* !,A*+"!"1!05" 1->@&'X
M<FB"%!3'?$:(PA <<#/FS<*-0]$#\*YP 36P8 @:&(,3/Q0_@A'A!<X! @5X
M8((AV&@L-'0 (U:EE@448@4\( ,!3' "" )@#H@0SC9B: (J*"!V0^!"!H9
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M80(K:$$&X& &4I"4!WXPF&WFR%4G  $.#>"" .[I !:UP (?6-%$CO$&)4"
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MAYBQ T:@B"& /HU2!A4&"0Z@ ICP EX@$<Q3CGV@&)#2!6"J'#R #DMPB0J
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MB[_YJ[_+Z/^,/Z $MW82DP< =P"X<&,C/B % I IJ+8 4@"V1D!Z$@ *C2?
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M$25.I%C1XD6,&35NY-C1XT>0(46.)%G2Y$F4*2ON09-#DT 9HWI V'2"U @
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M))-4<DDFFW3R22BCE%(E 7X#(P@7"ZK2HC40,B^\A)QCT*(Q3UI#H#-/$D"
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MX PGNQ.=3C2!F3]((PS (!@HE-">QAR7"-95!A1($Q@40((B1CB#,;GP/P
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M.#<"801&&$@ B  3^+<0P #.>24'DX$C *&J< ("6($]N"2 :X$C_Z B*%
MG:/(,O"3!2@# ?LH$R %/M@#1O@WH](%G-@&7:BU(2  E'PE1G!&,M  1OB$
M")" $<"$F$2!%: $ D ! B *,/ #-M&#9'$"%(  ]3H&)L@O(M"9"^"9S4@L
M!NB#([@ ?BH(LDP"%EB"3_G(,;  (K@"$A$!74 _BB0"%DBK.>B"CW*";3*"
MDM( O00W7% _(4 T?ND0% ""#UB!/O #%[$D$LG((=#+Z],[)V#)HUP 7<"6
M#!@"$^J.!3B&,Y@#_%H )> "LB0 ]6*!IG("]!  ?V,$.%#,(B, %5B %P "
M4- 5 - # AC- DLK'@B!,R0 #< K7"(%"?\XD-C\A#U0@STAD(OL&6KCH]V)
M#M<$!L.4SDXJ".C;*$R  IPP%\[D2MU4*A0PLIAC@?W+B2B @=;!B>SZ%*H,
M*X@\4 1-T @2@7CDD;/RE)"(EI00@0E@2)38GP4DDI:Z"07M4 _]4!!=B$."
M W;)D06HAQ@CD@A@- D5B0CX #&B/2-Q$ MHJA8-41S-41WUL?I)H!XA0R,!
M*0LM"?()FHDI$O+)'CK9429M4B=]4I"8S@V#THW8@P]YB.^X482X @EH4>@[
M0-EPCBK44BHM4S/-T4 3C'-;B#Y8RH<XQ#:H@A,8"CU@PH_H@WTI"C\#AB%%
M"!$PP(B0(0C5B]'_<H@%Z(,V *&2V@2%@Y7#@  &^B@SR(QD88$3V(0#4RK6
MB%18&;T+J9HE&:"Y&*^H2 AL(]."()"C7 @1V %JH8V2@H,]H -4/5-;O56(
M'!;%+!2]23G+20 :8(&) ADC>!,?V(9B30"]X8,Q@3Y/H0&,4=8$( )E[<)?
M=1'(N8,$LAQM99 ^0 0^)3\L\ 4*6(!>Q0O(4=9=L9R\@P'R\1P:@!0N/ @6
M0(05^PK*\P$C\!P!\ &!B->\R !#V"*KI(^$>),4X2<D<"4P&(,*Z)(%D"SK
MDBOR*(B;VP^JJ8#ZX==GS(E&^56+7=?*45<WZ9*/@CN2'0A,V-=I19S?_P&[
M._ <Q-F3>"4"!/%1P-E7DXE9LOF=0T$Y)R"@JJ !DY%6,*&N?0W/F+V<C$&Y
MR_FH!-@&2V..CA6?@0B[0N@"G069;?B8CI,"'WT4O #87\7'1E$4?RT(?076
M7V6P6A$!.LA07)U;NGU("OJL#] S-0@T#:""8]@)9"3+?[.K?2"%$E"R\73/
M1E26(M #1H!*('@# J "/HB )=, :"F1#.!*#:" %L""D7,^\;B$0H"V*S"!
M*?"*)4.!]<BGB5PEH-2 (P &&(B K1P""9B LLC25+V"BWP9)Z!(1]M**L
MP4J0BLT))VB"+>&!-[!3A) !+9)&1W2 4E5$%?_8 Q7 B18@ED[U%#)2712
M3,>JC!G\2$#-"18X/1$P 0G87$P:@3*0E6AC R0@A"\0E33] 48HI4DEA01H
MS7?1@N*R*RI@$73RA/(0):D2 @TPH5QP D+0.Q;82D: +4)D$4I -$:@%S-3
MLOXE DOBRC,0 <0= B/ )==4);R(1651!%AT @GP D3KRA#)SV<2@L>]2"<K
MA"0HJ4CZ2 *  Q_HE!:2IP5^%]Q\8&VIE1:@U;J-8BD.0>OJ)L_<DF]I@0DH
M51OL@Q!XV"-8 A/ +[AE@!=<C!09*L8M+J/JA.<ZQF #@&.HV#Z@(P"X!4_
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M62)X-I[&G.5=C(L-ZADP*5?F%"[P@C/X'68ULY+++3!K"M3^8R3:GY_[,B]
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M =>),(#Y7?%DY2,*$7B#4EV #4"^9=@O-7B]61TN2ZM"(I B#S[$?^^  ZJ
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M0!^F1PD)2"(+2K" \PC2!Q-4P -BBT &DL #/6B  2VH8MXJL( -A.!@:LG
M7@BRATF!005EF )9#I6.10&@#$.Y(OD6:,<[XC&/>MSC9_KP PK(  LVV( #
MB'((&Y3  D3H0,T*PH/D\. -_9N"#TPP$@ H@ ,G1%I!(O M$12" 0M@ 4I&
ML80NL6 &"F#.&9#SA0H@H0I90-,"L)6_Z4$J"LZ9R1WHY8$L*,4$ V%9"QR
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M/@T! :R <+  H&""!5! 20S!4("!*JV!$IS!'&A &X@A<KS!!6@ %W@3"D#
M43#"!12!XS0!$;"  U 0;S010?A !C#"$&B!%@Z!V'" "US &;# &X:A<*#A
M)Y++&T# M\"%&6@ (Y#"[[7 &S""JSC!%G(!"R ",'!!5WR:!ZQ &9A OI !
M*VH !0B'",#!-F2 NLD>#Y"!$2B!"2AB'!K-$?3 ##S!#LKBP0C!)F+CS7A!
M(;KB'AS!!5 !!8C $6C &$@!FU$!)J2C!@P$.EZ %!)!<6E ))9)!J  (Z3
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MC:J0PK: (7L9#:7FCA[@3P0@31\P0A/XFRKU03JV@0K<;48H3AF<@ :@ !#
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MV)3B!QR!X6@3)OR %I3!4)8 =D'$$[X!M=2.MOR @J%=)2J@0E""!GP (X0
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M6H4&<K3OF!/Z8O% ,09+>K0F,Y.&H(R&# QS"280XZ8&"VR"2F\&IISY=BQ
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M>2-,\-B$$!5B@_:'&C?Z$-;<J"ACB@ _\4^3,JKN  B,H0T!/R0\.6JR4=0
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M@P(RW84%E$#;(\BS!"BPA@30 !,U6H,48@/N%Z1 "Q;C-0]0K81J"P03H+#
MO65S!4%;[]Z8</:MMJ'G$AQGW,=@ ";(LQ#\Q'C/-<*$GET%@!9<0=,<P(MI
M@MV%05O/",,>];&/(P+\K%L"%AB!4 2"<C\00>!ZCDV@)2"%"N!: HU]J@28
M@,FN:L%Z=^ WI;E@:D@R:SF>H.V<F=YTIS\=ZE$7B !<LIPL2!WKA\H+&'Y
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M!5"@#;X 8UH@"GPA+QX"!1AA$X:O,$:!S:@H"XH*"<H.)W9D9G1'%X9-)EB
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MJ92N&]F2O,:)?MJ.!TA)XSX2"WZ@F/9"43S"8KH$V>QK"6C2 B0B P@!M9!
MPU;@L*Q"#R  #C(@93[16]012AB!"L@  IRL$GD%Q1I%-D)2L^#EMXXS5C;2
M.[\3/,-S)[[  4)@F[KN):=@&\X% #@@R,[./SP!'0.D$SXA0(S@339M2!3#
M(-!1#RS(?WZRR\!C2,J 81;"#(; T\9E%-0/J;H$9>(G6I)R034BHZ"I"PZ
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ME$+ ",@C0+J *S4A%XYB&U80FJA@* QB_U8@G<)E($(  Z2 57F("X3D$T3
M ;K +MR5!V@V(]3_PU#V0!+(1'33L7/AJ9D4\7;BT:,>D69X)B-\ "FMQXI
M4SVX8%5+0V_6X$MT( %8467EI3 ^A&P((U4FB(-+Q B$0&PF9PET!9((H0FV
M 4I?I FD( %H*W17\T$2P,(<P _08P\F(#LP,4EI1A+BT0?$,H-/%#R$ #,W
MHA9\@8I)F(H4@7.MAV0);>/6 !,P@@>,8!N -67OX$UN< >8P%\2@*Q0. ,@
M60'P= %>KS#  !BT@P8Z("TP  \0PPCV8'X* 86C8#'TV&*<%BBBUE&9<RUG
MZ.9^ A. H(\;;H>[8QN0"@!^PFS1MH*S69NW^7-XX H:H#PQ9I TX /P_XF=
M3. -V&\V-,!&]T#EEJ-:>2 D4<!DR@ BZ"I!<,O;HN!KB6V/H E$O40"ML@)
M9J8,3 ::\N]O/0,,2A::*K1*X@D,4$ #Z.I"4$L(4, $LB 7R&!=>6T.YB7/
M;N4*#$4(WD #G" ,[+F7)F/%VNY\'0 %0+,$9/ID-P(, ,I$-  VUD (', $
M1$8((.+J6 !_D,5D7(:0#"*C0X"D"H,%0N!-[PT,9.9Z-X#4H"6!1L8"( 8)
M?F"F">,**#H0=Z73N$4"",,## 4,0#3)JLD"T+8/4, !TD+7WJ !H$ M[EER
MN(((;ND'?H !6D ')B/0K&<#.]?41'>P94P&R/_R&)A@4@B@ <37?3Y@72NB
MVA[[B;G9LS\;M#OG=A2Q)JPIJS='@=4V*K,NM4/;M5\;MI^N!!O !( @@F,"
MQG@OMFOB5^AYMW\;N(-;N$DB98V@LX>[D]A0"9&;N9O;N4,;0W6;(Z1;)%J[
MM8G%ND/BNI^;N[O;N[^[Z;C'%S#GL*J5^'2A<$F"!4[@:]=@%%P@(CVB#]K
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M0^W>]F\?]Z]PNP%@]R?WXEL #N);)&ZH)"BCHW(?^9-?^7=[-HHI96F^,/K
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MC>101)4,Y\ &;5D(-,<B3NNLB"3 T"4".+Z882%8:IJH@*4Y:!8R-IN<0)I
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M[,G:Y,")4?!+#'P!BG$1Q@;&*1%1BH6$3L 05CYMVC@S@ 9Z*.)7#LH;6F-
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M0RU./@<55( 'P-(Z .94>C#\@.<">#ED9$L0A/<!"".@WJ= ?Q_B5X\,(3C
M'.B@@.*0'O0% ?UCI&\6 6A^#60 .O13S_V!%*?XI#>U60"P!MI73P!E"(&N
M@O05Y^M>(,[/?.G)[_GJE][Y\0=]<69.?^K%GR##YQ3E5WX)AQT=M0!^-5<'
M 'WE)P1C0 1:(P #:&K4\1H%2 ,8"'\9B('_)26!LZ=_\.=]&/@:&4@=)B@
M?3 $>B$ &?@:H%=^&J@UC0 I$RAY-GB#. @2,K #7:!>P' D8* 8"^ $65 "
M;7 !7S [._ [<F!%+$!O(L (3=$'*8 )9+ )$#!W2(!Z$: !6G!Z_ $!+@ .
M0]=Z1# *85 "#F $&1 <5P !$ !TOE$%R08&;>!+7. 4F" :+L %&0 !0] ^
M&P !1V@(94 *>L$!01 9%W !56@";3 $'00&G2 ;^E '%P !>1$4@,@69E$&
MC- &ZW8%FR"*1C"(%X QDG "4( $8K@T(D '6Y !+O SSE0&*+ )AK 'XK0
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M2V"E7VDN4; $+$ %)J %9* %D'!R2  'J-F%7^@)0N &D=*F<J,8:#A 9@4
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MT@D;AK - QPRFCG 9N$!040],"NJS+< )9L!0S<0(N %*-2[+*I^E$H$V:<
M6L.NB<J;;\ 6KIH 6BP0'="$C]P$QLJLI?$%K[284M7"@.,T<S +SS$*?;@?
M&="L;D $3H 5'* 91S TKMHN_[<0!$_Q 4UPRP*@QB,PRC 0"26J MO@!0R@
MO%G0>/S*%K6P#X'DCR9@1>,*5U0P)7CP"0SK :BG!QI  8>@!NJY!Y=@H4-5
MH05,MBHXHB7Z@.;LIRJ@*X2<?F5@"()5Q4M#P=/CJ@H0 0Z@!(;!1C,0 881
M$PTUPZ3@C<K9OHY7PA(EQ!J]T1 'M4:\ +4 N$'91!PKE"Y  "@6"?+! A#
M'1EP FK4G&9 ")N0%Z='Q<M(AGEZL5E'!& @1['1&B5V!%_P1'>X:[8,9[33
M!N,!!D 31[J\"2 Y Y$!-$&P#69P M X$!O0&GV0R&30!7U@!FG415V]"8K!
M C2= O\)X $_@T==K0%8 (>L%HNYX #!ZD=E0(@+XP&$ (?(R7RF27Y(0-.*
ML0>=0(B3&B3/^"N_YE,#882;@-0Z"313D #76ST>@ AJ) ,9L ],C3Y'$K[Q
MJB7PJ)%(< *9J*]1]Y] V -#8Z"XRQAER+]XB@1-H!5#((HV\0D82I$)#%<_
M0 0^LPGJ6"Q[!8]',L&24HHJD !+>!:8XP%?P"_N>08"X*J@\@,!^M=#X)"T
MO )E<-0RC'I"2P%7 #1?$ (L &^&/0**N+0</=_T37"G)]_U[1"MB]\:\;$0
MT0=OQQ)J:"X9@*40(01PL'7SQQ%<]9"8E]\0'N%CM@![4 C_8R?A$P$P#I#1
M(Q$R=K<0"X )WXP2F" %=\"#]<:=$K$'%G"Y*B$#QY!V&#[C-'Y1-ZN1$;<&
MQ]"<9C<00C"Z#.*+)HL20O ?#+$ QZ"I&\$#1B#C!1%R#F!X-L,"79  _$U^
M1>OD><QV-=[E7O[E(), 3M<;1O!^%.%0$K4&4K!X$!&O%+ ! 4ZI7<!_LB7F
MO$5BC[3C_6T$_R<@(B#(%"$$NJ#E%8&D_7T'8P[FBK[HCQ<!(>")<!5X&R$
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M>6+4E9=\@,&01@:4P7.3?> @'E09R@GXF ^8A*T[N# "&F!1E1>P!@<-KLG
M,8U@/H8$3[BNTV_&%@W4?&@^T( &1O"S8!RT!LH$\LM,'L$:ZLR#(.6:R@(I
M6VY?+6NQF-D(?[XTHU@M CIP)]-^7@"P/4V$5E_YTZU>0 N83 0:;)G::U!W
M MQ=FCOX^0!99A1/\+T 7^,9V&B^];BM16@RU9L/74GUL,'\Y%9CP@BY2( 4
MT'QDBE?<XA?'>,9KR(-X:IP_']N#^;JS2I$YKUKIX=7TQ$)R^JR2Y>59@ 7(
M18DNM#H]$?6X=YQ'KISWW/_G/P=ZT(4NG@5$H%?>'KI[/-R&$:8L B'@N7DJ
M1@JDR[!)]D-/CN_\\Z=3,^E?!WO8Q3YVF@+,YB(S,PW>O#(SG_T\9JZZV'T@
M!;?#G DG QC2L:6?%FR]/US ='<PP0<>1)WLAT=\XA6_^/2480=^_XX/6)V>
M.QAA/'TP 0865QX>2  _US*""#9_'AZ@F=MQ[PX/[@#YP4V\/:6/_#&48 $+
M<*'NW^$!%UXN'QX4@@H_/L\<NCT>.:/\&'463U#\SL]<V-X^289/L+SBG2:Y
M 0R>0#[CM;]][G=?Z P!_G>N8(';AZ?+K@=/"1RP!3F<7#P\R-A]SL^#T9L'
M#'#_( *W6>\=L'P'#%GXF/88/\CC 2EP@A[H KKC/.>KCZ+)OO,0@6M O6JJ
MB*P[AOWKCE !%NCR@3)ZO@B"#QGP J_K#KE@@2DH/^]3P15DP1:T(7\A +[8
M@ 8P#O:1+2<8+3B0!$* K4)  3?8!L$: @90'R%<@34XAC-8 S PJB8X!A.X
M@"7!/,W3 @\XFC[H@H_I@R8 #">0 C>H"A2X .@8BY= @;,Q(PTX E)0 I_)
M'"'XF2PX@&/0!=UQ(>: 0KX0@0^X@+\8G%%0!"J(DAZ# P<1 A";GCTP 2(X
M!L]BA#,HE4!4@#XX@J%: P] @<]R MMQ@V33 \0A@A; _P)"X(OO.#T?.9Q2
MK*:S6H(^>"7,&P)&R(+->(,+R"AK:0$)  XD"(,^F( &D,56:P$\4(21*(,C
M&()"Y($H0 'J$ M_2<:>D ,%N*HAL(TUT ,"(  +, -%:()M< !&@!;/2BG(
M@:KZ:10B% +;D:!G%*P?2),^0 $"R!QU$8$LP(0Q (PKX(+^0H%/>)TWZ 07
MP!$1^"/OX  J,($AZ )U4@@DD9?7N0 "@((#V(/#.8,P_ TR\8 ZN 0&,,,A
MH( U4!>">B1D;(@KZ)<&"(L]L"(7A,F8E,F9C#XRZ()<B((PD(AMV $NN(,,
M2(*7,8(UP 0!RK\Z4(-M4(*&</^77""#(3 ",#"$JFB"1*(S74L E%B!$F@
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MCEKP!2WH"BZ( ANPKR5(I%!4R]3("W;[D=3LIXOHA!6@ ;4ZN.*X BI@ 4]
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M0RIT!1P<:** " [H$$6@$K60 1=1-*& #![\L", +9B@Q0XK])'"J IT "<
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M!85DX ?5NI8)[H<.+\! "+M2R$.<I85H-01AZ"E!%/07J6E]:TC0"YE#X,B
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M E A'&*")?+!7,A!.FR='0) $TI!_+G)'>CA&@B!&QP 'R9@'5H+$NP*'B8
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ME_VY(W$6IW$>9^DL@.^9BF'Q"A:H00DP @/_^,M$N9T>E,;M@5:XW(OV<!
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M$N!!"C2 "0!#@?7-9'08!OR =Z:'$Z" &52"\!".])A&&VC #\0(!CC!$##
MTT&E?75;YP15O,@1<BR +J&,(NR&B7$+>IQ&:CA!::3,7*# $0 #HP(!$7@
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M'L;Z *("%CR!B  8Z-I@%@7<@F$-)V:H:8\)&#,LB -D<(**$6I*J8F4$%J
M$L#H6D"/I_9(@8@6@!B*!1(!X"$*-A18@(4A5IQ%)##0J,0A%@[<* ('PF A
MAA\7  .AC?\6V&#(_6S@08.YLOP@NY3:TJ _[9!$L(\7;RP"@#D K D,H2[2
MJQ8VZ.)AE L0>^B_XQ8@Z@@&[IC@#+I$  (&,&)0 </1%' BA):P+)(%0@1]
MJ+KM>-!E5*I,^ 3!+T<0CC4PJ,"00"&)Q.2()4JH501<@)G++2XRR"Z_:['-
M5MMMN>W6VV_!#5?<<<D=;X$CDBCQ",8V H,4/FHJ8PR1>,A@B3Z&&'2!*ZA
MD#,,.[@PPT(<^+%$,MX0"H!2RZ"COP4*T0N3#))XM Q&^-Q(@!)V('*4,!9P
MH@B-#M)H 2S"Z,,!&.E" @XE@'B8C"RV$X#%A6,606#_L)S#!9/_*5&CA4\7
M.$://Q@(N0L$ 5@SG4:F.&)4KEA3C J1/+#!+#YE^$#1ASQ@HP4-TM6.!R^,
M!0")%G$L48Y! 7BTRYD-H[0FX<J(N<1"RBYRE"Y,Z"(Q'DR=@XX?FEB8M"O&
M4$(%>+63(8HL3-@U R9KDF$'P3<28@PBB<K@#!%2,%;EXR;.F(44$FA@U#V
M<&#41W,1O:8U[J @L7)Y[]WWWX$/7OCAB2_^/DO3+?6XA8=@&>=T85\QU@W(
MDM $##5,&]="))@ PSXTT$/A*V;(!0]*)?^$) U& ,N%C&N2D0C884CIZP4.
ML:'(PSP'G4Z[-)"V/IA@2-JY0A 4(QG8__D/:C59&UT:H0D99"!/%I""),+
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M,1(/_RI"A. Y2D4DR@ .Q&K>(F#<$$0$(@8U-F(/:F4-]. "+B&4@@,XVO
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M+,PS"PA. 5K@#;J #]9  4J@,_;@"/AD 6B@!>IKY,B@"P2@1(;+$$AK![C
M![XJA+#.!%9 !!J@"1) N JB#X !ZUR'!OC@/XR@.3SA "8F"U!N<@Z !68-
M06#,40R! @ ,_L#M!8:  D+FY/[#?S; NQPT^L  \1) "%X4 /0 PY @#GB@
M 432 W*PS(P =OP*%Y9 /AWBLT[K#NCE<A*@!13.>I8@_P&J8SU#-$>Z\+3F
M$SC%=$SE\*_R\S\Y0!-$0P-XX;T>HAZ@@$[*(.UT:P(.9,2(12:3;@5XP ,B
M"Q/TX L88 ]0H*&> RI" $<<0P,,%5[ AP)80$WA4 0^  HL"D%X@/N@X@V<
MYQBJQ(<X#7]Z1.OR260^4@^(TDO((B5FP%4B$@5&;0IN*@>?Z$PJXB=!IP.\
MX-/,P!"@<ZWBI>U*! ORDYLN(B,LQ/4.@0WV90P4H.JP,V1LRD]E0 ,Q0<;D
MQLZZ@ =DK(@T:G4T0@:\@+2,0S&" !-DY\6B( G."G0"E$SA-5Y%#V*&[1TC
M2$U40 I0[2&6\\4JIX6< *&8H_]D^N '*H 6I8 /(J ->BP(B&1"?J("P( 0
M,D*Q*J /&,$G]F16:$8('FHYF8PHS] \(<"W,E7U(H!3S[)CE(33 .!CWG1I
M!/0,>(! (V "NN!;^\7D $\C3E9N"L0"MJA16(0(("$.Z (2U& #0F"_INEZ
M'$582<U1IJ T%.7,2,4+H(!!@\.Y N,:S$@C@G2=]((%Q(1JL^3> B9MW&D[
M)HLZV& .>LJ'X@ 3T&'8,J (>,!.95)>_?9OG\U,14,7E@"CH((*I !M#F94
MZN5([X8AL* )I" #AD ']@ "(, -XFD/)6L&=@M&ZF4)/*".?!0(I. 2O*)>
MT $%H&#_<H&!#][P#$7 ##I*HJ1+"D9 D[) "E2Q#.2@"UY P9JD,AXB \9
M"HY!C[)@;8/C"$B!^;Y" U#1!'1  Q%M.<' %T#AJ09%AL"*!@B-+OQTTK9A
M K!KDP# (-@L89M-<:)+!5Y@L+8C.0"C?4>#"%X 2(64@%[@ I9@*!H!&"2
M08A 0UIW0[FK2?"@NM0F#@@5#BB7 4[VZW($)7]@"=X5<#5X@[,*8J8B9)YC
M[12C.X.F:1H 1ESBJZ#B$HP@&"W@#39A0!8F!9PG@ZM#!$( GX1("W1!+5H
M!3!  R=$!X[! BP #WR!"3I%#>O%!=).)S7 B(.%$7[  KI@_P'ZH!/0P7KI
M F:5A #@(!PO0 TPP51T;?84 P)"X /XM(?H!/#F@!#@H/U )P*(UA.,MKK@
M5HU&H VE 'WCIA/"F *FUKH>*@-2( ,(P<I$HZ\,>2C"JS0B:P'DB >N[PT@
MX/VR%QT8H8YXH!/ <6E8RVT9N#HPXP>. ,HR%=!*Z>O"DX-A.981R5*6T@).
MDP7(SXRYJ/[@K0I<( 2*;@V6\ U0P+;BIECHH@N7!PPTP $F( 3Z0P@:P 0<
M4 $FA/TT@#*EV0&J^2M$U@PQX0UTP G )$L<X!,THN?@1@AT0:,Z3<1 EE_5
MH%32YL06C06R '2,A&E4IG"%8D+.:_^]S@0EC#1<%4T(+* =*8$4O(?>A+4#
M.H%M-0%0?&1WA,A8=%5?OLE)1D:RV$ &[FH!\ !IT59.*(!Y'UD[. !+$BT)
M5*8"1 !E6.@)^P909/FF<5J0?&#B5/%V[L (X&HC=GI#LT0*R,XV?GKBWG -
M<F$[SJW"(A2U-,8'P(UIACH!8#&J$P,3@GH-S7,)4D*59:>#WJ!O4@2QZ&2L
M8A9$O*:,;>0D??4K2,'I) 0(\ F$^U@H;J2 II9%W-.\'@()*D*:B60.)$%0
M@W4H!/MA@2 I1&9A".']LH21KFQ.#@6?CL$' 4!78>">%N6PJ/99"Z$+=,;U
M,*Z/>&54?"3_6!R@/U(*71DW"LC"Z21'#>(JIW$[MZ\J@]&#MQ>14GL$$J8
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M\;T^YVLB!VK>\UF>T8T?XZL^W67_Y6>_YI5>YT^_^*E_^N.^)J+^^5?_["U
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M'UA@ :M(>))0+3;XA<3_"6?,.,<B;-PE AT*".$%'!]\,(:/ #0"C!(9I,"
M#)+ P2D?QWQ@1@J20L(&0@L@T80"X:B@A DS*%"+':R>K$E"R'Z "!42;%/(
M)X,ZL$3'HTY@P0=+*(2$OAE000$/]&8= IU@*"+!&QJL((($&6Q"A1][>+S
M"PZ$X,0;/8-Q0A SBO##T0B5T  <3MP]@@A8&'(P#V2<,<<4"JQQQ1B"+@!)
M%HZ^RWGGGG\.>NBBA[YS$7SNL,0"$B]4QBPU@N$""F<@U $02YBLAQLUXKP0
M#QD,,<:U(M0Q!*LBR$'$,3M<*T,4.2,L^1ID^,&#' <GM( '.>_\_ ).] S)
M_\1SJ$ $$HH$?S+$"BTP2A( +!#%[ #PX, 9'1/A1!8F(\3!#/-_ (4K4&%;
M0J "$2)W*S)T84:8*,3!K-:"'1RM!29(0A\V00@8 " "@5-:!A8XOPPT009>
M((3_9*"+)H!!<@ 0@0DN!H8A7&]T-*RA#6^(PQSJD$6U\-_[G "' X1O?4(H
MV?L.H08GJ&!&C?#;0EC@B1FI;F(*F8,ARK V ,R!#B\(P0&L5L1K 8 %KH/>
M^W9P!AE8;WW:0T@MNL<S?$VL#QI@  =4\(:+-2)IZVO?^PIQ-!$X( S'JX 0
M@###A/0/ #)PP@P*L36$1&!M*YR? EFS!Q,\T&-.T/\=0M:@/3"HP -^BX #
MW(>0/J# 3P@I8@(*H80OW(L,3=C#%!PE!!7DHA#RVZ$O?PG,8 ISF%[B0!P2
MP@(#OM$S"1%"&?O .# 00(/+7 @'@G"7-? .>TB(@PP*D04 0!,##6";QX2@
M"S&*  @:1,@*,>$$#5"@ W* P1H<E;WG(<&'E8*# B"A!DR8( M$X( GRO #
M/C1"?0GY)JL6P$L:+(!^]J.;'B  A<TMH'\'V ,*)*"!=LYO!TQ8(1%8D$50
MF<!/]\N?CW*W!U)H811AX& D 1#&A% 0 SO@PL,6\+@5UF@!E&B#$XF)U*0J
M=:E,;>J)=N;#,5+A 'C8!P'_4KJ!DNUL"A(Y@NEJ<<R%>$ 1C& $"JI 182(
M0!(,V!GYH*D %HQA;@I0GACW( <?-4(1;2#$Q3K0C=@-\'W:NQ423/<^GOF,
MKR[P4S<=!P4.\!%[?I3!*" P!$;TE9 >XY,7])<0).R#$1 X R92.M(5L("O
M)P#M!AW80NOI(:HX=4,9R+>'66"@@^_;0#H3TH<=: $(*^#!$7005!8B9(LB
M=:ISE^J#15E  @PS @W*I"I)@<H/>VJ!KOC &L5 RP)^$-4:^D5=*?!A<]'E
M5 (<-29ST: $7;@N=Q,"+3%BSP>:\H.Q$#(F/VR.!YLB[WOG=PR&28I:CSI&
ML\X+_Z?-K4$*3& PJG)CJ%\-]1@"UJD$^# J"6RJO)O3#;3\ZRA,E.I: D#5
M" 10 FW-CU,I/D:C$!+=7;5W3]&E0**:!:I?Y4D)TR7OY,JTIT2M5S??%9<$
M])N \1I!4)!Z,H#](*@]3%<)2F"5BJE;7@;[)4V" T )+/#?NK$*6426% WV
M!ZA-+;AWI<IFOXJLA"[PJ\!H/E:!PQPF[B%$!@K$7%I;Z3K%J<!59E#!",!P
M5$5&=8C()$07I. !0JQ@#M=0@""50(<*9%6,+(BT4%%* 34F,I_O6R1"/ "^
M,*QAH!L]YARHD &&Z@P+[EM /2+) W2<H0.A3H@(&)>01O]$]9N]G"0,A%J&
M,71WI2T\)_K>EX$9C(\("\C #U @.%6VLVYCP$1/QZB!!JA0N2U$]G/?C=0%
M@*$-5<A! &YP A5L0Q)_J!$2%@$Q2-#C8GU@1!5B4%H?10 1H< W(4:(!2OT
MX 0]2($1WB>$-IR@"B=H[8Q8@ 9?W*L,54A!+@Z!#5+,: ^2\$4BU^ $C7<\
M"(/"@Q4L0:V=+2(&-^@!(99P@#G,@^<;3T&9)9(&8(P E(B(0;X9C(E(*.)H
M/,##U%N(AE!@4ZVX4,3U=D:/&2S@$ &8^ D(05"&@ $"'.<X*>["@D5@0PW.
M@D0//K& 2-C!3RRW0P4FAX08,!3_#&B8PK4XL(A0S.  .^M!$42 AC]<CP,Y
MB,/.;$%TQO4!' %@(0OJ,#3L]8'>9T_C*+#AOC7H0>,<1[L"&K$(5&P/Y0R@
M020:/G&:QYWH^?[O0M8: !>(40:X"(#!Q%GX4:&!'E7 ]Q<$5L7EMST%-WX?
M)!9AAS"$\.#S8#XA=! )S'=<!0< PR*8W_$44""\7=JH_Q:P 0U<' ^'AG_)
M-C $.##L#5^ @0AXZ2.5PE#5Q$BCH (,HP1MH&V&,"-"P BA5@9 L'(34&:5
MA D$L +T]')M-$8I\#=H)$< ($H48$S8!@Z3I3-^!%' 1C56 P ST@=KU&I1
MM0 L0#[._Z(' U1)//!",T)!FZ0 +=  N]('!,  >Z "!S-OP"!2F/ !/3,_
M+X0)Q+5!1^!7*[0YA01O6SA,&;$'D4 /68 !?- !N& )U],(5> )VF0':H Y
MMD *1G ,G[)!9F '9Z 'B* (2W!Z4" %>! #0],':* (<( !+] &=F Z\!.(
M/# *>^AI>K@".Q,#;& R(%>(1E "\K-Y]?8\ $!Y0; -'K (4T $(I &OL %
M4A %B^ +=-@!:6 (([ '(<<%"2 %^I4]@<@QD@ ,@L(!ME %BM!.(H +P,!*
M !!X^G,(.2"&3M!TBZ<0(H (/4 %7% ";1"(-8@& 2!R #!69__ /G;0:QY@
M"WZC.*^H-%A0"O?R;[9P2V,W=6M5"E)D?IYP>2I@!%(@*BUP>T8C@E7P=DH#
MB*2  5)  >R#>F,D"8IPC7=@)B(8 [;@<N"(>C* !W8 !1BP#44!<M1W#&:0
M U- A^\#!K9P MFG,Y$0 &$( +&H":,"#J6PBE$0 U=G;&A DU)@ HM C(-B
M!A-)<PN "1B@!S$ #!A@!)B !1HI!4:0&V"0 TD9DC%0D5ZR,R[@ "90-HQ7
M"RG@ !:P*\Z4"[1D%#S8,WNPE0Z@ 722.U)$:>+D;B(X!&70:8R$!SBW 5Z@
M 2C@ %U08D)5*2J "9*@ 2%@ 7C":N__0P8H\ ,#)2A#9%Q+T$VI) F5L!#?
MU&OQ,VCU0VR&9 (.@ )0R#^T16 F\)A@(X*2,YC7$@$3P%)T<"_'8 (:4)L7
M,P>DH)B0@).I] $H4)L6, (.A1 LT -L, >*X  .( %?9 ABQH71N4,+$ X+
MV4(M5R.(=TP"ET:XL'<-$0%M4 H5@"_T  6GYSYQ-P,T  G8X%IS$'+"$W(9
M4 7D9WWNN0>(\(T-Y9W:MSY(T ,_4'C;HITM% G(B(HLA FC4'G3B ;74 &-
M@ 8HJ!!@4 6W-$8QH#G$IPAOT .@M5:$\'5(0 ]L,';T@$IE@ :68#)(8 NA
MAWPNQP(QL DQ_V #F-,#DQ@.Y*A6>I<$ .I:[X,'.8HO)Z"?1, #!_HM_.9O
M&J.,V$":&Z2'$[H 92 ),\!^(M &?R!2"ID$F& &YKD_C9 #+E %;FAW2; &
M9I (9::>=Q$!6( -%Z,0EF4'Z,"+C!0)/; )!@-Y7-4'B*!T\P,)<.@C8( (
ME3 3/-">0U.#Q&,&XXE,:("9C(0%7*H0L,='3#EW8"("1G '4*E3_&A=GY0;
MZB$18I07_)@;-,!@/*"+ *(S'^$#QG9QYY4 HMH[ ,(#17$'9&$N$L%@,H"+
M1B!&F' 7?X&D.=<"T DJCN(#^+0&]U*KF+"/OC<HT'E>1J"KN#$HF/_ &IPQ
MJY]4+@CY2:^: ,$!  )0KN:R /=$K@> JPD 8@L@J]*)KSF$+SQZG:AP"<LI
MDFM(HG17"U8 #!FU$!$0":60:AFI ^C9/!^:=]^YDHJ 2BQ@!:C@"\D8=3?0
M!ITZC6E@>+TS"G9 F?3@G[!G>5=PH30@ O!8(QG#;J@(# I0B_2@ B4Y/U('
M SC**AFC"7,@"2,K ]VPL3H3>&)7"]C@G_C"M V%!]9Y1-GW>:2 !;Y !![0
M ^*H=\G( K;@ H):DC/*!DF: AF0HVOE-_H@"=CPKPX0L!L%MLLY.Q$ #F=+
MCI\GC8.&!SD B>^#GGT@"8VE=CDP Z/PB^W_N0*610]@Z0 ]^WE+]#XS.I#
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M./\YT'_D4QWW&&A!# Z0?QKDH #?ASWN_4U_ P$?"9NWOQ+F#8#.&R'@RJ<
M 0@$A@(A7 EA&$'TY<V& [E;_0;8P_<%L7D:9%S_)&A$'")1B4=D8A*;N$0G
M1A&*4WQB%:5H12I>48M9Y"(6O;A%+U(0<$5<P )H  JU3>D"/+E E%#A /7M
M18YSI&,=[?]X1Y]@8A/4RH$$='*'9;5A27@D9"$->4A$)A(B?D!8#E"@$U!
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M R*8/1 5 31(@1)23\J2.2Y -4: 3"0(.9ZR!=0:B$98!.]# Y+,K69#@QZ
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M!@>:@'2%+F6\!@ F*"S14P0-K-!'!CTL<0P7?>#441-7:8+)!UDXO55/"WC
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M+V8.#T2!#+K1'7Q 0:1 !:Q!"628!J"C'FC $;@ %^#!$ 37%2Q!"VA !D
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M@I%%%('C !:J8 , "[.@ 8S,VJABB@4@B:$*%73;#8D <@-@@0T^5*0+A_9
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M%@JH#UUK6Y\6Q"'[9;D0>,7SBFD!_+%!F JC 0ULR -QZ,KC("6"6>QW*PL
M P3HB!(>O, $0V#$AL!@"&A;^PUA8(%I4,(!"*" $1KH A$6X($<<T72M+[U
MO.D=T_\&^(4#!EH." EI&GX $1*F2Q^ H!LD*+LK0G##C[[=:4K_#-LJ'"#0
MB[T]%AZ\80DL\ 2E69 < +3 !$0:-5AXL(,5-+S><-N& QK@@!^8P $L=SG,
M9?[RF+?<YC6G.<YW/O.;^USG/\\YSX7>\Z$#G>A!5WK2F8YTIQ\=ZD:7>M&I
MOO2G3]WJ4:]ZT[6N=/%Z-[PDX^K7[F):LPB !]N(0GWILH>"HZ06RFZ!$TS
MD36TX ,F<$,9&$&(,V!"%PK@@1/>H '.^. *<# !%3C,(GIIP %GH($0#.-"
M.'KASP"8@[?[X( W4(%+5_C!&(A0AI8SH2,B^$#&5="1!32""BZY M.$P(#!
MOR$+1.@#"ARPA$\)@?<6> $A@ "#P:. _PI<.,#MJ2"%#S@@!"A/N<LLP(D
M]-7Z., ^HK:O?;5DO_OA_S[WQ^_] ("__.(_/_G7;W[TMU_][Y<_^^?O?OK?
MW_[YCS_^]Z__]/\?_@"P_O;/!/I+IM:IR/[FG09'3$8!X@8."/"$ ^) !BR@
M":0@ ]0 $SX #J2 "S"!#(:  D3 $(C  \Y'"HKO=9HO W+((Q;@"JC "%[
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M2 Z(X @80#R08 82@T_ 8 I2K_A81 A"@ ;P !?GH!JOHMODA 6FH 2&P#6
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M"18@"OZ1"2< #N13!PY@#F8! S)@/_%@"A+@"B3 !*#@0#GP)(XRXSQ!*35
M/GL((0[A*4T@1_I  RQ  II"0SG4"/91!O5 0BU@!Q@@,:+R&.13 QXL.%\4
M1EW&E]BBBL8.7DH+O?:B12R&![@ +[T"$YR 0_U@!/;@.3 !/2T@1UI /NGH
MVCY0 @Y@\GI(EM9 "AR"!U!O-X2 2NED S+/(%Y /OU \%;S#C@4 [C !Y3
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M!C"A#4[ %CR!!:@V3[1$"MK@7O9@$8@(#_X !FJ!H/IBV!*'"O @!B!@%U7
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M$RB00H-/>S"BJ0ATR(GHMMQVZ^VWX(8KKE-BD=56;FFQ>.YM>KP$QA0'1=
M%.XYH.R.]9SAV)9-+'#%)@^I(8(A1&1@PQQ,CH(? !YDD1 +*K!@ P]'N* $
M@ A]25$?0!!!QA)@I)"+ TLTH@E"$0PA)R80P\"/)GTT<"T=%XYK__/-..>L
M\\X\;^4;<(VBN^(-F$C*0D@+--(<#V10T9J_(0T5&FI]F) $"RG0@(FQ"XP"
M!Q C($Q$%/@M0 FO!_4QQ!%):'2""L?!Y&M"W,VB  NDX#&Q=LAF1LD9K;%*
MQ(MEQ!4CS3TGKOCBC#?N^*$EFIMB#CCD(%%NF)@ Q1V?:O0%%PE(-%@7-4^T
M1A1P)"#%&Z(VHD("95Q &@M5S*" X%@;48(D,^C8M2(H@2%)$)+!0%X4T_EP
MC&(<C\ #%KXHP(.QL&:10 ('8'($%$8DH >3IY;P 4H#=_KX^>BGK_[Z[$NE
MZ(E!X_9H #$4K5O5&M3%0P9#..! CBT8'_]1_-4 $_SG(/O[00@L0 &[F.!:
MI!L,"GYP(+IM0 4=P81V5O.",^PA Z3 2 ED=9 6Z$(!,7'8 B00'Q&8  54
M:&!TAO &/"D ##9H@03P(H(3MN^'0 RB$(?8LW*A2#<J8M'E0,0"P!'QB5",
MHA2G2$6O'.,WP=G-!X:6BQ MP =^JJ(8QTC&,IIQB)$[8FY45+DEGO&-<(RC
M'.=(QZ.\CU&[F5_],+0 NDTI*8[YHUL$69NXU?&0B$RD(C=DQ'7=)BTXB($;
M;3.8-D!D!#'IA$ZR0 /I%*5KA+C $,Z B1V<H1$P"@I#, 84U?  "-.9R!R&
MIQ@P5"$+-?, '!3_L(8,C.$O1EE !@C!A=(II&L+6Z0RE\G,9G(%%*B WW @
M9;_;+& /$ZB #/[FD8Y$@&!]&(,Q%5(=C/%@!TR@01@G JLD"(4'48!!.3F3
MAA0TT".0L(,-CLD8&GC #?<R2@2B0 B: $9ASDRH0A?*T*(T<G)*U,W1#L*<
MA,A #DF0@1-\M*,>+60'2VC!$FA0 @DHP2\M4()W#B #++C) GP0@ !*H 0)
M\&$!+T!$%NZP PN85%L Z(,<+H$:[6F )SCU*1]T21C#\. 82O #1GA@4B;4
M[#U.8!( 6@!5"W0!+YAX04VQ@)^26N \9I7",7Q:@37LP0)*^.J#3,K _X;:
M]:YX?:*B@)9'+N9& !Z D8QJL@:LH0='XUP(71!2SE.M@4+#9( .E6"")? @
M$BI0P@=""(8Q#"D+SVI#%K;1AB=]X)<(V0.9+( 1#JC@ T483 AJ2@0/$&((
MAO&7 Y3@@%I]  Y.^ $K"3*#/7S!("P@!' 9 8/!C$$)&:A"&. B@0^X(1<9
M4 0<E( "]1#A#A^8;0;4L <4:$ ")NA=7M?+WO8R[J%(7%&+<N,!2L5H"N@I
MPQ%.X+"@CL%\%.$1!%#@  >9\F4'D<$.2+.&Q<R@I?L409P@$>%D48P!,O!"
M73 1!7=B1PY2H((\C["$#V1!!$.XIV:J,(6_B/]@#/'I@Y)"T"6(*49[ XE"
M%A:P 4-@4B7[PX\,<!&&%^"RG9"P7<CB\Y$0=&0/0) ""J8C@I.X]\I8SO*W
M?"--W4 R4KA9@$\. @;EK($(99A%EPH'3*# LPM\4&=C?Z*9' 6U#3H) D,T
MM8!"Z" 2H62$(2J B5$DX9P&P40&, 9ECQTK!1HL0IDS@X000$(Y8-@$!"YP
M 0UD0--#$*V..#!H #0"& <00M14XD(^*PP2BF#$0[A0W]64H0U4H,$& : ]
M/PAW65;6LK"'3>P0I=&1MDGB?'$3LHXT(@@)X8$7W"D$OP#F2 O1!1?H!  P
M4,%9;,O+#+JV3QX4@@C_>$BF78Z 82!P85EOP%@$@%"!.5!A%#;X2!'VD"R8
M7 $./"+% 42@ FU5N\TPP8,B.-V&.H2!!7;3#!LX[,X%$-D#8)I41B[] 5[U
M80*@^$%\.A#L8IO\Y"BOS5ZSZ"A(&=(VF"!#%PIGD!88X0YZ .A'. H4&=1C
MM. 1@2E]@@E&4.%ZV_!"%_8PBAE@(A)!P( >B <Q+MS!"  (C1I:  2#[ ]C
MS9/!*'PA%]B:C0K=\R='1! %*N2"#"$P@A3X(((&I$X*P)P#P1#B@2"\P U]
MK 4;!D,%*>A!NARS.GAJC0DI)" #12A# Y@@A0RPH04_<&>5 9SRSGO^\U<I
M_]<^D%V;M*R%]+0I008TT(750*L!,=RJ  'C!/\Y()W'H, <SM "$_B/QF4P
M 1PLL 1APJ$!(6@@3E_XU9B,@4(2X<$+[LGK*^"E#!Q90PG>'1T-.& %&W@W
M 'S 0!F0X0<FJ/D''# &ZN\^(2((P1TDT!$P3.=9__L  Q90!@>@8,=E@!]]
MX #(AQ%E\ .L<P \H ,2L26)!7H0&($2.!128 5=EAM;5!POUR%"P'-%\8 3
M&((B.()3!%]"HRXBX@,(1X(LV((N>$8_PW(G"&8O6(,V>(,N* $X(#GQA8(X
M^(- &(0IMU=XU'(!< -=)(1*N(1,F%<FB!O*-DE-./^%5%B%='1'\?-(+F>%
M7-B%7BA&3W@;;!0#J/>%9GB&:,@X,9B%M:$ Z;)':1B'<CB'-[-".ZA&4"A?
M4DB'?-B'?O@G6#@<T42#?UB(AGB(O!&&R29?28B(COB(D.@65\177K:%D7B)
MF)B)4Z&#/(@;"J BIZ>)HCB*I$@4@>AE@[B!I;B*K'B)BE@;RE:&1R%,:! #
MMM@#*6!;2[!.I@,),9 #BJ!532$"6# %J@A_9J (J*$1MO@V6N 1VW!6(&@S
M"X 'OA!0NK$ OFB+]C139A #+@ %JB$"M6@'7R"."V&-V @5+1!=BI %Z[@
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MVY%/;9 "4F &Q8HVDVH';3 %V]#_JR>0 N]V:R=@"%I0!EZ@$T.P C(0"7:
M N0Z!HP0 RIP $A0!2Y@!G:@ 0SK"Q302Y;DKEUC!Z'6 RLA!*\Z!&APC7J
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M3P'<$?&L!OF$'R)0NES0&O>:4>& "H2P#S$ #&6 !B>S''<\J5$\F?7&J@K
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M\\PG)Y^$,DHIIZ2R2BNOQ#)++;?DLDLOOZ2I$4620(D')ZIP 8H#9,#BK9F
M"N.G-I!DX0073,#&!H+VH2**(/90$% DD<M""*VHL"N"T.Q3B3<;]\#BD@@S
M."$%"F0HB,;;6$ 3@RCV@6*4.%K @@HX(6M.+YJD0"6 *J0 $TN< K@AEUAO
MQ35777>M:0$> OR/5V&Y[, ,D89%-EEEEV6V66>?A3;:!7R@ 1,\[$ M6EPE
MP,$EGK0]28F<<K +7'//17= ZV90-=UGUZ#!1G?GI;=>>^_%-U^?>" #A38(
M(:5=?:$\!A5_3H#U7#AR_\ A!AH&ACCB*7U0P@^!)<8X8XTWYKACC[=<H 0+
M+.!"WH]E4J*EE]#%J>%O3X8Y9IEGIKEFFV_&.><G06D5899SB@$3G8<FNFBC
MCT8Z::619@F'E<\55Z=REZ:Z:JNOQCIKK;?V28J67D5WX88?YKILL\]&.VVU
MUWZ6)6_1C3H'6]FFNVZ[[\8[;ZY!R:D*(]#] &BR]2:\<,,/1SQQ=]W>9QNX
M<T!E)\4GI[QRRR_'W"967?U;X1SP<3AST4<GO733LT[9:<?/G57RTU^'/7;9
M9X?8:\Y_#B!TVG?GO7???P?3[:?-C?MEX(]'/GGE???:Z83-73CWP9>GOGKK
MK_]/7'CCHXU[;NR_!S]\\;/>'&S6!1\_??779U_FU(<'%Z?(MV^_?OOOQS]:
MVWUF'96Q\P=@  4XP."IC'[/*AX!%;A !C90)LWC'_08ICL'5M""%V2?]AZG
MDP-BT(,?!.&6,.$$1ES A!<80@B(<#$MK6$;&3BA"34@FULMX 5'B.$%J$"!
MZ56I?,\#5^!HY;T0%M&(1WS2KW+@CP PL5LQ"(+)NM2"2#31BMV*#0NQM :*
M6"$ .&!B &P!#-)<:0'<>AO4QC4U)+;1C6Z<0PY2H(4U$,$'";A#:,X@12T1
MQPY4($(":)" !)0!#<"@ )A$( E"Z( //K#C-D!""C[_2@F"0-16](*6)7@-
MD@9:C%(G!4:#'I(2E.DR94\6 *]<K,%&I!0D7#IYDDXFH)+1@M<MG]1)72Z+
ME+A:P"^IM(95'B"8O'QC,F>"A)#$A 4].,N7>! ) 7T'#W_(EI?F@ 9-Q"0"
MB'#3E31XOH:QL4I1N4 ;OI#-*\DE"#T,D2=4Q:]$WFH-MM02)NS2@B.PDR9+
MN0 ALO P/7B!$2KH'(/D"0!,9  "C,@"$<RU!A\H0 :ZJ&>59' $#60T6AS0
MQ"FKY(,#", #2SAG!H:P@JBX0 *ZT((R99H2#C13)9Q:TI<60,U@#>408P+3
M'.H0A'9]<PH]G%+!7(7):,UJ_Y-;_.0"\.")+"U "&9P01EI&@>5!#-78'"#
M2)T$!J)&H! ]G8DK 3 '+R2A#V.0J!ZX0A S<!4W9^&!!S[1RV1AP@2D^>25
M6$!4<RV@$53]$B8^@%*U4JD//T"-"(X 6+'.](,ALFE*6%"':'I)!CSMZB@4
MP:@NS6$1.7V/),)II92ED7B0(Q>7XEG9FO#@ TTH!)( L(87?  .4Y4":A:@
MBUP<8P0M^( #SN 5)3@@!$8X@,@<8 $H*& -=S@&6GAPC$2*H M$*$%RO]L"
M$YS@NV8*@056B)(6.,&YB2R#!))+PY.T !+ L  &\$"%#X2  L&\@F^)P,<]
M> $&+/^8P55:L(,*\( +'N J#W: 4@ X(:Q0Z>T8N&!#!RC75Q9H[D.2"X,U
M'&-D#BB95S[P@1JU0 D6\.T(>*"$_E+&O?Z5 1D0D04I&'<-X77 =Q=P!1C[
M=W +N,.*X4"$%F1 $7" 45I>X-R2[>$, D R$S !8KB>Q*KR#<&!;#O=_QY#
M M/E HWA8,QMN+<+UA6";R'1392L00CII4 $OHN)8Q"!M_U-)":NX( &P* $
M3Z'!%8C@A#8@]!@PZ -CN3O"]*ZWOD6F0%[W08H$. $1,S#",?:97"B+0+PC
MZ ,<;BN%%2\!J985( ?L<"S-5F$&?*62#%SDT:%$H0?^W)+_4 F;$A& 8PH2
MO=(EP_8Y"F9)!%B(DQG[8 (8>("H5FV 'Y0@"4]X@"MS& (&CJ"%_@9WA%0X
MAA* H!U"P$$/AK"N$Y)R'SJ1H@5 D$!&FM!0.FAA 4Z  ZN;(("3$"0+$G "
M*8@ "1=TP0D:T"HF/  ,+FRC#:20@@G88%4J2( ,O8D)!U*@ "14%ST9*",2
MN)KCY?Y[##!:0QFRW6<6J"#=#>#"'MJMA".XP ].&$,N1I$""2B!VK:U0$8F
M @$X',,$:BA!MOUP@.V"@@PSF(T7SI +.<!@#SMHN@F@@ DLD"(C[$+)'AI@
M 3^0(01\,$UKO'R%'_AAREQ@@3R'_SP&3$C"YG#AD H0CB@>B#@$-, #T3T
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MZP*"V\6:TXL-1#8AL  ]T+N'Q 0Y"!;P_X@3$=" %1"!B&@#%Z" *$"I/7
MU.  3^ +$VJ#&0##D^"'4WPV0D@G#<B_49B"$8@ 1K!*%&HN^8@*D6@]7<P
M&SC)Z( ",N@"$:B#33 A2KK)"XN...B#94R+*&  &0""%3#"G^@!$_(1%J"S
M)ENG<]S&\"G"S/H)6P.3G:JF!SD$7VC#8%N$H8P+U8+.F&@_<$D@+!& /B
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M AB"UFB!/A,")6"$;9^-"CD#*=CD(4 X'1+6U^\H'K" JPW_AL*&'?(R?M(
MT&RR'@ (*A0 $*S%AB  'CLR#/%#Q@$C%436.$$QQ(@3<,"8*"#((P,5)T-&
M("0HP@N7*U0Z]F&$8@R%!1X8*/_@80&&B#$,-0QL86*(12,=%UQQ,[0$D(X
M1,@AR2%+QS4O4#!:V8*A0((MHNQ3D0L+E9]+ *PI\1.*4AX2*/2!$T7#&"(
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M10(O-$#!''10,"LD!Q'4@21EUPE% I#$T4<#7*RA "91S" 70@ZF,%"M+$"
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M(4HPBW2*P!!$R$ 15+2"CD3@!^J9*YVH( 4Z5."M$SF9$Q@$@%J\$0"-N!8
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M_%8#O!-:BL 0%!D87$"SR,0DU%\) H%[:)\R=81-'D,#D$3?B 8+E)V-)03
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M)OB?_XN)U'KZ7G0L0+5^@'QX !6@0Q0H0@68:8Q8  I450:\DHHTK1%,G@B
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MK,$?7S)C] $H?-T11[);_3%"[('_&7^.*7=$[UP:%_" &.=Q&!L!0C@;)%,
M)G!!'2/$-@R6+IOQG B!'TB!-RW 'V/"'ON@!+S  BI%"QR#%)PQ#1P#*$B!
M%OC@2OF,$M\!$?B &!M!,9,SWQZ7/BW%+O=, A!!/;D5#WP+-9^Q>;1 $DL!
M#5!"%IBQ+\]%$GL3#Q1/"YA'(9NQ%!09)2NQ $2QS\A%-F/. D0Q6=R!&)M'
M*^N!C>4"$?S/=!#$-DA FP@R!9@R0J"S!'#$ FBT!)2 4$UE.@_%,6CS!O%
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M?R,!;*@$CWK BF>\S_\\T >]T \]T8O[> MJN[?<RZUY!/BEI!T;981&K1$
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MQ40 PX)-0(@B7$4$=?2 @KW+  ]%00,_X,(Q3$#B$(S_<!,7R(('%.$  JC
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MSF[A\/]%?6T2!3MH42XZK#1!;@M$JFF+B-EQ%G E(IP05 "2UY8(#Z( ED0
M%VQ E-Q (/BH!#2 ,CI #OB ##8#"2+HXE@@!;;! 6# KU" $<9@&T(-M9),
ME+(@XM /D?QK%G(!".8DD!1)R6""#I8@*\:B$)A  2*@$$#A C0 O88 %*B@
M0D1 #HA %[I (*)""BYA*QK!&V9D![A@%%+  =[@"[2 0$1@#'RB%H[.)I).
MKDK- 2II!])(#BBC#Q0.$EQ /H:@"SKDIB+N-@)I"?K@#0K.!QQ D<  W=:
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M/.#%>$ ")'T/>$-_M,T(2>0%HB!2/0 .!%V:?"/JXR0!/B +I, )Y.=HG9T
M_*,!_( );I,- "_I,^ $$LU$1BT7/"QJOE[0J0P(DOY%W@=,I" *V "YNN 8
MI@8,(,#MHZ#IG<"0C!W.H& W<$3KZ,2Y<K[9CB %NB#B>F:S;F(*0,$)CA,S
MG1WH.$ 1+$ *B! )3M'ES>=!0J!/B*"0). %-( +]H!$E( 1-$ "G*#@MF_@
MR4\@=M_9O1N+)  4@*X$)/_A)Y_C&)1@4F>-%+H \'+_ODN $(XCM:! "2:
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M/MYV1 6?G^3+FS^//KWZ]>S;NW\//[[\^?3KV[^/W[V2 #A.;,L/8'E*Y!!
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M@9D6I@ \"YK#% Y &ZOU@5XB*D$#=J4V"^RH;:# E!)GD0LGL.]N0/.("!R
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M@828@ %K( -8*F,$*4C  [V- @S"![H9(#4$4O #'^X0%2!@("H'^TF%+0B
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MHR?=S<W+UG&=HTLMOEHMUW?]HFK\U1L-UWCMURH:QTP=TW]-V X:U:VCFC%
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M]P'1E;[=,S[/'JSIEE[>Y1S@GT[=5,[.-4[JTYW<NVJSJ;[IH_O(26P?[)D
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M(2R)C>U#< Y@:E<#!9*(?#2@]TOH5% @GCX@ 7$/=.AX!4Z([XMQ]UJW!Q)
M!NAP=!]0% "@]?)&-1&X 'J DD3  [KPBUJ&]F*IA!\ !2.P@O]*$ (?@.]6
MCXTKH "B*&^\[X08L -W=@QI" -5Z/(B@ (_8 &9EO>H3P1KX(1U[P!=L".G
MAY)"(@028/=+8+F E 36Z 0GT$3'$ *8X 5*$/8@H?<1R&[R'QJ"U@)6> !7
MP(^B"! .+#3))<7"AS$4 /B0<D"(A \AN!Q8(,3!Q2XT &Q<T,?!AR9$>"CY
MX(;(QHV8G#@( 8.'DQYPN!S9E&7$GH@6%.ZA\J'+,247N2A84^+CBFW'3D:
M<@#ETQ9!F]"XX^? GBX*6JS,"*#%!P=-RIP!L."8$1\>>H3\RI+(FF,6&L!X
M6M?N7;QY]>[EV]?O7\"!!0\F7-CP8<3_B14O9MS8<5XIJ )4D?(XL84< 6)H
M1"PBQ!( +%*\L$!$B$0R<(A4/?9FR94&?I@H*/%!@I,Q(U!& *)#"@,P*D:P
MT.!'2:<L>PC!D6"BR],%&T+X<1(B088L9894\'%,2A0V"UZ$D*#4B9<S>X#
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M $B$N./AVN8+!2R@#&W81!LJL0T3<&XC>RA$!8!7 4Q$P0\_^!H JG:""YS
M!@O0D>!0DD,5[8&/_QL!0P->8*;HC&$;ZZF+#$;A,Q&,P251.$$;@,$%*IG2
M : AI!3 @<8VJ, )R!M:&TBA&Q8$ 5,B(*8;PX $.,@(#+/(Q0[VHRE2F(&1
M;1C"$H30!@C,$!.D7  DCN:5/38-@PF+P ]\!CP,,&(?=QR"%#*POT;8$0([
M\@ U>;"#+N!A?SPP$%XXB:81@.$/7+! XX# .?/Q @MH5",7>J:^4JZ!!1#(
M@H16X(34)<\0&/ G_RK0I04 TI0-6,(A]L<\A*%D#4+HQ"80$00 E"":V8N
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M 9/>H 89?.#%"U8V([X) 1.]X1,\"-)M'%"!3Y>'"RTPP;/P,(5Y E/2-))
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MX5D &32EU- )4U("VI/ *]"_$Y0!78#!C0@8% 0#(,K_E&/0#1K9DC*@O3.
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M4VN:8P""<M(:6+X."& $"% #%O $I[ >"2B$;Q.J&-X(W#&;/=@$7T4!Z\@
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MK;334ENMM==BFRUEQZ#BSPE2:#N9!3D$$ ,FX8:[ "4:H4LM&'8UMP,#?GK
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MF0<NT) %",$+%Z "'WA@@0Q<@ "'V0,C4* !!GP.!G,PQ!TL@!0P_*0Q?6B
M'[R@D1)VH0^MD]T/&,&(@V#1CUQ\75)0<($W!) '5=0 _[&B8$8)F. "8W"=
M$SYP 11( (RD.  /E+ @&11B!'H@ ".@X %$ $-L?6 $ >!  P\P@ 9E\*,&
M9I$+GC#BB8U90!],( $S*&*2L[K"!1B1!9NM\@*D($(RQQ D%J3@"%30BR%A
MQP,]#,&8(^@#.AB1 B)4D0!-L"$J_7 %C?@. M]C01\A8+U9S9(1*B 6&:8X
M+X[LP)($6 ( ]C !% S!0'HAA [,4(46A0",)N*(!X: @A7P8 =O^((6/$"
M@"(!&& $I!,H($4G0L%Q(D"B$F%0PB8 ( )'&()=>! %#5S@#%@D  I8%@$3
MR'-D_D3!&(AP#." @1'%)(41*O_)B"%TX4E]L,D5/G#4=Z+D!"[@ AB<=Q$F
M[*%U>B ?4")I""+X( KJY"<TCY"%H513 ;STXSS70(8W$ (&#?VC#4^0R@7,
M4IPTY"%?^^K7CKUO']N('[GH]YD(M($4?"@#$"88 @K(3 L9, 07UD@!&BP
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MA2GP'AG@0@5\*,'O3"L13& A!0D@C@D<THGOLF"22%BO$$*0"UP$H38[N"P
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M](0;B!8*H,,.0 H6_>@/&$%NE9"''H$+P,#"<<29;D2>M1YY.4"#HHC)__
M(] I$,!!#/G@K+R \%":'HSH#D08EWHIF%8 ]?1I$UPI/_5!6K3I"M  "TS5
M$94%')PG>-)KO6Z?Y6!-YBS,UK3C9[2@!-B(HS#*;S".6'B'HG3'=ZC5A8@%
M$1S P!J!J_ !)_F 0"#!=G[-K/B X:"-JVS'1FRLV4C)F'R'L2"%\GR'DPA
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MBA3! C"8S%BE"RP!)YU8^@'#" "&@*8 '_C !RP!)  #AQU,=M6;&A $'"C
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MM'"+ ?]PN7S\96""$G@H*\I0D<^*NVM !HP!# B!A^+R="\YE'A "G!!+\I
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M$/C"&40PBZHL0 AMN$ ;J-*'+SP%(A: P4/X\HF'B* 387A(!%10 C=LPP2
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M++[NU9S \K8/(CQ@"LSNK4JO<7C  :!@X-; Z08B ;8A :2C^9POW&Q%^N:
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M!5H@V 2 ^/A   0".BN &YNBXH+R"H:   M!V.8@!""O#P;P(6(1$_ QW**
M#3KT$.)  <PQTR0S%B'NZ##@#58 $T;!#BJ@!21@&_I/!1O ". / %H@ [C
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MZ;+M!\H Y]0N!0Z@$40/.E= !@ZA$OBB8KU +V@@*R*2 62@4!^B5 %  ")
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M:@$PX0@V@1#DKN"D#P\^[0N:((*KH@7@@#\W80@:0 )(U0S(40_&#1V^\0K
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L[/##$$<L\<045VSQQ1AGK/'&''?L\<<@ARSRR"27;/+)**>L\LHL3QP0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g19382bgi002.gif
<DESCRIPTION>G19382BGI002.GIF
<TEXT>
begin 644 g19382bgi002.gif
M1TE&.#=A\ ,6!7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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M1 %T^&<4I G/&?A3#39@2#DE\LPH%#,A-[#$#Z+($ 180 TAZ(1**6)/ %R
MHA:=R!,RZH\?&)4D58TJ09 J ASLP*$ 4(!3 Z &IDY$ 7W@Z@U(\(."=FD!
M.I "7E$B"#NXM2(*T$,FKEH00=@BJ)L$P +DV<Q=)F(-QX!G#_AHD7YFXA8?
MJ$, ,B'7.AJB!'E< 1@Z>Q$%__1@#4QEZ5@EPDX&B""E.'U %CBI@X9&TA+
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MH@FL5( %YM"$1'@!'XD&P! ( (( X&,'H26(98_0 PAL<@&+F*= LKWM6@)
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M$!A59\4 ?/\8 ?= 8NS <UX@!*BE6H!P8AR  GB@ BG0;IN$ '!VB'@0 0$
M6Q= !6=0?&"0!W1D69%0#%  "#:P6?; B(F%!Z7( (FV %0 "5*P 6!0B_D4
M56<G!8C8 7DT RV0"0_0;AQ5$#?@;EG  LQ(8F>U R'  TQ@59J56(\8 83%
M23.P 4G  P68 \JG Z*P :*@C.@% 7@ "10@ E2&>!  =6<0"%Z@B_<0!5&%
M6"+PB%XP!W*&;3T@3&;0BL&T [IH!R*0?   9LY( RMH$,'45P$&"/+E9X$
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M'5  38>,B%@$XI17+X"&ND@!]Y &@L0(]D!H28)84A!:W<4+D#0"AD"'#;
M7F /X$"(ED"+I%9W"# #>-='RZ>#2@<(2O!)0W /D@9/ZB1A@F0! ?!K # "
M?Q95(H4/BS40 R<#B9"&"*<&5VFCRFA6WH=U""!DQU!#+7@(>? $=- %))9Q
MKX6CB[!@TFAN(( #^:97)%5#B< $1  #2I>29B4.=%A#?7!E+L4$N  # 28%
M0K!(*. % P9.I_\H TVW ^6%"#CV9"\IG04P!): I&<E!6!74SKP= +Q1\T)
MF$O0IYLEHTCU:0.! "\@ A4E;^ME>J5Z<_ I2,8P1UB(?=+$#F:J4".U>'N@
M 'FU!*OV<$4  <"@ # P W[G>=K% 19@<Q#*"5&P:XP@ KF0<05)3R=0FNHT
M$)@Z"<F490$@9]@E#-\Z$"/09$GPB6I@!IH)C$*00^"4>050 "< "7,0D'4P
M5&[ D0#P!%I6>G\@"16UES5V EYP<BAJ!$B@ PJ' ,;04Y&%#ZD':4%Z5@"K
M :7J ?*V6D3(@P&+JYLU!WVT"8:P27>7"4=H$)L9"%=EI"2VF:2G;T7_0 %$
ML%T<.Z ",0*KJ'D897-BF:8\EGT59@&6$ E190&HUUZ@L /YN02D=WY>$ !$
M\'?,NDEG980"T7<ET%-_8&NV( QB"0E0.5>QE@M_A(IWA 1UL*\<D AY>64C
M4(DR@%UIT%-$:E:^UDQPIGE--YGR)@(Q!IT41ZH!@*ZLN4I,@H+CI&=ZN@"<
M\)$!*PDS%5D$0'MYE5%&L)F?5@#70 +I=@,;^JTO%F,"<4,?D (20 #Q)6]X
MYT--![-Y)6"L%JJ0< 0RD%.'P \]5HL0ZU#R9@AT6:-#5D-/P DT6;)XQ0$*
M" @/D (LIWC2.)5),'JUEJM=H ).<+T$$ DR_W -!FE?=#"^ & ,M4 %)VD)
MPB">=5>>E@"O H$(EL"A9P9U-?A_3"L'#G -+?"U A&Z!SD0 OM(/;L(1NM2
MEB"4DA2%T9MLT3@0B 4"<+F)"^NC2R<#^T:7 H$$,2"]^AI:*ZE06C9.$+6Z
MH4F'9C63\B4(11 %&,!20$E8T,4)CF9A>#:L!( +>F4/186V(A#!V 6^Z5F#
MDY9QXA  ^2 %%* "%,9[U)NDN2M?3V!GN" 0T"D"-5MRW[L')V +Z%D0-)8+
M%P!-XS"-<C!LA'F^GY "29!8CS4$#!"D*'!TT?L Q"8'HMAQZ@2?5X4$*&P+
M:E!>-]!+=8EC(= $WO]D2IZV>#(U:A,)4AK,E-L5L'H@:AEGMC900Q9  #\@
M \\;O=/[I!SKJN.@ &>GIYJ53R!V U) >W8I7S=0!.WK:C5T D2+ .F; CQ@
M";KKQ^?$"/>P#(AEA'>'"W?(=N@E! _ GH8 :$A[",W\ %Z@:V:U"$@ZD835
M $T7Q?LV"0X@?6(J$"?@:_H5HA"+"=Q%M!:'<<D+J9%E"5=LH?+\E90K$(EP
MB@Y NIK;M4!*L3,0 1OP #IW!!C@56J @9(;GWE%8^JX3K9P!!5 B!"0!-O*
M>T=PA$CK2^>E!E8 IJ @INRD< -AI-<I"A& !XO%7XU:QE.[J8>(TJ)0 GO_
M(+5J*+XW]P<TL)MX7 2T!Y],Y<IA;$=,YW21>@9-"0 UBGH 4+Y@]U)N14<<
M:\#<A=2"A ";@ 9-<*GO%=,I78=Z9 @!L .B$ (1P'6[=DR 4 B,T (T-4:0
MD DA\ !M*$TH8*8-@%0&? (T( H/\(QS\-$N# B?= %N< 1YD&!$[%P.D+SD
M!6U!#*[U"P2SB( -'0"YT%Z'+4CES&<&L:Z\8 5)=&4SVDQ1%P^?%,_SG%/G
MAE?'Y&,S  $_/%>,())KU0)!  4^MEGQQ5U]+01.@ ?V"@#L\,H]-00<=X@1
M@(A7S+1J>'\UP%_+_==M^*(HNU4*ZH>4)<&<*4WO_XQ7+Q9\R$VV)\@')!!P
MBIU,_-4%30"M_D !>T@!NOBDB"#6 K4!=O"/3!6F^^3*;G4!7J"[>64!1<!1
MO#=A71N[&$4! RT!%! )#7#@+0O9N7#;F*#;'C!L/H8 4KN'RXT'(5 (&;6'
M>"#?F>"$"3;._$7#30<!((8"*-4 B6 (GLU=>U;)Z"Q."I !+EA$^"2CW4Q3
M,T#C-11JR P%QRL0(=D!#?!MJ)N QOUP-9@'J$P#O0UG2N!#+UM,37J[2>H%
M1-R(X%F+=8"'-<2J<09=>I#D/VX"34=2!*& B08#=+X')'<#@ANMM<;ACP0#
M!N#G!@  C""Z?212XXNT0O^I1VY MD =JB&]3PIXC]D JHGJV828EZ#;J V]
MS5&I90ZUMRZ%=^>'!IE@ G1N '8^5T;:;P$  OW6G#[4I6YHL'TD8DM%J#,P
M!U^ZDGDDM3D 3E'0;3 P;^PE23+J@X3-4KCY=9PD4[MV#?>0K?>T"%&(!FRI
MZH1+L2B 7'F$7>EPQ*PI#F<KP5.<R7-P5?5ZQ:)H#\ (8316 CJ0"9;=T#V)
M:J(P23*@8H,LZ]VVWKUPW%T0I+ (!'0. W8.N]?^!^XP82Q*BS#0="005?WU
M7TJ-!$M N.<$>\DI8-'(7QWG $- Y =1Q9AL5M"43!PPC7+7=T9 \'Z^!W0T
MN O_V.JPOLKCK,WU=58"/I&+7@ *[XVPFV[[5FNH'.#Y/IX&D839*JFB8 @I
MM0#^*4WB2P1[H %5#_.H9@1[8 !_GNH7P F14'C36%_O7%X*X,+?+GU1@'%Z
M%+_GC"0B2J+L# KR7KDN'L\4UP=+.0=!,+@L"P/="@C2Q,]8]%$.WZTI90R;
M<-@R@- 8J '4:O8A202X*G 174IZ%7$NZE7/5PC&$ -NL%0"@:5SQ-_\)8/&
MT <.H &+$ A!X.<9P +W2A"#A9X78 C:.9$$,.<&0$0^Z,-Z;PD9AE3N"0,Z
MC?$!Q@L@MJF5  2)VJ@M7EY1E]2$V+3;;@]*T <GP'%1_VU*E]P!>P #?W0(
M5]W)F]1(.P!_,& ,NH1MK_G0$-JJV7MIAL  4C#/$V6$@'\&<^!S?2=I *$@
MFY0<"W3LR $#Q2(I5@I<*"*E!! 4DJ3@*K#P$ 8.%EHHX?"$4Q0? !18$&%$
M!@R3>D2 ")0#P$R: % PL0?,F"<H4N04 (#HS"$'-6>. '4(G-$+D(Y@F*G!
MI1D@2"P0 +04A1<S2'1((=)@IJ B(/ 1X6#4)!U\?@#\@10 GQP "YR"T[!D
M#J8]3<$"17$O*XR\+8#M09"!15$+:I0 K0LE4I +A@#9T)#(UAQP"C89,E(
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MPIK.G4#_:I@)!5LLF>.GFFI,;Z8+OE)CJ=YL61,?0(!)RR9(+%$#& V8LP$
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ML+D?(: 6>:ZL!FI!:.PBP*(VF?:/4+"&:R^@#:I5TKXKGN4K(KC;5_>R BY
M@*68Y :27M(0S%"'^U#V"?#FT>40Y:H(\-S!B5@:!"\0 ?\%N8+\@5S9ERB$
M 1U'"-2N"2-&(98;; "6$*QU Z0S B\$8J@:X $\?:1L%8C'[IF5)T]K-0F
MZB$-Z99['#@%OB7(O$<+J /4*7N!!^0VNSY&.N"-@H@V7/L"V5[228)!_]PR
M#WOJ6 <^CN>>VZ_+P!A("$Y-CM^'T_8(\D$8P1IRZUP8] $)0.@4 F"P!V,(
M@/F0,<9!$<!% !3 &-;'?DLP+6\OM$@#DK@.!S3@_3VDA?I]H/]NJI__F;16
M \CO@Q<P WX@.IG"O^0#  [8ON,CA#U8&W]3O<_!/^;;JQUB/@XPANJ[/M%
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M"B]XG T0@BP8@0C(+<;S@-ZP8 T!S/OE&16=/#TH <C(2G=# #V(.Z.XACG
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M))))*KDDDTTZ^2240ZIUVDP2R<>'%0%N<(O_5AKL810"-W!H'H:"3#*82LL
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MO.#^)GC "5 $*>P[X0??=[_W38&)ZYO@%,^W".9@<7P?W.#]-GC#+1YRBU,
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M2-"GF^:GF/IGI]XGC19HJ.;GFH[$CH:JCP(II((HH29$AV)J?0Z60E" K :
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MK%$4P-'&;!\81;Y&+;;ZI\]**\8JQ!YD;=.V;-3BP;J.;-3&JYV&[;V.Q ;
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M0/!"Z+#KS@"[7/_ +^R!#FMO)^B$,5"!$5N!+6D %?##(."2"2?>":0PC:0
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ME=/]CX S>Q_Q ".P BXP9/7;BHJ*E#D&3G!@^T.@[RB808D%\('KT^ '_75
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M 1(!. 05J ")N!ZBF<8%P893T&(I=. \_C4P&*A0AQ&#MYB&V/& 40P,@BH
M$44(S Y.F<H,;.(#H:@#"';0@0]0(0L.6( .\A$%#E,A%.L$P )TNN$/\$!G
M '[J#R<Y1+C]< @VO2Z%19"628##IXN8PS$*@ !&--4#+@DQ#BA@ARX88:(A
MMD04,"L$#%@U &FH:DN>H -+I*,!$Y[!/7  "!N<525J9:M;X1I9>X#7KFKH
M0*<O( [MUI/_H!<PA(L+4<XEB$ -<NCT J 0@ X,<Y2\UJ9Q<5#?,V,V"F:]
M1GN;<&D ($*^D>AI(D QAS?_% 3"T-%;00 (&@3 "*]MR7H#\6:57+;;G6Z)
M<>E[Z07,H @XX"F<*2"6"%$J@C^\P:.O^P1.J&$#D)@#$7PJ#C4$H0 :T &N
M7[+43"3!#5%PI<-%8 1&^$/9;ZVTM%?B7Q",PMVB7()-Y4!J  ABP0A7P(,!
M48=X.[/"2A@F'7"P R4;F@Y2@( ?6G(!2-"VJD(/ !&&J0 +=.$(V@1V $I0
M 6):  1S\$"LI6 &<T_=$ET NJ./D&L &%T8]XEO '"1B"(X->+D_RUTR!]N
M!&&A><<3!< ?'O[='[YTCO'#X1#(&_ *=X *;K V=_V,4T&+8,>%:*E*;H"#
M*'Q !_X 1JD-G@-&!$#2E,Y$(?H0^@]]>=-27PD*;MT!D)=ZK6U5@!ZZ$(E^
MV&('E!#E73M0@*A* 1"3=DE410"(GI:3#R(X0BB_[(]@#!/OP6_F99-=54%7
MMQ HZ *#2^[3%@L#E2MP@QH*'6+Y-CB5%G##', A=!(0X?&0#P OU+UL'!R"
M'Z'OPX?L"G6[*^ $9R WOL5">7J'77)HJ0(AX'QA#G[@ B1!"E*NN_0.\0*#
MN8+@/B1.$XK/"-QJ$PP!$&2 #J#.OD 0'_\V  ],L!(Z+;9 ( VRC^[,P.Y6
MPM88S,&Z8!+V@!&ZH+XH+,(X0*V@K@%4[@+DB^0HR@(L0>\N(-@"89;P@
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M^E'96H+E&(R8'FP2*B"<+,$(8*#"%#'62* $8##D.($$1F'U%& &CK#06"P
M,L'*1* +HFW=2K&]-@ ,\D AR6OG6.(":*#;4(D#=RS'Y(JNG D'(_ "XLX-
MW8XEOBP?A $)8  &]@ []! &4<#_-#"'^,XO$LB'3(@=1. 0<RK".FT(_PC
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M04H%(,;:2_5^$3/?JO1*;=P"(#2)3:KPP0QN 0CZ0 !J(38TX.0H$?20@*@
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MKB*KW##MOPR:HAAATXHA!NQ L<P- 6JA!YHPH5Z+_YC #&(I ESO#V(, E3
MEE)I!FAK' HK$!:KA6$ !9S %BB@N73DWQ 9!DZ@KT( $P"/[8@)"7K "W9[
MNYQRJ_A*TA0@ T2+ KPI@S>GD:,"BH*'R<Y #8@ WKQ6Z6B:!G:  0B@J=(Y
M!F@:#R"  G2FV5")J[<*E9CX$*I* ^I@K/QJ+OWRDAL!FM=*\[IVF 2M:Q/A
M'G8@B@76'UJ4 0JSF:(;$D@ 'RB  ;(.".SVL,2" DB.Q?\0TDDMH$CL8*Q
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MY_\03R QHF 2/\(8?S #,B<F%Q> /4!82( \2,%F:K$ @S4.?? )-( JKZ$
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M!/C0B@[!#ID!# ,C!:H"%O&SB11!,Y^!I;&2 Y"S(5G3 (R0@QI"!U+P W!
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MU#S [2H1 GAPA:.%$<TNNMNN$N9^"SR! +6 $;;8%HOE!,UN#%3 5.G5OR&
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M&9X([*&"%#R EQDP6B >D,L I(&702*.>294(13H<H8/J(0#MI0=%*3@=X$
M*!6]((40I( ']P"$^:"4F$P\ !)V&@^"('@V"H3@ 6X 'E+DV04_1$0#@RD!
MFZJFT3 FH1/@B%08\1 "($;!3-<D04@E4(0^2N0^!"/;"2#7! &);GP;2 (-
MPJB$9ED  @!U@BX+QD1;=.$!XQ-+$VF$5%N0T R+.V8]<9")$/!@03Z37EGO
ME(1;P+.#3DO(SH(8L">D92T ^ \@("&%@CR!#R(PJ$:E<%8=)2:;#U#"!5)
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M[N;>; X)A<N;;O ^;_3F[>/6;L$QZ/1^;_A^;-8VCM8([OB^;_R&[.RF;Y3
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M"H300*(XH( ^I.1A ,A ')"V/@(H:@%>H"D'_@")6]9O7EEY39S2D/\'&*
M$D<(6D_V.L(_B)$B$G@?Z4)@@[T$XA;T0E\0"G"X)A1@!&B@*0(R0 -%W8!
M3YD!&S,B "!XE@^*&@(!2G#8$U2E !F01"90^(<ZN X!%LC$8WLPOAMH<2^]
M?9"\1 *[6S;I1P P1A\9HH>0.,0G@E% +3#P%]74S7\5\H &9G!+%-CA&(=Q
M @&@^Y"-Y,$8GZ"!'V3F$),X  :XO>51"- $ >R!=DG,H@R&L$8@9"4$L-$K
M314 V5P\)0.$2$GT,*" &Z35*/"-2?R.(P034$\P&!VC9H:")0Z\ &DZ? J
MOWN9)_C"#.. P1#P((09#\&R4)-$!_9@'QC_("$J]F5(3I3:D"<X 7EM?$TB
MTG 7X1* (QYQ B7VXH=3I<5E4B()$O2E@_-"XL/:D\!J5&($((C'"Y,8FT/^
MD-N1#*$%J$/L&FYB ?_R PB9"X("Z&"8MR[D G%(WG$4(0,$\"$002BK=&]
M7+])H&\/><(2$>N%'!S%:7^A04OYT*?Z*:9"MB,1:[><B#8D[P_C<.L0/@P
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M7)AJ-<1!&5EV(>"KA<PD;1EE\ 43A9='$1I,[(7_8+S ^!Q'P1%>  % (I1
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MEQZ5H>&$%&87]P7J2<R $/"#M?3!]!QF777I>816#3KD&L[E-?P DZ! '*C
M!.CD+\#/)/ (4>2!'?8$?:%/T/29$<2&$!A%04TA#(4>Q20"#=C6_YP>)MX
M#"&"'21!%N"GUB#*,5Q JK00,&C FU$$'QC<>\W&A0W32QQ0<MZ*A2$%X]"
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MP]DJG/@LLGG0;SZL7^:6^16(%@8E1HS  Q1">$DFI15+3U2<J3 +J!6:^LQ
MWJI0;TJ)^1G92;W:+1/C2SP!BBH %$A%?U:7\GS90DSGSY8'[-07X7V4"NPC
MG@I=2G[!@6);-'L.#:!46Z9H X#O__  =+WR>\Q;-&<$?8*,4<S;6AY4'I3S
M':+SE7@R1;#H<9AH[^Y(:FC4*/M1_R80FIKN00H.,V5J1 > 3 ,@@!XHP>OA
M[Q9.KTTYJ<M=;V1\@!3HQII,ALT%S=S6L0QU'6K*!Y/8G4>0XFH017GTV9NL
M-%.@P"*XS@OEP$(XB$>85YDP!5T=PS)[!E*-T,1Y@5 *K,TNW&0-![;4$Y6(
MQ 7H@*(:".[^A09ARPH.WG"I!;9(A" 8PE6N!(CH@4*^9_TTP7"XF>L(0A'(
M <<DRG%<)&R5E_1X;GTZE0F8Y"@4!*XR1,C=1>FVQ%)XCA]GQ.G)0'58C)2Y
MF:29L6&TD1VTP66L#4^D8/*(!Q,(G4-D-)04#I@F)@))BP)%37*N *X5!':8
M*^M=AJ"YZ/^.H(H)& 1"  6H+O% !XG5KE0@2)5'O$#$$1KZ>88-18T<1RN]
M95P]M>58)N[_Y/!4T, 3I8@;JA BX,I2A,E9M/53?,6PF$%2:$0+) $E\.F0
M9@=3J$25W Y5'X<.L$3,DLBW[H7L9, BJ*I9.($(-4=+,\0)C )-$XM&^*=Q
M9XJ@749=B.!0I,_2QB79I#$ )8]48P4@*T\/M*&GN%4J.8L3@@/IF&& LS;E
MX4IVD")LP*T"##8,S8?>&LN\'.@)&)LIP_AQ$#'9>('@ C,N(6R_'F2$9P3^
MPM;$X618@LOK\FGL9F0%E$T2;0QG//(@-BT"&")3&$/*L<: T$#_*$F;ZCEM
M"'0$:?AT[%[)Z!KT0I3M@0)&"5S4@7P58/]/LDF:C,0VISF7\/*.$'0Y0_ M
MF+<1F?6*5_>&+N[&1X,T3E& ,6RO<9POG*3O4^1.$GQ "H#!>\K;&Z7  ZS!
M13PZ0Z@DZ3Q $E"!YKC.J80 J:> UL1OH\0?&% !#W1 'MBO)H4 K!>-88PE
MX>U(5H!-I5,07:DZ#43">]+5;)?%"4@ I:< ZD#%X"%:"'0"%:1 58V %Z1Z
MJ3NKG11!W&+%":1ZI:_L'MA<MCO!]\P5%)@!J3L!*,[5LE.[:KC5^!K%E)O8
M\<D&&)A (L!Z"@A!9[W7#B3!IDN &6K$_ZU3NQW$)4%% < _5T%$*K4_ !HL
MR?_H:!-YP4748@VP1D -_ -,VWL\H_+, ,)7PBTT !63B!7O^HN>A0I,NW#6
ME 6 ,5N*X/ THPK-0 M<J)W4EDB@LHG) (IIT1\4H$G>^@=H#A_A<1,-0H/K
M[J0I]I);Q>.VIT,@@BVH0 I8^FJ@@!/ O*6[X TP@%$* A.@+%1<V0GT.SEA
M!KB#@;BSIL%;M$BP"KM#PLU.Q!_TP-=8.@TQ1:NQF8@VB=3\Q5TJ0 ]8IZQ3
M$5N50!:8%*]1CQ+0AB)Y1D5(.Q70T([=<D_P0-B#P;$5AK1\N!9"5@B$P@>H
MO@#H@!#$_0=, /\05(0*A$*IKV?Z1IVBHE?%UZ:L4WND/05]RG.<)+T3[*=&
M),$U&]T6!13 0\3L=\(0WML[A\O: L&^.'5E,7LC T"%9L>\>4D/N/<,J*A#
M$!0$V,X%0$*Q/T5$<D9_:Q;VVXG>DVY ?U6VIP /%#0?(]=[WH#>  28%#PJ
MY0$ ($8(,%2<"+%Q<(&.%N .7H 41<9!#9L44DEQRX$"23D*'#1Y$F5*E0(H
M!& @0&5,F3-IUOR +P %&#5YFES0R8'/6QQ,(O)Q4($GCYT*$4WY)P:83D $
M  &P8"A21 \!(% *)HL %B45U**R,$^!L@8!*%B1@LJM/0">T,-P$,'_B;,L
MG%@IH&%"T(J42@*XT&EAEL(9SMY",K2P3WIS*P8ARS@%4PYN[YI$\"D%&+D
M--#C]R&%%:LF+S"AJ!*!V12%D-1R,&02D*BA*(^0@.G36;9MC2T=YS3#6 7T
MAB]@(?C/)BJ%/*7(/$XE"H&9^47N&H,*TUJ$R)[ Y%3!";:?PX]CL1JE)\5(
M3Q0J\&<"?)/I0Z<(!3^#ICP++H4/@+C/,J3&Z^H#P0RCI $ D) .$R#XR0B%
MHY"R"X 3A"A$I@RF.ND/*L8I3(/WKLHJ0 [JLNHSN&BK1:U-.GOB@XQ(HT<_
MDU:P(;+/3&AKA011^J,'ZP2BY* )X0IB)P#^_^B$K8V".&D%##A0*C3L4M)
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MF P" :#2R\!2%I]N!X(* 5# "[9)/4N $ S@"7K@%)_&.U' #G+ L I! Y:
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M,-H $(OT9K=R!#_S=$%Q =3AE_JR70NW$K?4L8+I<@1K&<75!P!R=POC!#;
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M&AC&(W!Q=*L!%6,O%&X#-Y=\^1__V:D+T36'2+#A#3"1OD*33]7KP,U+E%L
M#$B FCF5T]] 0&LSV&X9YD^I"H#>N&!U&F%Y!-<G HG8DQ!Q7;TM/?5*J@H#
M7Q,^1>.G,,2P@0^<8D296G(G%61A#S#P5XL6H -L(4!O/^  5H(0&?F,#0$\
MR(6&VO.;"SP@(04"1K2H5)8V= 4[W=*3 /9@@%H8*C(!0Y5R)A4;LR1D2DI
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MAYFZ61N9V1*),)NW%Q'^>"(@&2]5-)**R2$=H9#_%Z"2[Q>'+3F'4+2!+*8
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M5^JC=D>#.)H'H*(M<LHK_[V')0=2JV"@8,!9JRPZ/A/ I34Z&$Y  "HP30I
M#^VBIFSZ/"]024[UJ\%Z L-JJKVT"1) K6*T%HX*I98Z ?_2*5F ;6=$J6YQ
MIQ$P6AN! ,SZD^-#!9,*J11# Q&0!#5@A#!08*+P +E!54'@ISH*'*!J=WZ!
M"$*P!P<H9A\ !$OZIY'1*>,@KBO*9W^1L1"1 =-"J[!*%GE)GX#P 6VP1#8Y
M1#IRHY1Z>#28!#GZ%)M0!VC0 7@UC ^! .[JIX7P8]LEIS%PH<WQI)A0KXG
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M0RP!V (<=M" %B TVT4%^IN8_P&$"_$X!(# #TY0B#YR"TN00A13O<"K%AF
MOYV0 @_P';70 Z( !K+V!/#0"#)\NV#,R5?! ]!, P00H=1BSIU !88B;K7@
M!!O0!#S9'/_'+Z$2 ?X+QK-\N)W0R)Z%&7Q@J(DYQ4,<QBNA 9S@O_YZ%O<"
MS0A]%?!@$&OCOV8,"49@%<,D!+,K ;GA&@3M Q3#T9MP"\5G#)\ !6;  @\Q
MS1#R5/CL%7@!""D OW8$'^-2O9M<B]QA8 ?-+E_SQ&#< =KF0:1".XR< N@\
MF0JP FS:H]G5.F1\T-(K8RSI@_5'A3)Y$_41"!1T,';P'4-@!O\2&4\ !;8$
M%C1@!O\R@"N%\P3-K "8P1I+10/ $!N>L @=(* ! T($D$)/L#>Q\0+:(6IX
MD<O%E2&"T )R4"G* 0$B!!R:4<Y^^) AD"$+( YW$V,P$!DPX,8<\0"<2C'K
MA2 G'!9)H@ CL-8":A*\45=>X(=XD5  (#[)-0(2D+E_@2\<\RA9PQ"(LQAN
M!:#OP1T!O7Q-D1_NLQ%,8A"ZA"VXH@/X))LKX4,JP9R9, XM0K$_@6UY,==$
MX!:K%@D:M0(10"G (0&D@B![_1>><15B@40ZD :]ETU.0J=6 8_5B)G'X !^
M8A2EG,N L5@:4&(0L02+-4$SU@-=%3UMW1E$,#YUD,L,1-__SP@ O_<J:_ >
M\<%5X?4V*33-T14D.XH<!X.>Z?U-:JV;G8T9%"40B<"( 8("*%[*X?T7=7 9
M>(%2AXU\(^ >'_'( ['&U=W,B0,([2)2">/$@'(#T0>/?Y$"8P$ >C"?+<$.
M1R #,?X33#4. E8IU8=:DI(';S-0\I$D$&6@"I"9"P )=],\:R4I$C4$%*!!
M?!P4Y)2F'=QRQ2EFFV"HWD<0O_D$?(#F2M*QC' K"%(D\'@G>]HZ[45B;TZB
MFR'(0415N7&1DA4;?P );+U4,:@ B. 0K@$(S.(M+@=@\1@1#_47J;L2 I(G
M<[<$AZ!)9D$33$++--+G%^#F&MT#_RT8$>T=V+?".B3*%9@Q _8PF3(A![ #
M%X91RI6=(*_'F@KHF@%0A@68NDYQ.#.+C*W#&!XYUVJA 23$7@N[X4J"'A.Q
M"3$<'0;9$KG9O+]1'YMQ)[2M7S$X$'=5 ,;L(,LQ(8CA &%.*'&@'ICYF6M!
M.O()0^0<%GZ  $KB[OL!@#51 G9XGEUA%A+%%B>L$$KR2%;0<DJ;G(5S%1-.
M%DRR=:F;+28:!ZHAB6T@-=T3&5L!'>U)$Z(SJR_ %9,!#!(/2T(!X2IO!Y1C
M\JI!$ VH'\HAO7,%'*T2,_<S"0T@6Q)5 "]SQ9G)*T:!?,8L TH"&)\A6_7>
MK1N!+."2%/_MH2MTX@!]K23WDP858&@2)<BM37\1L8]6!0B-F!^R(B RD$W=
MF/<;,03"J3\#TMFZ!)\@O^[\I+.W.;$!^BI/\Q8G_!+R"P/RLX=K\YM-+;UA
M<1J]W "NT0'042P&X<0-"'W0,3TW(S*5(D#),>HRD &I3J)R0.AJ0MT*  -]
M72#,PO 8OU10J>EQH!8:#P!+,!$;D1EZ,7<Z,$"NL3$(0XEY0P/V,"W!4>_R
MA#F'SGR<PB;P4=%YH/@\,!8+P E^0!;L4!4+D!%B)AV!DYDGL64V(6YM(?'!
M01^O[D^X);$  4#@0 5T< D<L2'(0 TZE!08&/&/A(<"_]"04]#_2 $8'%"L
MJ1$QHJ<X"P$HV/1+Q@(O.3C 0& A386)-0H\D>1G( I[-D0*5'!#2)Z=&WP4
M&&''PT +&R'^A!IU8#\& 2@(D)I5ZU:N C]4);"GJU8%,THX0-G!@< G.G((
M1$0CTZVU.-\">*+NF$ -?.04$-2%0@11$2*4:&!!" :@FRJMA7IAT=(+BF0
M;0K#$PV3C4,0%;B !Q$.0X1<%GAC5(.!0RS?^,R0AQ('"R0MY;M)@N$BPB#^
M<9(#(@HO!"(,CM !R TSH '<*($:ZA 50$ZB:.-\Q@_6?ZC0&$S@+X +$D)*
M7= &$T0-,W(]Q8ZA+(/"@P&MAXI=._?G_T98X]7KN:$&.J$-&2[P @+"#!L%
MB"><>&\G2(3 1*P%G  & $&.D$Z022Y;H0W& .CKH0L($*6PXU83"AP"18SJ
M"7B64F"("(3( K*?;N@B1<(H( ( _0;:CK4%!O'I)#J"!" ]X0#@X(4?"KB
MB4 ,(RR-!EH<")'%I$($1@4D.6B@"^S![:<+A+ ! 3Z"O"""NU*;I (%$%$!
M- L(&,Q')?X3"8%/>#B. ",@L^ QJ>[,4Z A!2IR" J,,XR"#@ 5R1@>.A!
M@#YBP*B  OZX;: ;_%- #]($NJ"-($:5),G^6-, U,%::((# !CIY2F1%-A0
M!@UZ4(*#"^+(H_^O'SAXH@X("DMQ@QI0@$1!+$M@[*,1[6K2U=94P."))7!Y
M2@$H(E33CKU,!40&!5 ( 1Q?LTIDC;<N6,-%@2P(9JU:=Z. @M7Z(N(I"Y@8
MC((4K7" 6X&&2*>!8_$3*!$A@-"@5.:L.VF($O8HB#YH-WAKAB9\_:..3)H
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MCO5) 144 K_A"RJP@P:$P=)!*?+8C0U(@CJPL42 !* A$5#!@PST"06XD C
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MTSE$*7(>LY7>@;VB'P[(#0C#%')3=XG/C? )V8Q9AX06"F1% 2#!.0H?)IQ
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MN-)]0B8I H$&; (3/-<%F  ,9  -D-(HRH&7T(6F*( G=%-1,)XI,40B@""
M2%X-U5?EJ=1]<<0--0%DU@(+=!T4KBB!T=;NB!Y+W%)7P(!''5/HW4I=J)\G
MW$(!J-Y"%=W/$ %%_]1!"\ *]JF- *C?0?B 0P "6AB#CYY81W@!GVK )_S=
M'OH +'&=!EB B<+ PW#7N1R?@G$*CU$.)?&$_3E? VS'#<* ,7Q ]"D-&IA!
M(6A #"!1152-.UG!'M >.%RG&FT$!O8$$4C')PR%)Q "!WA"'(C=6 S6"Q!
MN-B!L'5$!  #9,9 J**)#VAJ>'JI)SJI)(A",ET',:G>,WF)#&%"D4Y,!73A
M5M; [@$7'PB!)EQ0)RS%0^2!!KP  SC@EY@!,1U/5Q6 &@[-FGJ!*# /<@!"
M%ARK#A@5)7;)4I#B.,  $G3"^NQIKM8!7P89$QS"./QH"%P$772 CVX"N/\"
M0 ;DFD5]%0(,ZL%(SQ/,P'#\J"T(R0G8P5#6POW5%#@:#)A(B1:NA%KX 0>0
M:I- R)W600F,@P(@@9UV8,38%!38@S)>@ Z@!\S5  )@Q7 8 S\X@!I%!Q?:
MV5%Q)8K)!0*@ )O\P<0"*"[ 0"V K1[\DB"1$PP4" G8P 5!Y@VDC52(E5<(
M9UDQ1W?9P8-Y@B@-B" 0@"8BHEP=8G0FXB+Z!B*"27ML$X*]5F%Q$04(P2>\
MF-TY;'Y B',L0!TP .HR  $<PE!D8JO.% &H+NJ:*$:\0 1T+A0E@BV@+@4P
M@#T08'-%  %DPF_]#P]$@#TT02+,2E$0 ,%2"23_,  $A&Q-I=VRJ%$$:8K!
M;(+P9H**ED<B[")+%,?A>.'#2.2F76/T]BX!E$#G\  %B$(3]( 5-, -, $!
M4$ %=I<M7%G"S0 %0( H!,MK:22CM-?G><?.L6.%! YJ5 02<E8&P._P4L*S
M8,]DF8E@"945LH8%4(#W#@%M56'$K!L%,"[=_$$*6# BS*/1U $%  (8^-.8
MM,&BP"\#W*!78(7TEIL.A-P?P' .-Y$:$8 1<,OOQ  -$( H]"$ B$T(Q<&N
MVJ!YHBPDV(,<S%>3")D ;2TD$(#SCIFI4,$7^Z_NM(&*_@P%4 #)4@DPT@4P
M_ $.F2X8WV#P,K$RLL8"__  'O? +>S!$ZC#5R[Q](;JP7A!YWXNAA#<%YMH
M#T@*KHA"!Y#KP53"(I_ $LNO<VQ"!=Y*"@3!$)QP[#)N5*C1[5(M9>3K[79
M?UC5'K?O<IDA$UM!T6&+.)8*) BPF)V,'4  K)@R'D^.0%! ( 3!#%S)TL2
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M#+4T*I>A%S! )FS[=O0S\@+# LR MG.8[4) F+#&HU'!$INH810Q&ZN?'C#
M/3# (9#'3-D"!,"J-">!OFM)VI9Q$X$5(S" "#  ?8#)!^P[/"E 8.1O?;9E
M!V %!/]H"N=J;Z'LNQ,;M"@@BND./#[\  QP\G+I0!#P@4@W07MT:"Z+ C76
M-5'8[O!^9X9( B;H .LZ41T<M,(@!R[HKKT7PLW9<+K4J-[8[C9[#('(.WTF
MXW(M)&F \;47BJK5RY@\ !GG#Q6 00\(-)X3P8-" )@FPC>+<W<U<D)L;24\
M: XKS$'>@Q0$ M[=2C;G,-13B1!\ "3<>Z$X02@DO3UL>WF(/'TN2[9# !$
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MH*%'";T6*!25:$:&:,0+).6X^F?"GJE>MAHNT9-/%R(<) M'9$=)@S\SA)@
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M<)!HA$#4SJV+)7L:H7P+>"$3FPFBP0>OF<89;\=LNR ".1#R68$,%@$7(9?
M^4,2N:?UH-4<?.;@A4KTT@"*#@JERFH=7D9H@3B^'")$A.)68!->I6RCD L(
MD)4JN8%.VP(C"D6$:-&(*/2&'1>P8\RK%FB#8A2\\&,@QXAP+"^$3JCY"7&
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M4Q)G35S08W;ZTZ$>=:D#@%.>$O.88TJ F5;J"4N8A,L!4X AB%1TR4L((HZ
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MTF7_$_(H)NS1#DBSZ6J!"NP1#SI@'!+B*6A@-/M"(:B >X!+ C8@"?#F#ZC
M8%C%"4( #RH! T,S9Q#!"AKK!=(E$4( -3?D*D8 ##SI CK!0/X@!:YI 2IS
M X)&:GI@.TT/)3:!'AU@!4H3 /1@>"X _B+$">R@ SY  GBOW1)! OK38!1
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M7)'T*ND"G.C8D2VT^:':47+/H,8Q47D+[LWWE@E U_B0+% +P'0$R5QE6UM
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MAVEA-Q(^",I'PVS#!@S!M$W4@ [F2UTS)8($1&@ 2\TSJ3(.);IBON&7[P6
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M7/.D6_=B%$= ='<%B9$H;P&9%5& D@(6-^Q C^WX .<W$9 P49-&< OX3!9
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M5P7P.2\'ID#EI/87*PKCE)$($?":%B?ZDK%&+4=@&DED! K(@&/8!TA*7I!
M N_X H: 9MQ&@;UY5E D9HY1&1[TLC_Q%/,1">-PEZDB%8GR.6AP"&^$(3J0
MK0JP MLZ'3X*?VOC#X)$2#GX@N,6$8@@#F[5J*H!"H%@.#![@4<HKN'Q40@C
M0A_%+;6R'?+%C/-DA8P'$7^@%'Q%4U5"<&+_!E6V6GY9"6D2I#O2EA%2X >\
M]JMI\0>$D&?9-$W5!*)\***;ZTWJB3=A93T5):%#H%H-8 P?, &?4 >A59N4
MZ&X=0"RPPAFCUIL=@8/#TB_V,#SR*CXG8 O*)1&) $CC=981L+0_<0)R:+9>
MV07V4(<Y G1X5P$(T ."<@O]0 5U1'>P)J]Z*2<T$ "\T#"2P)TR4%0?JX\:
MTS ]\'+)$3(!( 2AL#^/*A\J P99$ -@X$E>$(X@(P4=^4_W  (] 66MV4CG
M\S+Y(B 4L0-J4E0JD494 #UG\I5)T D3X%V2H$%U0 ![I7=N\#N%D"^C,P'G
M<POI F!SL1@BP%B-_[,(2.LKV(.&AB,54G!FVS$#)*!0"R ..P10!JP6=A4
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M'@0"6' 0J*%6(88")4HT5HL?$ 7TQ@FLQ<+!P%KC"DQ$@*1CGST22QHT,1)
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M!)W(@S$F60 .6& .97N"+P*A1FYYRQ@?Z$06= (#)&RBF++Z0PS \!BIZ0D
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M 1.,T( +%#8 $-B $9G%Y@A0  +8=D"(W'"(18^[ X>,]#U P$%/T(  HB!
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MLLL#CSG#/<L+!"N (<58&O.!$M;PKD6HGCW@ *N1@DS(@GZ@GC&# AQBGQT
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MJZR9 KB!IT21/8BB94$" 3!"+Y("6SFQ$R   /.$)=@!Y7@6-;C$K3BRHQ&
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M&9C797$)U:#5D2@ N)0<;>0SECFC_9S7-"B*>>E;M\B_G?R= ! 4/XN$"K@
M*)C);7U('DW7K]!13D0!M+RZNLF$<9C1IM16M> 7/DV7HXJ5NS(]6!6'OJ6,
M&V@!4=P\"86?L92*9_D@WXT$OPD*X/$0AI 9-#*<>W4 01A)%IJSGT&<?9T-
M.&J3!6F0V0 <$D 6/CJ"#[D!-P"-$P5;4BF">X" >9.-_P4 A5_MI4[MF#D0
M8&2E1Q!ZV/9P&$O@("]B@!_H QW8SV:-Q@Z  TE( Q@ E6+00-1HQ$>T@$@T
MF_"%GVXQ1;0S(AE8 A  67P0M1M>"I7;.QV TP*(X$Z5B.DTPX0]'#K@,2G@
ML>'T@#D+1LA IV%%G"XHQC-(A_9((:T+#6!+%$A@  8821-8*P+FF#YJ%=S=
MR:HI@M/87?*]&L/!C#F8.5K1MS3&(%?E/3WX#@ H5H/KJ$2P!%'C,7RP!^61
MB"=P/G"X3"5PP1Q 7NF-X$P8'#K AYW9LU,QQG2H#:N) ILAF1$:" T, L2A
MXD7F4D75 _E 9"8X!""PTZ>5"/_AFHP_Z $\8((T[AN= \:/N$X/=0G/$9^E
MP XC<&,.:K^W6*NTK!HH4(,G:\NWE )!01Q%OKS6(> 9"(#U"T0C:@_4.0+#
M@1!#^+:$P>(%R$DL%<"[^)TY,#C$R0>0#0 1&,EQ*%:L[2CLF ^L2Y?-L[J.
M8H0YD";%=#/5%(:4@&:YS0&T!5DIOH=O.Z=43E*,C3A-$R[EF!0>L(47Y$IM
M,P1F$PCL5  ^R Z.L84 _@-.>%G(C1P' !R_ (0X3963-9<A" !'9)LA4AO4
M<0R=(P')Z2A4; 1.N8[A.YSY&HDBDI@HTF=]E@(V<B!:P0.1%@$UP,C_:@NN
M P<46#+_*6PN;J4+():IK:F7IS ]#)A?6)ZF);@\( Z 3$B;3=-AJYD#Z>&C
M)XUF^"AK"K3%P9E.0[D!$-#ABS-J"^)4,+*,&?O2_P@6'&.-(RO3J9"$8Q&(
M&! '8:AI-*+'F>@!+P#&8279JUL <9"\/,6:AO!1Y3%@,!8*'6B.<;Z -/L
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MJI,D\K8DA@+:M:#:[#JM!(6Y;;<Y>UH/^A!5$=&/P P1T X.$844< /2<0G
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M \J:P=00771 \!].@)'"=W(^R,@.!K$'29UWAF"Q7=V"34FX#(@"-,O:_^K
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MS-\I(.;5:X9>]FK\6UZ7B<G"/O>ZWSWO>^_[WP,_^,(?/O&++_F\)]'W3PQ
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M#I!A*H)C.(HCYQ%@_>G> ?+="KB2)U!!YBQ&#*1 *##9H=56"H!!YI@*.Z8
M5@5*"@1!/18"#/S!)H!!%B '#)P &!!"/Z1 )^0! K C&&Q8/E(!&#3&0BA
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M U - 0!"%A!"(E@"DEC'/4" %2!!9#* $@C #!Q&:3 "FP1!9+#)+7B"#@1
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M 7$\AB_2:]U" BFNQ65L[0E 0A^M!?W(@&[,SN)VB0<4 ,B ;>EV 6WXHB@
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M!.$ CUD)<T=DB,@;B9AZ;$5)FH0:E("%M0='U8?R7)O^6J!G@(;5M/]& .0
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M J)"T"  J%"!"TR.3+S!9,<&"1$L1?%1(,,B""JH. FQ\*(P!Q8?@'&2\!B
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M( ,T*%.M+@")(X #?6"Y !JB0+^Q+  2:O#Q6)ZP"3L PU9#$,$H+LQ !<Q
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M&&KM8):  4( #%( $@JMQBPO"0R#!P$@ U+DVU("!0S!#":"#O"$)^J@_QJ
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M!O#A,[>%T)0S90P")$%@+X*3"'9/!PX!U52KV%+RV#@+4PS!-Z/" B@CT)[
M%P@$R&)M1MQ &)#C#+PSU=+L-QEA#OB2X6"2SPB 43@O#QA."D"/ I1/"#ZA
M4CB-#E&M,/XB>"+! 1"@#N8 $QAB!#0- P1A)E/%"Z)@];9%U80" '#32,1E
M!J3  5&1S31.#3J324"/ %IS3AA"U:0  F*O(3(O%QR"&!FB---O_:Z&YQI@
M$T !'W24 >9 #E(&&YN4+Y; 0Y_B#,U@02W!.^,PT2KB'$F V1C"/Z2  D"O
M\(!! S0G!]XT-%K4$O_45$?Q@0@.S<H48!-NCP)F##/L=$T+!2H8% )@0S!#
M V$TKR$8H<J>+ #P@0+6]/U^1+Q*2[#B+K5Z<@Z.(6(DHQ6;[0G$@3;JH_-2
M32>'0A">@]-0P U:D@X@1".>  TZX\G:;E!N; %F8P,>P%>+XA/.X%0KM% E
M@0$Z8 *N<AC $D;\0$,X8=-84Q,OX#U0#1%2=2#$84JV!4::(&+NDWZX) <@
M,D=^]0$& RJ,(1'Z+LP2TR$"H"31% TH<3:N1A!BI0%NP W*]5>S8#+\3RER
M;33;34N5(- <[Q"   %EA<J&;5M*DR^5PA)(PEP' WB,@"QS$ !(E )"P%S_
M*>$H<;4A_N!"(@(<AH "9M!7V\ )D"Q=?_ >YB '+%(YEP#1MN5/EJ$P,\%C
M?;42MD^VF)!7G'"SC*$.,M$ 7XX]/%//.  1P!0<%+0A]-456[0_&T0!$ %
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M+^J#!.KW*);- 11@21F"'423(WP8'H7X"93-B2.@_P8V523!3031#;Q1)8J
MR1HB/@WE8;L@8GM8!3Z@%O^".#KB$Q_L(0=F51^%X!9D$0RBF.WVM!9" 1J+
M ":?($M4X!8^X0.4P(PRH!,^8 _GH&9WP,]"U/"H !8)=2X#P84_(06>!+?2
M4WW7,[06HP?L@(DL#S_X+E(WP JBA?-2CFI7 X8MX0@J ,W4K&.^%LZ\A"-.
MS_<V;B/\8E(IP(8/1  #(4SJ$"J>@#="+Q2,MP(XU!Z20@RAM4%^L3HR(0E^
MV=DV00 #!0%BP [:@DSBEB)JC/86T!X.;_,09%(C0 FDY@;L # R 2]YT7&!
M</\(0$EM@B$0@0%Z[D @84TSP5M;E ;N 1^$P D K5GZH0X$<"<,<&,MP2%U
M-Q?_(N8<W=A@#,0)\)D"S.,I&"X :'$!>@"A2[H2X% /$%1<+.#U @-=C2&5
M)Y5,AA@%(H "&& #F@ &,L=[&R(&O*#P2D+8OH0'?!J9T?52)8B6-'6U8*#I
MHJT/L@-48L[!!"[I.@U.Q 7;!@,&R&T@^,%,%* 6=*_=!H[DJ@4&C ':B(XB
MQ&[2,L#:D 8)!."NMZ\/:&[<*&XCL(T0RIJMD<83:@%O&^*J"WMGD. *KJT?
MZ-I:]IH%LOIP;.[@Q%#A*"+G .X%0!H LJW9-( %3$!M^^#=,)LA/AOI4#OL
ME@Y\GL"L08(%FNSH/G6O^8&U&R+;)N5,5+OEFNWH/%NV_]5EKULNXY[-W^AM
M\VY[6SI. &3 M ,7 ?H@YL@NMX1V5XA6P:@(5%PNU?#.4\]""1/HTJ@K?7=E
M?;^[BQ#  H(G $1@0(?8O6N(E-G;E.][BNQ$ O @"0Z;OV]H[HRM[@8<P9>*
MNW7%NQ/<P7EJO76EO1^<PGLJOR5\ORM<PU.JP-7SP#<<Q$5JP7.EP4/<Q"<J
MPG-EPD^<Q3'JPE4\PUM<QA&JPTOYPV<<QP-JQ'&EQ'/<Q^4IQ7%EQ7^<R.?I
MQ84\QHM<R<>IQO7[QI<<RL%IQV^EQZ/<RJ,IR&]ER*^<RZ7IR+4\R;M<S(6I
MR3'\R<<<S75IRFVERM/<S5\IR_]M9<O?G,YAZ<OE/,SK7,])J<QA_,SW'- [
M:<UKI<T#W= E*<YK9<X/G=$GZ<X5/<\;7=(%J<^1_,\G'=/_:-!II= SW=/E
M*-%I9=$_G=3GZ-%%/=)+7=7!J-+!_-)7'=:[:--GI=-CW=:C*-1G9=1OG=>E
MZ-1U/=5[7=B'J-7Q_-6''=EU:-;CHM:3W=GQZFY,Z[.\ZMFKG8A^/2[*RMJW
M/:XP=:JY'=R)/;G>B(!^*=S/W89R/=OWJH_0W=U9"-O50MO?G=[#R-NMB:KK
M7=\Q:-G5HMGW'>#S1]WEG=T#WN S*-[38MX/GN$7J-@A_=@;7N*GI]_3XM\G
M'N-59^#_%;[@,][CZ2FP:(FP/I[DI>?A43WB2U[E\Z;BT>+B5Q[FVV;CT6+7
M8][FXR;A:3[8;Y[G>^7D@3WE>U[H<:7ES^+EAQ[ITV+FSZ+FD][I:27GF7[G
MGY[JR^+GUSWHJU[KP:+HS>+HMQ[LL6+IS:+IP][LN2+JR7[JSY[MJ>+J"3[K
MVU[N6V?<,ZG<YQ[OQV+LY:+C\][O*2KDK6GD_Y[P=^C>V2K?"U_Q&:+KR^+K
M%Y_J]YXLRA[RSS[M^?Z9*E_S&?_P+0JU-A_R&Y\L'A_TA5[RQX+R2[_J+W_R
MUU[UD_[M.3[N7W_H17\L2)_V8_[TQ2+U<Q_I61_U7=_W>3[V_W5^]H??YFU?
M+' ?^4E^]\.B]YO_YH&?]X5?^E>^^*7^^*^_Y)4_+)B?^R?^^<$B^L-?Y:D?
M^JW?_#T^^]5^^]<?X[T?+, ?_@U^_+^B_.L_X]&?_-5?_QL>( 00"$!! ("#
M"!,J7,BPH<.'!S\P(+@'HL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV% B@$8-#OIL5.$R-H\$FTJ-&C2),J7<JTJ=.G4*-*G1JRW\2"
M3B6"H-"'JM>O8,.*'4NVK-FS:-/:S+G38%.)!&&HG4NWKMV[>//JW<OWJ$""
M;IG"I5"QK^'#B!,K7LRXL>.1;'DZ!?\:0.CCRY@S:][,N;-GE58!9V6PM>OG
MTZA3JU[-NK77R(&7#I;KNK;MV[ASZ][]%^O;JX5W"Q].O+CQXV4C]VQ*V3+R
MY]"C2Y].O>K5V$JU<JW.O;OW[^!MPQX=-[SY\^C3J[?;&WO2P<'7RY]/O[[]
MF<HG!QUZO[___P &R%!HO@DV$0/N":C@@@PV"!T+.B'H% L#,<""@QAFJ.&&
MJU'1!4%(.*4!!?@$T 9M'*:HXHHLXL4!'B52@.)2!80 PE8L<-#BCCSVZ*-3
M,% QD0@I0(5$B01]8$P!/S;IY)-0FH0 (53H%, ]0$"%P ,@X+/5!@]\(.:8
M9)9IYIEHIJG_YIILMNGFFW#&*>><=-9IYYUXYJGGGGSVZ>>?@ 8JZ*"$%FKH
MH8@FJFB?8$B AQ0!1$J%5!K8B$.D 4# @*:<;NIIIZ!^*FJHI(YJ:JFHGJIJ
MJJRNZFJKL+XJ:ZRTSFIKK;C>JFNNO.[J:Z_ _BILL,0.:VRQR!ZK;++,+NML
ML] ^*VVTU$Z$:0 @)#&C4P7T\< ] 7AY[;CDEFONN>BFJ^ZZ[+;K[KOPQBOO
MO/36:^^]^.:K[[[\]NOOOP '+/# !!=L\,$(!RPN/A%\L&U4,*00 0,44&QQ
MQ1A?K''&'&_L<<<@?RQRR"2/;'+)*)^L<LHLK^QRRS"_+'/,-,]L^7/-.-^L
M<\X\[^QSST#_+'301 ]M=-%('ZUTTDPOO73%!%! @00L*$ 6#%AGK?767'?M
M]==@ARWVV&27;?;9:*>M]MILM^WVVW#'+??<=-=M]]UXYZWWWGSW[???@,.M
MP1Z#:V!UE(@GKOCBC#?N^..01R[YY)17;OGEF&>N^>:<=^[YYZ"'+OKHI)=N
M^NFHIZ[ZZJRW[OKKL,<N^^RTUV[[[;CGKOONO/?N^^_ !R_\\,07;_SQR">O
M_/+,-^_\\]!'+_WTU%=O_?789Z_]]MQW[_WWX(<O_OCDEV_^^>BGK_[Z[+?O
5_OOPQR___/37;__]^.>O/_$! 0 [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
